<drug type="biotech" created="2005-06-13" updated="2021-01-01">
  <drugbank-id primary="true">DB00071</drugbank-id>
  <drugbank-id>BTD00031</drugbank-id>
  <drugbank-id>BIOD00031</drugbank-id>
  <name>Insulin pork</name>
  <description>Insulin isolated from pig pancreas. Composed of alpha and beta chains, processed from pro-insulin. Forms a hexameric structure.</description>
  <cas-number>12584-58-6</cas-number>
  <unii>AVT680JB39</unii>
  <state>liquid</state>
  <groups>
    <group>approved</group>
  </groups>
  <general-references>
    <articles/>
    <textbooks/>
    <links/>
    <attachments/>
  </general-references>
  <synthesis-reference>Bruce H. Frank, "Process for producing an insulin precursor." U.S. Patent US4430266, issued November, 1974.</synthesis-reference>
  <indication>For the treatment of type I and II diabetes mellitus.</indication>
  <pharmacodynamics>Insulin is used in the treatment of type I and type II diabetes. The primary activity of insulin is the regulation of glucose metabolism. In muscle and other tissues (except the brain), insulin causes rapid transport of glucose and amino acids intracellularly. It also promotes anabolism, and inhibits protein catabolism. In the liver, insulin promotes the uptake and storage of glucose in the form of glycogen, inhibits gluconeogenesis, and promotes the conversion of excess glucose into fat.</pharmacodynamics>
  <mechanism-of-action>Insulin binds to the insulin receptor (IR), a heterotetrameric protein consisting of two extracellular alpha units and two transmembrane beta units. The binding of insulin to the alpha subunit of IR stimulates the tyrosine kinase activity intrinsic to the beta subunit of the receptor. The bound receptor is able to autophosphorylate and phosphorylate numerous intracellular substrates such as insulin receptor substrates (IRS) proteins, Cbl, APS, Shc and Gab 1. These activated proteins, in turn, lead to the activation of downstream signaling molecules including PI3 kinase and Akt. Akt regulates the activity of glucose transporter 4 (GLUT4) and protein kinase C (PKC) which play a critical role in metabolism.</mechanism-of-action>
  <toxicity/>
  <metabolism>Insulin is predominantly cleared by metabolic degradation via a receptor-mediated process.</metabolism>
  <absorption/>
  <half-life/>
  <protein-binding/>
  <route-of-elimination/>
  <volume-of-distribution/>
  <clearance/>
  <classification>
    <description/>
    <direct-parent>Peptides</direct-parent>
    <kingdom>Organic Compounds</kingdom>
    <superclass>Organic Acids</superclass>
    <class>Carboxylic Acids and Derivatives</class>
    <subclass>Amino Acids, Peptides, and Analogues</subclass>
  </classification>
  <salts>
    <salt>
      <drugbank-id primary="true">DBSALT001735</drugbank-id>
      <name>Insulin suspension isophane purified pork</name>
      <unii/>
      <cas-number/>
      <inchikey/>
    </salt>
    <salt>
      <drugbank-id primary="true">DBSALT001736</drugbank-id>
      <name>Insulin suspension protamine zinc purified pork</name>
      <unii/>
      <cas-number/>
      <inchikey/>
    </salt>
    <salt>
      <drugbank-id primary="true">DBSALT001737</drugbank-id>
      <name>Insulin zinc suspension prompt purified pork</name>
      <unii/>
      <cas-number/>
      <inchikey/>
    </salt>
    <salt>
      <drugbank-id primary="true">DBSALT001738</drugbank-id>
      <name>Insulin zinc suspension purified pork</name>
      <unii/>
      <cas-number/>
      <inchikey/>
    </salt>
  </salts>
  <synonyms>
    <synonym language="english" coder="">Insulin (pork)</synonym>
    <synonym language="english" coder="">Insulin porcine</synonym>
    <synonym language="english" coder="">Insulin purified porcine</synonym>
    <synonym language="english" coder="">Insulin purified pork</synonym>
    <synonym language="english" coder="">Insulin, porcine</synonym>
    <synonym language="english" coder="">Insulin, regular, pork</synonym>
    <synonym language="english" coder="">Porcine insulin</synonym>
  </synonyms>
  <products>
    <product>
      <name>Hypurin Nph Insulin Isophane Pork</name>
      <labeller>Wockhardt Uk Ltd</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02275864</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-04-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Suspension</dosage-form>
      <strength/>
      <route>Intramuscular; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Hypurin Regular Insulin Pork</name>
      <labeller>Wockhardt Uk Ltd</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02275872</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-04-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Intramuscular; Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Regular Purified Pork Insulin Inj</name>
      <labeller>Eli Lilly &amp; Co. Ltd.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00513644</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1980-12-31</started-marketing-on>
      <ended-marketing-on>2006-04-03</ended-marketing-on>
      <dosage-form>Liquid</dosage-form>
      <strength/>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
  </products>
  <international-brands/>
  <mixtures>
    <mixture>
      <name>Hypurin Nph Insulin Isophane Pork</name>
      <ingredients>Insulin pork</ingredients>
    </mixture>
    <mixture>
      <name>Hypurin Regular Insulin Pork</name>
      <ingredients>Insulin pork</ingredients>
    </mixture>
    <mixture>
      <name>Regular Purified Pork Insulin Inj</name>
      <ingredients>Insulin pork</ingredients>
    </mixture>
  </mixtures>
  <packagers/>
  <manufacturers>
    <manufacturer generic="false" url="">Eli lilly and co</manufacturer>
    <manufacturer generic="false" url="">Novo nordisk inc</manufacturer>
  </manufacturers>
  <prices/>
  <categories>
    <category>
      <category>Alimentary Tract and Metabolism</category>
      <mesh-id/>
    </category>
    <category>
      <category>Amino Acids, Peptides, and Proteins</category>
      <mesh-id>D000602</mesh-id>
    </category>
    <category>
      <category>Blood Glucose Lowering Agents</category>
      <mesh-id>D007004</mesh-id>
    </category>
    <category>
      <category>Cytochrome P-450 CYP1A2 Inducers</category>
      <mesh-id>D065694</mesh-id>
    </category>
    <category>
      <category>Cytochrome P-450 CYP1A2 Inducers (strength unknown)</category>
      <mesh-id/>
    </category>
    <category>
      <category>Cytochrome P-450 Enzyme Inducers</category>
      <mesh-id>D065693</mesh-id>
    </category>
    <category>
      <category>Drugs Used in Diabetes</category>
      <mesh-id/>
    </category>
    <category>
      <category>Hormones</category>
      <mesh-id>D006728</mesh-id>
    </category>
    <category>
      <category>Hormones, Hormone Substitutes, and Hormone Antagonists</category>
      <mesh-id>D006730</mesh-id>
    </category>
    <category>
      <category>Insulin</category>
      <mesh-id>D007328</mesh-id>
    </category>
    <category>
      <category>Insulin, Short-Acting</category>
      <mesh-id>D061266</mesh-id>
    </category>
    <category>
      <category>Insulins and Analogues for Injection, Fast-Acting</category>
      <mesh-id/>
    </category>
    <category>
      <category>Pancreatic Hormones</category>
      <mesh-id>D010187</mesh-id>
    </category>
    <category>
      <category>Peptide Hormones</category>
      <mesh-id>D036361</mesh-id>
    </category>
    <category>
      <category>Peptides</category>
      <mesh-id>D010455</mesh-id>
    </category>
    <category>
      <category>Protein Precursors</category>
      <mesh-id>D011498</mesh-id>
    </category>
    <category>
      <category>Proteins</category>
      <mesh-id>D011506</mesh-id>
    </category>
  </categories>
  <affected-organisms>
    <affected-organism>Humans and other mammals</affected-organism>
  </affected-organisms>
  <dosages>
    <dosage>
      <form>Suspension</form>
      <route>Intramuscular; Subcutaneous</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Intramuscular; Intravenous; Subcutaneous</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Liquid</form>
      <route>Subcutaneous</route>
      <strength/>
    </dosage>
  </dosages>
  <atc-codes>
    <atc-code code="A10AC03">
      <level code="A10AC">Insulins and analogues for injection, intermediate-acting</level>
      <level code="A10A">INSULINS AND ANALOGUES</level>
      <level code="A10">DRUGS USED IN DIABETES</level>
      <level code="A">ALIMENTARY TRACT AND METABOLISM</level>
    </atc-code>
    <atc-code code="A10AB03">
      <level code="A10AB">Insulins and analogues for injection, fast-acting</level>
      <level code="A10A">INSULINS AND ANALOGUES</level>
      <level code="A10">DRUGS USED IN DIABETES</level>
      <level code="A">ALIMENTARY TRACT AND METABOLISM</level>
    </atc-code>
    <atc-code code="A10AE03">
      <level code="A10AE">Insulins and analogues for injection, long-acting</level>
      <level code="A10A">INSULINS AND ANALOGUES</level>
      <level code="A10">DRUGS USED IN DIABETES</level>
      <level code="A">ALIMENTARY TRACT AND METABOLISM</level>
    </atc-code>
    <atc-code code="A10AD03">
      <level code="A10AD">Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting</level>
      <level code="A10A">INSULINS AND ANALOGUES</level>
      <level code="A10">DRUGS USED IN DIABETES</level>
      <level code="A">ALIMENTARY TRACT AND METABOLISM</level>
    </atc-code>
  </atc-codes>
  <ahfs-codes>
    <ahfs-code>68:20.08</ahfs-code>
  </ahfs-codes>
  <pdb-entries/>
  <patents/>
  <food-interactions/>
  <drug-interactions>
    <drug-interaction>
      <drugbank-id>DB06655</drugbank-id>
      <name>Liraglutide</name>
      <description>Liraglutide may increase the hypoglycemic activities of Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09046</drugbank-id>
      <name>Metreleptin</name>
      <description>Metreleptin may increase the hypoglycemic activities of Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00082</drugbank-id>
      <name>Pegvisomant</name>
      <description>The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01132</drugbank-id>
      <name>Pioglitazone</name>
      <description>The risk or severity of adverse effects can be increased when Pioglitazone is combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01278</drugbank-id>
      <name>Pramlintide</name>
      <description>Pramlintide may increase the hypoglycemic activities of Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00412</drugbank-id>
      <name>Rosiglitazone</name>
      <description>The risk or severity of congestive heart failure can be increased when Insulin pork is combined with Rosiglitazone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00166</drugbank-id>
      <name>Lipoic acid</name>
      <description>The risk or severity of hypoglycemia can be increased when Lipoic acid is combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00974</drugbank-id>
      <name>Edetic acid</name>
      <description>Edetic acid may increase the hypoglycemic activities of Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00187</drugbank-id>
      <name>Esmolol</name>
      <description>Esmolol may increase the hypoglycemic activities of Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12212</drugbank-id>
      <name>Landiolol</name>
      <description>Landiolol may increase the hypoglycemic activities of Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00218</drugbank-id>
      <name>Moxifloxacin</name>
      <description>The therapeutic efficacy of Insulin pork can be increased when used in combination with Moxifloxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00365</drugbank-id>
      <name>Grepafloxacin</name>
      <description>The therapeutic efficacy of Insulin pork can be increased when used in combination with Grepafloxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00467</drugbank-id>
      <name>Enoxacin</name>
      <description>The therapeutic efficacy of Insulin pork can be increased when used in combination with Enoxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00487</drugbank-id>
      <name>Pefloxacin</name>
      <description>The therapeutic efficacy of Insulin pork can be increased when used in combination with Pefloxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00537</drugbank-id>
      <name>Ciprofloxacin</name>
      <description>The therapeutic efficacy of Insulin pork can be increased when used in combination with Ciprofloxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00685</drugbank-id>
      <name>Trovafloxacin</name>
      <description>The therapeutic efficacy of Insulin pork can be increased when used in combination with Trovafloxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00779</drugbank-id>
      <name>Nalidixic acid</name>
      <description>The therapeutic efficacy of Insulin pork can be increased when used in combination with Nalidixic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00817</drugbank-id>
      <name>Rosoxacin</name>
      <description>The therapeutic efficacy of Insulin pork can be increased when used in combination with Rosoxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00827</drugbank-id>
      <name>Cinoxacin</name>
      <description>The therapeutic efficacy of Insulin pork can be increased when used in combination with Cinoxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00978</drugbank-id>
      <name>Lomefloxacin</name>
      <description>The therapeutic efficacy of Insulin pork can be increased when used in combination with Lomefloxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01044</drugbank-id>
      <name>Gatifloxacin</name>
      <description>The therapeutic efficacy of Insulin pork can be increased when used in combination with Gatifloxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01059</drugbank-id>
      <name>Norfloxacin</name>
      <description>The therapeutic efficacy of Insulin pork can be increased when used in combination with Norfloxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01137</drugbank-id>
      <name>Levofloxacin</name>
      <description>The therapeutic efficacy of Insulin pork can be increased when used in combination with Levofloxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01155</drugbank-id>
      <name>Gemifloxacin</name>
      <description>The therapeutic efficacy of Insulin pork can be increased when used in combination with Gemifloxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01165</drugbank-id>
      <name>Ofloxacin</name>
      <description>The therapeutic efficacy of Insulin pork can be increased when used in combination with Ofloxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01208</drugbank-id>
      <name>Sparfloxacin</name>
      <description>The therapeutic efficacy of Insulin pork can be increased when used in combination with Sparfloxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01405</drugbank-id>
      <name>Temafloxacin</name>
      <description>The therapeutic efficacy of Insulin pork can be increased when used in combination with Temafloxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04576</drugbank-id>
      <name>Fleroxacin</name>
      <description>The therapeutic efficacy of Insulin pork can be increased when used in combination with Fleroxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05488</drugbank-id>
      <name>Technetium Tc-99m ciprofloxacin</name>
      <description>The therapeutic efficacy of Insulin pork can be increased when used in combination with Technetium Tc-99m ciprofloxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06160</drugbank-id>
      <name>Garenoxacin</name>
      <description>The therapeutic efficacy of Insulin pork can be increased when used in combination with Garenoxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06600</drugbank-id>
      <name>Nemonoxacin</name>
      <description>The therapeutic efficacy of Insulin pork can be increased when used in combination with Nemonoxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08972</drugbank-id>
      <name>Flumequine</name>
      <description>The therapeutic efficacy of Insulin pork can be increased when used in combination with Flumequine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11404</drugbank-id>
      <name>Enrofloxacin</name>
      <description>The therapeutic efficacy of Insulin pork can be increased when used in combination with Enrofloxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11443</drugbank-id>
      <name>Orbifloxacin</name>
      <description>The therapeutic efficacy of Insulin pork can be increased when used in combination with Orbifloxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11491</drugbank-id>
      <name>Sarafloxacin</name>
      <description>The therapeutic efficacy of Insulin pork can be increased when used in combination with Sarafloxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11511</drugbank-id>
      <name>Difloxacin</name>
      <description>The therapeutic efficacy of Insulin pork can be increased when used in combination with Difloxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11774</drugbank-id>
      <name>Pazufloxacin</name>
      <description>The therapeutic efficacy of Insulin pork can be increased when used in combination with Pazufloxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11892</drugbank-id>
      <name>Prulifloxacin</name>
      <description>The therapeutic efficacy of Insulin pork can be increased when used in combination with Prulifloxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11943</drugbank-id>
      <name>Delafloxacin</name>
      <description>The therapeutic efficacy of Insulin pork can be increased when used in combination with Delafloxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13261</drugbank-id>
      <name>Sitafloxacin</name>
      <description>The therapeutic efficacy of Insulin pork can be increased when used in combination with Sitafloxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13627</drugbank-id>
      <name>Oxolinic acid</name>
      <description>The therapeutic efficacy of Insulin pork can be increased when used in combination with Oxolinic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13772</drugbank-id>
      <name>Rufloxacin</name>
      <description>The therapeutic efficacy of Insulin pork can be increased when used in combination with Rufloxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13823</drugbank-id>
      <name>Pipemidic acid</name>
      <description>The therapeutic efficacy of Insulin pork can be increased when used in combination with Pipemidic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00232</drugbank-id>
      <name>Methyclothiazide</name>
      <description>The therapeutic efficacy of Insulin pork can be decreased when used in combination with Methyclothiazide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00310</drugbank-id>
      <name>Chlorthalidone</name>
      <description>The therapeutic efficacy of Insulin pork can be decreased when used in combination with Chlorthalidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00436</drugbank-id>
      <name>Bendroflumethiazide</name>
      <description>The therapeutic efficacy of Insulin pork can be decreased when used in combination with Bendroflumethiazide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00524</drugbank-id>
      <name>Metolazone</name>
      <description>The therapeutic efficacy of Insulin pork can be decreased when used in combination with Metolazone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00562</drugbank-id>
      <name>Benzthiazide</name>
      <description>The therapeutic efficacy of Insulin pork can be decreased when used in combination with Benzthiazide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00774</drugbank-id>
      <name>Hydroflumethiazide</name>
      <description>The therapeutic efficacy of Insulin pork can be decreased when used in combination with Hydroflumethiazide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00808</drugbank-id>
      <name>Indapamide</name>
      <description>The therapeutic efficacy of Insulin pork can be decreased when used in combination with Indapamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00880</drugbank-id>
      <name>Chlorothiazide</name>
      <description>The therapeutic efficacy of Insulin pork can be decreased when used in combination with Chlorothiazide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00999</drugbank-id>
      <name>Hydrochlorothiazide</name>
      <description>The therapeutic efficacy of Insulin pork can be decreased when used in combination with Hydrochlorothiazide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01021</drugbank-id>
      <name>Trichlormethiazide</name>
      <description>The therapeutic efficacy of Insulin pork can be decreased when used in combination with Trichlormethiazide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01324</drugbank-id>
      <name>Polythiazide</name>
      <description>The therapeutic efficacy of Insulin pork can be decreased when used in combination with Polythiazide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01325</drugbank-id>
      <name>Quinethazone</name>
      <description>The therapeutic efficacy of Insulin pork can be decreased when used in combination with Quinethazone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13532</drugbank-id>
      <name>Cyclopenthiazide</name>
      <description>The therapeutic efficacy of Insulin pork can be decreased when used in combination with Cyclopenthiazide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13989</drugbank-id>
      <name>Epitizide</name>
      <description>The therapeutic efficacy of Insulin pork can be decreased when used in combination with Epitizide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00344</drugbank-id>
      <name>Protriptyline</name>
      <description>Protriptyline may decrease the hypoglycemic activities of Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00543</drugbank-id>
      <name>Amoxapine</name>
      <description>Amoxapine may decrease the hypoglycemic activities of Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00726</drugbank-id>
      <name>Trimipramine</name>
      <description>Trimipramine may decrease the hypoglycemic activities of Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04836</drugbank-id>
      <name>Amineptine</name>
      <description>Amineptine may decrease the hypoglycemic activities of Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08996</drugbank-id>
      <name>Dimetacrine</name>
      <description>Dimetacrine may decrease the hypoglycemic activities of Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09016</drugbank-id>
      <name>Butriptyline</name>
      <description>Butriptyline may decrease the hypoglycemic activities of Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09167</drugbank-id>
      <name>Dosulepin</name>
      <description>Dosulepin may decrease the hypoglycemic activities of Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09289</drugbank-id>
      <name>Tianeptine</name>
      <description>Tianeptine may decrease the hypoglycemic activities of Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09307</drugbank-id>
      <name>Oxaprotiline</name>
      <description>Oxaprotiline may decrease the hypoglycemic activities of Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12930</drugbank-id>
      <name>Opipramol</name>
      <description>Opipramol may decrease the hypoglycemic activities of Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13114</drugbank-id>
      <name>Amitriptylinoxide</name>
      <description>Amitriptylinoxide may decrease the hypoglycemic activities of Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13225</drugbank-id>
      <name>Dibenzepin</name>
      <description>Dibenzepin may decrease the hypoglycemic activities of Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13246</drugbank-id>
      <name>Quinupramine</name>
      <description>Quinupramine may decrease the hypoglycemic activities of Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13384</drugbank-id>
      <name>Melitracen</name>
      <description>Melitracen may decrease the hypoglycemic activities of Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13411</drugbank-id>
      <name>Lofepramine</name>
      <description>Lofepramine may decrease the hypoglycemic activities of Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13496</drugbank-id>
      <name>Iprindole</name>
      <description>Iprindole may decrease the hypoglycemic activities of Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13782</drugbank-id>
      <name>Imipramine oxide</name>
      <description>Imipramine oxide may decrease the hypoglycemic activities of Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00540</drugbank-id>
      <name>Nortriptyline</name>
      <description>Nortriptyline may decrease the hypoglycemic activities of Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01151</drugbank-id>
      <name>Desipramine</name>
      <description>Desipramine may decrease the hypoglycemic activities of Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06292</drugbank-id>
      <name>Dapagliflozin</name>
      <description>Dapagliflozin may increase the hypoglycemic activities of Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08907</drugbank-id>
      <name>Canagliflozin</name>
      <description>Canagliflozin may increase the hypoglycemic activities of Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00007</drugbank-id>
      <name>Leuprolide</name>
      <description>The therapeutic efficacy of Insulin pork can be decreased when used in combination with Leuprolide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00014</drugbank-id>
      <name>Goserelin</name>
      <description>The therapeutic efficacy of Insulin pork can be decreased when used in combination with Goserelin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00220</drugbank-id>
      <name>Nelfinavir</name>
      <description>The therapeutic efficacy of Insulin pork can be decreased when used in combination with Nelfinavir.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00224</drugbank-id>
      <name>Indinavir</name>
      <description>The therapeutic efficacy of Insulin pork can be decreased when used in combination with Indinavir.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00246</drugbank-id>
      <name>Ziprasidone</name>
      <description>The therapeutic efficacy of Insulin pork can be decreased when used in combination with Ziprasidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00294</drugbank-id>
      <name>Etonogestrel</name>
      <description>The therapeutic efficacy of Insulin pork can be decreased when used in combination with Etonogestrel.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00304</drugbank-id>
      <name>Desogestrel</name>
      <description>The therapeutic efficacy of Insulin pork can be decreased when used in combination with Desogestrel.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00334</drugbank-id>
      <name>Olanzapine</name>
      <description>The therapeutic efficacy of Insulin pork can be decreased when used in combination with Olanzapine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00351</drugbank-id>
      <name>Megestrol acetate</name>
      <description>The therapeutic efficacy of Insulin pork can be decreased when used in combination with Megestrol acetate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00363</drugbank-id>
      <name>Clozapine</name>
      <description>The therapeutic efficacy of Insulin pork can be decreased when used in combination with Clozapine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00367</drugbank-id>
      <name>Levonorgestrel</name>
      <description>The therapeutic efficacy of Insulin pork can be decreased when used in combination with Levonorgestrel.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00396</drugbank-id>
      <name>Progesterone</name>
      <description>The therapeutic efficacy of Insulin pork can be decreased when used in combination with Progesterone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00477</drugbank-id>
      <name>Chlorpromazine</name>
      <description>The therapeutic efficacy of Insulin pork can be decreased when used in combination with Chlorpromazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00502</drugbank-id>
      <name>Haloperidol</name>
      <description>The therapeutic efficacy of Insulin pork can be decreased when used in combination with Haloperidol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00503</drugbank-id>
      <name>Ritonavir</name>
      <description>The therapeutic efficacy of Insulin pork can be decreased when used in combination with Ritonavir.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00592</drugbank-id>
      <name>Piperazine</name>
      <description>The therapeutic efficacy of Insulin pork can be decreased when used in combination with Piperazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00603</drugbank-id>
      <name>Medroxyprogesterone acetate</name>
      <description>The therapeutic efficacy of Insulin pork can be decreased when used in combination with Medroxyprogesterone acetate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00627</drugbank-id>
      <name>Niacin</name>
      <description>The therapeutic efficacy of Insulin pork can be decreased when used in combination with Niacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00668</drugbank-id>
      <name>Epinephrine</name>
      <description>The therapeutic efficacy of Insulin pork can be decreased when used in combination with Epinephrine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00717</drugbank-id>
      <name>Norethisterone</name>
      <description>The therapeutic efficacy of Insulin pork can be decreased when used in combination with Norethisterone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00734</drugbank-id>
      <name>Risperidone</name>
      <description>The therapeutic efficacy of Insulin pork can be decreased when used in combination with Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00738</drugbank-id>
      <name>Pentamidine</name>
      <description>The therapeutic efficacy of Insulin pork can be decreased when used in combination with Pentamidine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00823</drugbank-id>
      <name>Ethynodiol diacetate</name>
      <description>The therapeutic efficacy of Insulin pork can be decreased when used in combination with Ethynodiol diacetate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00852</drugbank-id>
      <name>Pseudoephedrine</name>
      <description>The therapeutic efficacy of Insulin pork can be decreased when used in combination with Pseudoephedrine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00864</drugbank-id>
      <name>Tacrolimus</name>
      <description>The therapeutic efficacy of Insulin pork can be decreased when used in combination with Tacrolimus.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00877</drugbank-id>
      <name>Sirolimus</name>
      <description>The therapeutic efficacy of Insulin pork can be decreased when used in combination with Sirolimus.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00903</drugbank-id>
      <name>Etacrynic acid</name>
      <description>The therapeutic efficacy of Insulin pork can be decreased when used in combination with Etacrynic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00932</drugbank-id>
      <name>Tipranavir</name>
      <description>The therapeutic efficacy of Insulin pork can be decreased when used in combination with Tipranavir.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00957</drugbank-id>
      <name>Norgestimate</name>
      <description>The therapeutic efficacy of Insulin pork can be decreased when used in combination with Norgestimate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00977</drugbank-id>
      <name>Ethinylestradiol</name>
      <description>The therapeutic efficacy of Insulin pork can be decreased when used in combination with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01072</drugbank-id>
      <name>Atazanavir</name>
      <description>The therapeutic efficacy of Insulin pork can be decreased when used in combination with Atazanavir.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01169</drugbank-id>
      <name>Arsenic trioxide</name>
      <description>The therapeutic efficacy of Insulin pork can be decreased when used in combination with Arsenic trioxide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01224</drugbank-id>
      <name>Quetiapine</name>
      <description>The therapeutic efficacy of Insulin pork can be decreased when used in combination with Quetiapine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01232</drugbank-id>
      <name>Saquinavir</name>
      <description>The therapeutic efficacy of Insulin pork can be decreased when used in combination with Saquinavir.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01238</drugbank-id>
      <name>Aripiprazole</name>
      <description>The therapeutic efficacy of Insulin pork can be decreased when used in combination with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01267</drugbank-id>
      <name>Paliperidone</name>
      <description>The therapeutic efficacy of Insulin pork can be decreased when used in combination with Paliperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01319</drugbank-id>
      <name>Fosamprenavir</name>
      <description>The therapeutic efficacy of Insulin pork can be decreased when used in combination with Fosamprenavir.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01323</drugbank-id>
      <name>St. John's Wort</name>
      <description>The therapeutic efficacy of Insulin pork can be decreased when used in combination with St. John's Wort.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01357</drugbank-id>
      <name>Mestranol</name>
      <description>The therapeutic efficacy of Insulin pork can be decreased when used in combination with Mestranol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01363</drugbank-id>
      <name>Ephedra sinica root</name>
      <description>The therapeutic efficacy of Insulin pork can be decreased when used in combination with Ephedra sinica root.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01395</drugbank-id>
      <name>Drospirenone</name>
      <description>The therapeutic efficacy of Insulin pork can be decreased when used in combination with Drospirenone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01403</drugbank-id>
      <name>Methotrimeprazine</name>
      <description>The therapeutic efficacy of Insulin pork can be decreased when used in combination with Methotrimeprazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01406</drugbank-id>
      <name>Danazol</name>
      <description>The therapeutic efficacy of Insulin pork can be decreased when used in combination with Danazol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01590</drugbank-id>
      <name>Everolimus</name>
      <description>The therapeutic efficacy of Insulin pork can be decreased when used in combination with Everolimus.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01601</drugbank-id>
      <name>Lopinavir</name>
      <description>The therapeutic efficacy of Insulin pork can be decreased when used in combination with Lopinavir.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01621</drugbank-id>
      <name>Pipotiazine</name>
      <description>The therapeutic efficacy of Insulin pork can be decreased when used in combination with Pipotiazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02546</drugbank-id>
      <name>Vorinostat</name>
      <description>The therapeutic efficacy of Insulin pork can be decreased when used in combination with Vorinostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04574</drugbank-id>
      <name>Estrone sulfate</name>
      <description>The therapeutic efficacy of Insulin pork can be decreased when used in combination with Estrone sulfate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04839</drugbank-id>
      <name>Cyproterone acetate</name>
      <description>The therapeutic efficacy of Insulin pork can be decreased when used in combination with Cyproterone acetate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04868</drugbank-id>
      <name>Nilotinib</name>
      <description>The therapeutic efficacy of Insulin pork can be decreased when used in combination with Nilotinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04946</drugbank-id>
      <name>Iloperidone</name>
      <description>The therapeutic efficacy of Insulin pork can be decreased when used in combination with Iloperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06216</drugbank-id>
      <name>Asenapine</name>
      <description>The therapeutic efficacy of Insulin pork can be decreased when used in combination with Asenapine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06287</drugbank-id>
      <name>Temsirolimus</name>
      <description>The therapeutic efficacy of Insulin pork can be decreased when used in combination with Temsirolimus.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06663</drugbank-id>
      <name>Pasireotide</name>
      <description>The therapeutic efficacy of Insulin pork can be decreased when used in combination with Pasireotide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06719</drugbank-id>
      <name>Buserelin</name>
      <description>The therapeutic efficacy of Insulin pork can be decreased when used in combination with Buserelin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06788</drugbank-id>
      <name>Histrelin</name>
      <description>The therapeutic efficacy of Insulin pork can be decreased when used in combination with Histrelin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06789</drugbank-id>
      <name>Hydroxyprogesterone caproate</name>
      <description>The therapeutic efficacy of Insulin pork can be decreased when used in combination with Hydroxyprogesterone caproate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06791</drugbank-id>
      <name>Lanreotide</name>
      <description>The therapeutic efficacy of Insulin pork can be decreased when used in combination with Lanreotide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06825</drugbank-id>
      <name>Triptorelin</name>
      <description>The therapeutic efficacy of Insulin pork can be decreased when used in combination with Triptorelin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08815</drugbank-id>
      <name>Lurasidone</name>
      <description>The therapeutic efficacy of Insulin pork can be decreased when used in combination with Lurasidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08912</drugbank-id>
      <name>Dabrafenib</name>
      <description>The therapeutic efficacy of Insulin pork can be decreased when used in combination with Dabrafenib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09009</drugbank-id>
      <name>Articaine</name>
      <description>The therapeutic efficacy of Insulin pork can be decreased when used in combination with Articaine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09063</drugbank-id>
      <name>Ceritinib</name>
      <description>The therapeutic efficacy of Insulin pork can be decreased when used in combination with Ceritinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09123</drugbank-id>
      <name>Dienogest</name>
      <description>The therapeutic efficacy of Insulin pork can be decreased when used in combination with Dienogest.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09128</drugbank-id>
      <name>Brexpiprazole</name>
      <description>The therapeutic efficacy of Insulin pork can be decreased when used in combination with Brexpiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06343</drugbank-id>
      <name>Teprotumumab</name>
      <description>The therapeutic efficacy of Insulin pork can be decreased when used in combination with Teprotumumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00621</drugbank-id>
      <name>Oxandrolone</name>
      <description>Oxandrolone may increase the hypoglycemic activities of Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00624</drugbank-id>
      <name>Testosterone</name>
      <description>Testosterone may increase the hypoglycemic activities of Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00984</drugbank-id>
      <name>Nandrolone phenpropionate</name>
      <description>Nandrolone phenpropionate may increase the hypoglycemic activities of Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01185</drugbank-id>
      <name>Fluoxymesterone</name>
      <description>Fluoxymesterone may increase the hypoglycemic activities of Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01420</drugbank-id>
      <name>Testosterone propionate</name>
      <description>Testosterone propionate may increase the hypoglycemic activities of Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06412</drugbank-id>
      <name>Oxymetholone</name>
      <description>Oxymetholone may increase the hypoglycemic activities of Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06710</drugbank-id>
      <name>Methyltestosterone</name>
      <description>Methyltestosterone may increase the hypoglycemic activities of Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06718</drugbank-id>
      <name>Stanozolol</name>
      <description>Stanozolol may increase the hypoglycemic activities of Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08804</drugbank-id>
      <name>Nandrolone decanoate</name>
      <description>Nandrolone decanoate may increase the hypoglycemic activities of Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12461</drugbank-id>
      <name>GLPG-0492</name>
      <description>GLPG-0492 may increase the hypoglycemic activities of Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13169</drugbank-id>
      <name>Nandrolone</name>
      <description>Nandrolone may increase the hypoglycemic activities of Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13587</drugbank-id>
      <name>Mesterolone</name>
      <description>Mesterolone may increase the hypoglycemic activities of Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13943</drugbank-id>
      <name>Testosterone cypionate</name>
      <description>Testosterone cypionate may increase the hypoglycemic activities of Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13944</drugbank-id>
      <name>Testosterone enanthate</name>
      <description>Testosterone enanthate may increase the hypoglycemic activities of Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00215</drugbank-id>
      <name>Citalopram</name>
      <description>The risk or severity of hypoglycemia can be increased when Citalopram is combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00230</drugbank-id>
      <name>Pregabalin</name>
      <description>The risk or severity of hypoglycemia can be increased when Pregabalin is combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00285</drugbank-id>
      <name>Venlafaxine</name>
      <description>The risk or severity of hypoglycemia can be increased when Venlafaxine is combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00328</drugbank-id>
      <name>Indomethacin</name>
      <description>The risk or severity of hypoglycemia can be increased when Indomethacin is combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01104</drugbank-id>
      <name>Sertraline</name>
      <description>The risk or severity of hypoglycemia can be increased when Sertraline is combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01149</drugbank-id>
      <name>Nefazodone</name>
      <description>The risk or severity of hypoglycemia can be increased when Nefazodone is combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01175</drugbank-id>
      <name>Escitalopram</name>
      <description>The risk or severity of hypoglycemia can be increased when Escitalopram is combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04832</drugbank-id>
      <name>Zimelidine</name>
      <description>The risk or severity of hypoglycemia can be increased when Zimelidine is combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04884</drugbank-id>
      <name>Dapoxetine</name>
      <description>The risk or severity of hypoglycemia can be increased when Dapoxetine is combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04896</drugbank-id>
      <name>Milnacipran</name>
      <description>The risk or severity of hypoglycemia can be increased when Milnacipran is combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06700</drugbank-id>
      <name>Desvenlafaxine</name>
      <description>The risk or severity of hypoglycemia can be increased when Desvenlafaxine is combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08918</drugbank-id>
      <name>Levomilnacipran</name>
      <description>The risk or severity of hypoglycemia can be increased when Levomilnacipran is combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08953</drugbank-id>
      <name>Indalpine</name>
      <description>The risk or severity of hypoglycemia can be increased when Indalpine is combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09270</drugbank-id>
      <name>Ubidecarenone</name>
      <description>The risk or severity of hypoglycemia can be increased when Ubidecarenone is combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12693</drugbank-id>
      <name>Ritanserin</name>
      <description>The risk or severity of hypoglycemia can be increased when Ritanserin is combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13233</drugbank-id>
      <name>Alaproclate</name>
      <description>The risk or severity of hypoglycemia can be increased when Alaproclate is combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13358</drugbank-id>
      <name>Cibenzoline</name>
      <description>The risk or severity of hypoglycemia can be increased when Cibenzoline is combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14025</drugbank-id>
      <name>Clinafloxacin</name>
      <description>The risk or severity of hypoglycemia can be increased when Clinafloxacin is combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00233</drugbank-id>
      <name>Aminosalicylic acid</name>
      <description>Aminosalicylic acid may increase the hypoglycemic activities of Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00244</drugbank-id>
      <name>Mesalazine</name>
      <description>Mesalazine may increase the hypoglycemic activities of Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00795</drugbank-id>
      <name>Sulfasalazine</name>
      <description>Sulfasalazine may increase the hypoglycemic activities of Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00861</drugbank-id>
      <name>Diflunisal</name>
      <description>Diflunisal may increase the hypoglycemic activities of Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00936</drugbank-id>
      <name>Salicylic acid</name>
      <description>Salicylic acid may increase the hypoglycemic activities of Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01014</drugbank-id>
      <name>Balsalazide</name>
      <description>Balsalazide may increase the hypoglycemic activities of Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01250</drugbank-id>
      <name>Olsalazine</name>
      <description>Olsalazine may increase the hypoglycemic activities of Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01294</drugbank-id>
      <name>Bismuth subsalicylate</name>
      <description>Bismuth subsalicylate may increase the hypoglycemic activities of Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06251</drugbank-id>
      <name>Dersalazine</name>
      <description>Dersalazine may increase the hypoglycemic activities of Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06807</drugbank-id>
      <name>Phenyl aminosalicylate</name>
      <description>Phenyl aminosalicylate may increase the hypoglycemic activities of Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09543</drugbank-id>
      <name>Methyl salicylate</name>
      <description>Methyl salicylate may increase the hypoglycemic activities of Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11079</drugbank-id>
      <name>Trolamine salicylate</name>
      <description>Trolamine salicylate may increase the hypoglycemic activities of Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12445</drugbank-id>
      <name>Nitroaspirin</name>
      <description>Nitroaspirin may increase the hypoglycemic activities of Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13509</drugbank-id>
      <name>Aloxiprin</name>
      <description>Aloxiprin may increase the hypoglycemic activities of Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13538</drugbank-id>
      <name>Guacetisal</name>
      <description>Guacetisal may increase the hypoglycemic activities of Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13612</drugbank-id>
      <name>Carbaspirin calcium</name>
      <description>Carbaspirin calcium may increase the hypoglycemic activities of Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14006</drugbank-id>
      <name>Choline salicylate</name>
      <description>Choline salicylate may increase the hypoglycemic activities of Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14026</drugbank-id>
      <name>Thiosalicylic acid</name>
      <description>Thiosalicylic acid may increase the hypoglycemic activities of Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01261</drugbank-id>
      <name>Sitagliptin</name>
      <description>Sitagliptin may increase the hypoglycemic activities of Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04876</drugbank-id>
      <name>Vildagliptin</name>
      <description>Vildagliptin may increase the hypoglycemic activities of Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06011</drugbank-id>
      <name>AMG-222</name>
      <description>AMG-222 may increase the hypoglycemic activities of Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06127</drugbank-id>
      <name>Bisegliptin</name>
      <description>Bisegliptin may increase the hypoglycemic activities of Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06203</drugbank-id>
      <name>Alogliptin</name>
      <description>Alogliptin may increase the hypoglycemic activities of Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06335</drugbank-id>
      <name>Saxagliptin</name>
      <description>Saxagliptin may increase the hypoglycemic activities of Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08382</drugbank-id>
      <name>Gosogliptin</name>
      <description>Gosogliptin may increase the hypoglycemic activities of Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08882</drugbank-id>
      <name>Linagliptin</name>
      <description>Linagliptin may increase the hypoglycemic activities of Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11723</drugbank-id>
      <name>Dutogliptin</name>
      <description>Dutogliptin may increase the hypoglycemic activities of Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11950</drugbank-id>
      <name>Teneligliptin</name>
      <description>Teneligliptin may increase the hypoglycemic activities of Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11992</drugbank-id>
      <name>Omarigliptin</name>
      <description>Omarigliptin may increase the hypoglycemic activities of Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12268</drugbank-id>
      <name>Carmegliptin</name>
      <description>Carmegliptin may increase the hypoglycemic activities of Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12412</drugbank-id>
      <name>Gemigliptin</name>
      <description>Gemigliptin may increase the hypoglycemic activities of Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12417</drugbank-id>
      <name>Anagliptin</name>
      <description>Anagliptin may increase the hypoglycemic activities of Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12625</drugbank-id>
      <name>Evogliptin</name>
      <description>Evogliptin may increase the hypoglycemic activities of Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01276</drugbank-id>
      <name>Exenatide</name>
      <description>Exenatide may increase the hypoglycemic activities of Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09043</drugbank-id>
      <name>Albiglutide</name>
      <description>Albiglutide may increase the hypoglycemic activities of Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09045</drugbank-id>
      <name>Dulaglutide</name>
      <description>Dulaglutide may increase the hypoglycemic activities of Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09265</drugbank-id>
      <name>Lixisenatide</name>
      <description>Lixisenatide may increase the hypoglycemic activities of Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13928</drugbank-id>
      <name>Semaglutide</name>
      <description>Semaglutide may increase the hypoglycemic activities of Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14027</drugbank-id>
      <name>Taspoglutide</name>
      <description>Taspoglutide may increase the hypoglycemic activities of Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00752</drugbank-id>
      <name>Tranylcypromine</name>
      <description>Tranylcypromine may increase the hypoglycemic activities of Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00780</drugbank-id>
      <name>Phenelzine</name>
      <description>Phenelzine may increase the hypoglycemic activities of Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01171</drugbank-id>
      <name>Moclobemide</name>
      <description>Moclobemide may increase the hypoglycemic activities of Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01247</drugbank-id>
      <name>Isocarboxazid</name>
      <description>Isocarboxazid may increase the hypoglycemic activities of Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01626</drugbank-id>
      <name>Pargyline</name>
      <description>Pargyline may increase the hypoglycemic activities of Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00805</drugbank-id>
      <name>Minaprine</name>
      <description>Minaprine may increase the hypoglycemic activities of Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04818</drugbank-id>
      <name>Iproniazid</name>
      <description>Iproniazid may increase the hypoglycemic activities of Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04820</drugbank-id>
      <name>Nialamide</name>
      <description>Nialamide may increase the hypoglycemic activities of Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09244</drugbank-id>
      <name>Pirlindole</name>
      <description>Pirlindole may increase the hypoglycemic activities of Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09245</drugbank-id>
      <name>Toloxatone</name>
      <description>Toloxatone may increase the hypoglycemic activities of Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09243</drugbank-id>
      <name>Hydracarbazine</name>
      <description>Hydracarbazine may increase the hypoglycemic activities of Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09241</drugbank-id>
      <name>Methylene blue</name>
      <description>Methylene blue may increase the hypoglycemic activities of Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09246</drugbank-id>
      <name>Benmoxin</name>
      <description>Benmoxin may increase the hypoglycemic activities of Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09248</drugbank-id>
      <name>Mebanazine</name>
      <description>Mebanazine may increase the hypoglycemic activities of Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09249</drugbank-id>
      <name>Octamoxin</name>
      <description>Octamoxin may increase the hypoglycemic activities of Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09250</drugbank-id>
      <name>Pheniprazine</name>
      <description>Pheniprazine may increase the hypoglycemic activities of Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09251</drugbank-id>
      <name>Phenoxypropazine</name>
      <description>Phenoxypropazine may increase the hypoglycemic activities of Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09252</drugbank-id>
      <name>Pivhydrazine</name>
      <description>Pivhydrazine may increase the hypoglycemic activities of Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09253</drugbank-id>
      <name>Safrazine</name>
      <description>Safrazine may increase the hypoglycemic activities of Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09254</drugbank-id>
      <name>Caroxazone</name>
      <description>Caroxazone may increase the hypoglycemic activities of Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00614</drugbank-id>
      <name>Furazolidone</name>
      <description>Furazolidone may increase the hypoglycemic activities of Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08550</drugbank-id>
      <name>7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline</name>
      <description>7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypoglycemic activities of Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13875</drugbank-id>
      <name>Harmaline</name>
      <description>Harmaline may increase the hypoglycemic activities of Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13876</drugbank-id>
      <name>Brofaromine</name>
      <description>Brofaromine may increase the hypoglycemic activities of Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00721</drugbank-id>
      <name>Procaine</name>
      <description>Procaine may increase the hypoglycemic activities of Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00182</drugbank-id>
      <name>Amphetamine</name>
      <description>Amphetamine may increase the hypoglycemic activities of Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01168</drugbank-id>
      <name>Procarbazine</name>
      <description>Procarbazine may increase the hypoglycemic activities of Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00601</drugbank-id>
      <name>Linezolid</name>
      <description>Linezolid may increase the hypoglycemic activities of Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06654</drugbank-id>
      <name>Safinamide</name>
      <description>Safinamide may increase the hypoglycemic activities of Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04017</drugbank-id>
      <name>Clorgiline</name>
      <description>Clorgiline may increase the hypoglycemic activities of Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11827</drugbank-id>
      <name>Ertugliflozin</name>
      <description>The therapeutic efficacy of Insulin pork can be increased when used in combination with Ertugliflozin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00214</drugbank-id>
      <name>Torasemide</name>
      <description>The therapeutic efficacy of Insulin pork can be increased when used in combination with Torasemide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00263</drugbank-id>
      <name>Sulfisoxazole</name>
      <description>The therapeutic efficacy of Insulin pork can be increased when used in combination with Sulfisoxazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00311</drugbank-id>
      <name>Ethoxzolamide</name>
      <description>The therapeutic efficacy of Insulin pork can be increased when used in combination with Ethoxzolamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00359</drugbank-id>
      <name>Sulfadiazine</name>
      <description>The therapeutic efficacy of Insulin pork can be increased when used in combination with Sulfadiazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00482</drugbank-id>
      <name>Celecoxib</name>
      <description>The therapeutic efficacy of Insulin pork can be increased when used in combination with Celecoxib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00559</drugbank-id>
      <name>Bosentan</name>
      <description>The therapeutic efficacy of Insulin pork can be increased when used in combination with Bosentan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00576</drugbank-id>
      <name>Sulfamethizole</name>
      <description>The therapeutic efficacy of Insulin pork can be increased when used in combination with Sulfamethizole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00606</drugbank-id>
      <name>Cyclothiazide</name>
      <description>The therapeutic efficacy of Insulin pork can be increased when used in combination with Cyclothiazide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00664</drugbank-id>
      <name>Sulfametopyrazine</name>
      <description>The therapeutic efficacy of Insulin pork can be increased when used in combination with Sulfametopyrazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00669</drugbank-id>
      <name>Sumatriptan</name>
      <description>The therapeutic efficacy of Insulin pork can be increased when used in combination with Sumatriptan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00695</drugbank-id>
      <name>Furosemide</name>
      <description>The therapeutic efficacy of Insulin pork can be increased when used in combination with Furosemide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00706</drugbank-id>
      <name>Tamsulosin</name>
      <description>The therapeutic efficacy of Insulin pork can be increased when used in combination with Tamsulosin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00819</drugbank-id>
      <name>Acetazolamide</name>
      <description>The therapeutic efficacy of Insulin pork can be increased when used in combination with Acetazolamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00887</drugbank-id>
      <name>Bumetanide</name>
      <description>The therapeutic efficacy of Insulin pork can be increased when used in combination with Bumetanide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00891</drugbank-id>
      <name>Sulfapyridine</name>
      <description>The therapeutic efficacy of Insulin pork can be increased when used in combination with Sulfapyridine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00909</drugbank-id>
      <name>Zonisamide</name>
      <description>The therapeutic efficacy of Insulin pork can be increased when used in combination with Zonisamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01015</drugbank-id>
      <name>Sulfamethoxazole</name>
      <description>The therapeutic efficacy of Insulin pork can be increased when used in combination with Sulfamethoxazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01032</drugbank-id>
      <name>Probenecid</name>
      <description>The therapeutic efficacy of Insulin pork can be increased when used in combination with Probenecid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01098</drugbank-id>
      <name>Rosuvastatin</name>
      <description>The therapeutic efficacy of Insulin pork can be increased when used in combination with Rosuvastatin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01119</drugbank-id>
      <name>Diazoxide</name>
      <description>The therapeutic efficacy of Insulin pork can be increased when used in combination with Diazoxide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01144</drugbank-id>
      <name>Diclofenamide</name>
      <description>The therapeutic efficacy of Insulin pork can be increased when used in combination with Diclofenamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01264</drugbank-id>
      <name>Darunavir</name>
      <description>The therapeutic efficacy of Insulin pork can be increased when used in combination with Darunavir.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01298</drugbank-id>
      <name>Sulfacytine</name>
      <description>The therapeutic efficacy of Insulin pork can be increased when used in combination with Sulfacytine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01299</drugbank-id>
      <name>Sulfadoxine</name>
      <description>The therapeutic efficacy of Insulin pork can be increased when used in combination with Sulfadoxine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01382</drugbank-id>
      <name>Glymidine</name>
      <description>The therapeutic efficacy of Insulin pork can be increased when used in combination with Glymidine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01581</drugbank-id>
      <name>Sulfamerazine</name>
      <description>The therapeutic efficacy of Insulin pork can be increased when used in combination with Sulfamerazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01582</drugbank-id>
      <name>Sulfamethazine</name>
      <description>The therapeutic efficacy of Insulin pork can be increased when used in combination with Sulfamethazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02925</drugbank-id>
      <name>Piretanide</name>
      <description>The therapeutic efficacy of Insulin pork can be increased when used in combination with Piretanide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04707</drugbank-id>
      <name>Hydroxyfasudil</name>
      <description>The therapeutic efficacy of Insulin pork can be increased when used in combination with Hydroxyfasudil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06150</drugbank-id>
      <name>Sulfadimethoxine</name>
      <description>The therapeutic efficacy of Insulin pork can be increased when used in combination with Sulfadimethoxine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06290</drugbank-id>
      <name>Simeprevir</name>
      <description>The therapeutic efficacy of Insulin pork can be increased when used in combination with Simeprevir.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06729</drugbank-id>
      <name>Sulfaphenazole</name>
      <description>The therapeutic efficacy of Insulin pork can be increased when used in combination with Sulfaphenazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06821</drugbank-id>
      <name>Sulfameter</name>
      <description>The therapeutic efficacy of Insulin pork can be increased when used in combination with Sulfameter.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB07996</drugbank-id>
      <name>5-(2-methylpiperazine-1-sulfonyl)isoquinoline</name>
      <description>The therapeutic efficacy of Insulin pork can be increased when used in combination with 5-(2-methylpiperazine-1-sulfonyl)isoquinoline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08162</drugbank-id>
      <name>Fasudil</name>
      <description>The therapeutic efficacy of Insulin pork can be increased when used in combination with Fasudil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08798</drugbank-id>
      <name>Sulfamoxole</name>
      <description>The therapeutic efficacy of Insulin pork can be increased when used in combination with Sulfamoxole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08881</drugbank-id>
      <name>Vemurafenib</name>
      <description>The therapeutic efficacy of Insulin pork can be increased when used in combination with Vemurafenib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08961</drugbank-id>
      <name>Azosemide</name>
      <description>The therapeutic efficacy of Insulin pork can be increased when used in combination with Azosemide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11389</drugbank-id>
      <name>Clorsulon</name>
      <description>The therapeutic efficacy of Insulin pork can be increased when used in combination with Clorsulon.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11461</drugbank-id>
      <name>Sulfachlorpyridazine</name>
      <description>The therapeutic efficacy of Insulin pork can be increased when used in combination with Sulfachlorpyridazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11462</drugbank-id>
      <name>Sulfaethoxypyridazine</name>
      <description>The therapeutic efficacy of Insulin pork can be increased when used in combination with Sulfaethoxypyridazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11463</drugbank-id>
      <name>Sulfanitran</name>
      <description>The therapeutic efficacy of Insulin pork can be increased when used in combination with Sulfanitran.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11464</drugbank-id>
      <name>Sulfaquinoxaline</name>
      <description>The therapeutic efficacy of Insulin pork can be increased when used in combination with Sulfaquinoxaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12051</drugbank-id>
      <name>Setrobuvir</name>
      <description>The therapeutic efficacy of Insulin pork can be increased when used in combination with Setrobuvir.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12921</drugbank-id>
      <name>Chlorsulfaquinoxaline</name>
      <description>The therapeutic efficacy of Insulin pork can be increased when used in combination with Chlorsulfaquinoxaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13214</drugbank-id>
      <name>Sulfadicramide</name>
      <description>The therapeutic efficacy of Insulin pork can be increased when used in combination with Sulfadicramide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13248</drugbank-id>
      <name>Phthalylsulfathiazole</name>
      <description>The therapeutic efficacy of Insulin pork can be increased when used in combination with Phthalylsulfathiazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13283</drugbank-id>
      <name>Sulfaisodimidine</name>
      <description>The therapeutic efficacy of Insulin pork can be increased when used in combination with Sulfaisodimidine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13284</drugbank-id>
      <name>Meticrane</name>
      <description>The therapeutic efficacy of Insulin pork can be increased when used in combination with Meticrane.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13320</drugbank-id>
      <name>Sulfaperin</name>
      <description>The therapeutic efficacy of Insulin pork can be increased when used in combination with Sulfaperin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13405</drugbank-id>
      <name>Mefruside</name>
      <description>The therapeutic efficacy of Insulin pork can be increased when used in combination with Mefruside.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13430</drugbank-id>
      <name>Mebutizide</name>
      <description>The therapeutic efficacy of Insulin pork can be increased when used in combination with Mebutizide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13485</drugbank-id>
      <name>Sulfametomidine</name>
      <description>The therapeutic efficacy of Insulin pork can be increased when used in combination with Sulfametomidine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13547</drugbank-id>
      <name>Sulfatolamide</name>
      <description>The therapeutic efficacy of Insulin pork can be increased when used in combination with Sulfatolamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13556</drugbank-id>
      <name>Sulfamazone</name>
      <description>The therapeutic efficacy of Insulin pork can be increased when used in combination with Sulfamazone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13580</drugbank-id>
      <name>Succinylsulfathiazole</name>
      <description>The therapeutic efficacy of Insulin pork can be increased when used in combination with Succinylsulfathiazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13617</drugbank-id>
      <name>Clorexolone</name>
      <description>The therapeutic efficacy of Insulin pork can be increased when used in combination with Clorexolone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13663</drugbank-id>
      <name>Clofenamide</name>
      <description>The therapeutic efficacy of Insulin pork can be increased when used in combination with Clofenamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13699</drugbank-id>
      <name>Sulfathiourea</name>
      <description>The therapeutic efficacy of Insulin pork can be increased when used in combination with Sulfathiourea.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13708</drugbank-id>
      <name>Fenquizone</name>
      <description>The therapeutic efficacy of Insulin pork can be increased when used in combination with Fenquizone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13726</drugbank-id>
      <name>Sulfaguanidine</name>
      <description>The therapeutic efficacy of Insulin pork can be increased when used in combination with Sulfaguanidine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13773</drugbank-id>
      <name>Sulfamethoxypyridazine</name>
      <description>The therapeutic efficacy of Insulin pork can be increased when used in combination with Sulfamethoxypyridazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13792</drugbank-id>
      <name>Clopamide</name>
      <description>The therapeutic efficacy of Insulin pork can be increased when used in combination with Clopamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13803</drugbank-id>
      <name>Xipamide</name>
      <description>The therapeutic efficacy of Insulin pork can be increased when used in combination with Xipamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14033</drugbank-id>
      <name>Acetyl sulfisoxazole</name>
      <description>The therapeutic efficacy of Insulin pork can be increased when used in combination with Acetyl sulfisoxazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00703</drugbank-id>
      <name>Methazolamide</name>
      <description>The therapeutic efficacy of Insulin pork can be increased when used in combination with Methazolamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06370</drugbank-id>
      <name>Indisulam</name>
      <description>The therapeutic efficacy of Insulin pork can be increased when used in combination with Indisulam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00176</drugbank-id>
      <name>Fluvoxamine</name>
      <description>The metabolism of Fluvoxamine can be increased when combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00184</drugbank-id>
      <name>Nicotine</name>
      <description>The metabolism of Nicotine can be increased when combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00188</drugbank-id>
      <name>Bortezomib</name>
      <description>The metabolism of Bortezomib can be increased when combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00201</drugbank-id>
      <name>Caffeine</name>
      <description>The metabolism of Caffeine can be increased when combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00262</drugbank-id>
      <name>Carmustine</name>
      <description>The metabolism of Carmustine can be increased when combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00281</drugbank-id>
      <name>Lidocaine</name>
      <description>The metabolism of Lidocaine can be increased when combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00286</drugbank-id>
      <name>Conjugated estrogens</name>
      <description>The metabolism of Conjugated estrogens can be increased when combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00296</drugbank-id>
      <name>Ropivacaine</name>
      <description>The metabolism of Ropivacaine can be increased when combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00315</drugbank-id>
      <name>Zolmitriptan</name>
      <description>The metabolism of Zolmitriptan can be increased when combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00316</drugbank-id>
      <name>Acetaminophen</name>
      <description>The metabolism of Acetaminophen can be increased when combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00356</drugbank-id>
      <name>Chlorzoxazone</name>
      <description>The metabolism of Chlorzoxazone can be increased when combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00370</drugbank-id>
      <name>Mirtazapine</name>
      <description>The metabolism of Mirtazapine can be increased when combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00379</drugbank-id>
      <name>Mexiletine</name>
      <description>The metabolism of Mexiletine can be increased when combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00382</drugbank-id>
      <name>Tacrine</name>
      <description>The metabolism of Tacrine can be increased when combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00384</drugbank-id>
      <name>Triamterene</name>
      <description>The metabolism of Triamterene can be increased when combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00420</drugbank-id>
      <name>Promazine</name>
      <description>The metabolism of Promazine can be increased when combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00425</drugbank-id>
      <name>Zolpidem</name>
      <description>The metabolism of Zolpidem can be increased when combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00442</drugbank-id>
      <name>Entecavir</name>
      <description>The metabolism of Entecavir can be increased when combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00461</drugbank-id>
      <name>Nabumetone</name>
      <description>The metabolism of Nabumetone can be increased when combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00472</drugbank-id>
      <name>Fluoxetine</name>
      <description>The metabolism of Fluoxetine can be increased when combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00476</drugbank-id>
      <name>Duloxetine</name>
      <description>The metabolism of Duloxetine can be increased when combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00499</drugbank-id>
      <name>Flutamide</name>
      <description>The metabolism of Flutamide can be increased when combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00518</drugbank-id>
      <name>Albendazole</name>
      <description>The metabolism of Albendazole can be increased when combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00533</drugbank-id>
      <name>Rofecoxib</name>
      <description>The metabolism of Rofecoxib can be increased when combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00568</drugbank-id>
      <name>Cinnarizine</name>
      <description>The metabolism of Cinnarizine can be increased when combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00586</drugbank-id>
      <name>Diclofenac</name>
      <description>The metabolism of Diclofenac can be increased when combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00619</drugbank-id>
      <name>Imatinib</name>
      <description>The metabolism of Imatinib can be increased when combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00629</drugbank-id>
      <name>Guanabenz</name>
      <description>The metabolism of Guanabenz can be increased when combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00642</drugbank-id>
      <name>Pemetrexed</name>
      <description>The metabolism of Pemetrexed can be increased when combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00661</drugbank-id>
      <name>Verapamil</name>
      <description>The metabolism of Verapamil can be increased when combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00715</drugbank-id>
      <name>Paroxetine</name>
      <description>The metabolism of Paroxetine can be increased when combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00730</drugbank-id>
      <name>Thiabendazole</name>
      <description>The metabolism of Thiabendazole can be increased when combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00740</drugbank-id>
      <name>Riluzole</name>
      <description>The metabolism of Riluzole can be increased when combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00744</drugbank-id>
      <name>Zileuton</name>
      <description>The metabolism of Zileuton can be increased when combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00758</drugbank-id>
      <name>Clopidogrel</name>
      <description>The metabolism of Clopidogrel can be increased when combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00787</drugbank-id>
      <name>Acyclovir</name>
      <description>The metabolism of Acyclovir can be increased when combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00788</drugbank-id>
      <name>Naproxen</name>
      <description>The metabolism of Naproxen can be increased when combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00806</drugbank-id>
      <name>Pentoxifylline</name>
      <description>The metabolism of Pentoxifylline can be increased when combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00831</drugbank-id>
      <name>Trifluoperazine</name>
      <description>The metabolism of Trifluoperazine can be increased when combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00850</drugbank-id>
      <name>Perphenazine</name>
      <description>The metabolism of Perphenazine can be increased when combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00857</drugbank-id>
      <name>Terbinafine</name>
      <description>The metabolism of Terbinafine can be increased when combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00863</drugbank-id>
      <name>Ranitidine</name>
      <description>The metabolism of Ranitidine can be increased when combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00898</drugbank-id>
      <name>Ethanol</name>
      <description>The metabolism of Ethanol can be increased when combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00934</drugbank-id>
      <name>Maprotiline</name>
      <description>The metabolism of Maprotiline can be increased when combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00969</drugbank-id>
      <name>Alosetron</name>
      <description>The metabolism of Alosetron can be increased when combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00980</drugbank-id>
      <name>Ramelteon</name>
      <description>The metabolism of Ramelteon can be increased when combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00993</drugbank-id>
      <name>Azathioprine</name>
      <description>The metabolism of Azathioprine can be increased when combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00998</drugbank-id>
      <name>Frovatriptan</name>
      <description>The metabolism of Frovatriptan can be increased when combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01002</drugbank-id>
      <name>Levobupivacaine</name>
      <description>The metabolism of Levobupivacaine can be increased when combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01012</drugbank-id>
      <name>Cinacalcet</name>
      <description>The metabolism of Cinacalcet can be increased when combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01037</drugbank-id>
      <name>Selegiline</name>
      <description>The metabolism of Selegiline can be increased when combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01056</drugbank-id>
      <name>Tocainide</name>
      <description>The metabolism of Tocainide can be increased when combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01058</drugbank-id>
      <name>Praziquantel</name>
      <description>The metabolism of Praziquantel can be increased when combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01065</drugbank-id>
      <name>Melatonin</name>
      <description>The metabolism of Melatonin can be increased when combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01087</drugbank-id>
      <name>Primaquine</name>
      <description>The metabolism of Primaquine can be increased when combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01094</drugbank-id>
      <name>Hesperetin</name>
      <description>The metabolism of Hesperetin can be increased when combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01097</drugbank-id>
      <name>Leflunomide</name>
      <description>The metabolism of Leflunomide can be increased when combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01166</drugbank-id>
      <name>Cilostazol</name>
      <description>The metabolism of Cilostazol can be increased when combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01184</drugbank-id>
      <name>Domperidone</name>
      <description>The metabolism of Domperidone can be increased when combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01191</drugbank-id>
      <name>Dexfenfluramine</name>
      <description>The metabolism of Dexfenfluramine can be increased when combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01303</drugbank-id>
      <name>Oxtriphylline</name>
      <description>The metabolism of Oxtriphylline can be increased when combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01367</drugbank-id>
      <name>Rasagiline</name>
      <description>The metabolism of Rasagiline can be increased when combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01412</drugbank-id>
      <name>Theobromine</name>
      <description>The metabolism of Theobromine can be increased when combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01424</drugbank-id>
      <name>Aminophenazone</name>
      <description>The metabolism of Aminophenazone can be increased when combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01435</drugbank-id>
      <name>Antipyrine</name>
      <description>The metabolism of Antipyrine can be increased when combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01482</drugbank-id>
      <name>Fenethylline</name>
      <description>The metabolism of Fenethylline can be increased when combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01558</drugbank-id>
      <name>Bromazepam</name>
      <description>The metabolism of Bromazepam can be increased when combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01623</drugbank-id>
      <name>Thiothixene</name>
      <description>The metabolism of Thiothixene can be increased when combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01628</drugbank-id>
      <name>Etoricoxib</name>
      <description>The metabolism of Etoricoxib can be increased when combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01645</drugbank-id>
      <name>Genistein</name>
      <description>The metabolism of Genistein can be increased when combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01667</drugbank-id>
      <name>8-azaguanine</name>
      <description>The metabolism of 8-azaguanine can be increased when combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02134</drugbank-id>
      <name>Xanthine</name>
      <description>The metabolism of Xanthine can be increased when combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02489</drugbank-id>
      <name>9-Methylguanine</name>
      <description>The metabolism of 9-Methylguanine can be increased when combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02568</drugbank-id>
      <name>Peldesine</name>
      <description>The metabolism of Peldesine can be increased when combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02709</drugbank-id>
      <name>Resveratrol</name>
      <description>The metabolism of Resveratrol can be increased when combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB03783</drugbank-id>
      <name>Phenacetin</name>
      <description>The metabolism of Phenacetin can be increased when combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04076</drugbank-id>
      <name>Hypoxanthine</name>
      <description>The metabolism of Hypoxanthine can be increased when combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04356</drugbank-id>
      <name>9-Deazaguanine</name>
      <description>The metabolism of 9-Deazaguanine can be increased when combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04841</drugbank-id>
      <name>Flunarizine</name>
      <description>The metabolism of Flunarizine can be increased when combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04871</drugbank-id>
      <name>Lorcaserin</name>
      <description>The metabolism of Lorcaserin can be increased when combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04948</drugbank-id>
      <name>Lofexidine</name>
      <description>The metabolism of Lofexidine can be increased when combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04951</drugbank-id>
      <name>Pirfenidone</name>
      <description>The metabolism of Pirfenidone can be increased when combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05676</drugbank-id>
      <name>Apremilast</name>
      <description>The metabolism of Apremilast can be increased when combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06148</drugbank-id>
      <name>Mianserin</name>
      <description>The metabolism of Mianserin can be increased when combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06210</drugbank-id>
      <name>Eltrombopag</name>
      <description>The metabolism of Eltrombopag can be increased when combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06235</drugbank-id>
      <name>Vadimezan</name>
      <description>The metabolism of Vadimezan can be increased when combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06479</drugbank-id>
      <name>Propentofylline</name>
      <description>The metabolism of Propentofylline can be increased when combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06589</drugbank-id>
      <name>Pazopanib</name>
      <description>The metabolism of Pazopanib can be increased when combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06594</drugbank-id>
      <name>Agomelatine</name>
      <description>The metabolism of Agomelatine can be increased when combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06770</drugbank-id>
      <name>Benzyl alcohol</name>
      <description>The metabolism of Benzyl alcohol can be increased when combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06774</drugbank-id>
      <name>Capsaicin</name>
      <description>The metabolism of Capsaicin can be increased when combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08496</drugbank-id>
      <name>(R)-warfarin</name>
      <description>The metabolism of (R)-warfarin can be increased when combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08883</drugbank-id>
      <name>Perampanel</name>
      <description>The metabolism of Perampanel can be increased when combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09071</drugbank-id>
      <name>Tasimelteon</name>
      <description>The metabolism of Tasimelteon can be increased when combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09118</drugbank-id>
      <name>Stiripentol</name>
      <description>The metabolism of Stiripentol can be increased when combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09225</drugbank-id>
      <name>Zotepine</name>
      <description>The metabolism of Zotepine can be increased when combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09273</drugbank-id>
      <name>Doxofylline</name>
      <description>The metabolism of Doxofylline can be increased when combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09288</drugbank-id>
      <name>Propacetamol</name>
      <description>The metabolism of Propacetamol can be increased when combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09290</drugbank-id>
      <name>Ramosetron</name>
      <description>The metabolism of Ramosetron can be increased when combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11919</drugbank-id>
      <name>6-O-benzylguanine</name>
      <description>The metabolism of 6-O-benzylguanine can be increased when combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11967</drugbank-id>
      <name>Binimetinib</name>
      <description>The metabolism of Binimetinib can be increased when combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12026</drugbank-id>
      <name>Voxilaprevir</name>
      <description>The metabolism of Voxilaprevir can be increased when combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12245</drugbank-id>
      <name>Triclabendazole</name>
      <description>The metabolism of Triclabendazole can be increased when combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12332</drugbank-id>
      <name>Rucaparib</name>
      <description>The metabolism of Rucaparib can be increased when combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12406</drugbank-id>
      <name>Lisofylline</name>
      <description>The metabolism of Lisofylline can be increased when combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12531</drugbank-id>
      <name>Lobucavir</name>
      <description>The metabolism of Lobucavir can be increased when combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12926</drugbank-id>
      <name>Cafedrine</name>
      <description>The metabolism of Cafedrine can be increased when combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12927</drugbank-id>
      <name>Theodrenaline</name>
      <description>The metabolism of Theodrenaline can be increased when combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12945</drugbank-id>
      <name>Dihydralazine</name>
      <description>The metabolism of Dihydralazine can be increased when combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13203</drugbank-id>
      <name>Bamifylline</name>
      <description>The metabolism of Bamifylline can be increased when combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13449</drugbank-id>
      <name>Proxyphylline</name>
      <description>The metabolism of Proxyphylline can be increased when combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13573</drugbank-id>
      <name>Acefylline</name>
      <description>The metabolism of Acefylline can be increased when combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13592</drugbank-id>
      <name>Etamiphylline</name>
      <description>The metabolism of Etamiphylline can be increased when combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13634</drugbank-id>
      <name>Pentifylline</name>
      <description>The metabolism of Pentifylline can be increased when combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13812</drugbank-id>
      <name>Bufylline</name>
      <description>The metabolism of Bufylline can be increased when combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13952</drugbank-id>
      <name>Estradiol acetate</name>
      <description>The metabolism of Estradiol acetate can be increased when combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13953</drugbank-id>
      <name>Estradiol benzoate</name>
      <description>The metabolism of Estradiol benzoate can be increased when combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13954</drugbank-id>
      <name>Estradiol cypionate</name>
      <description>The metabolism of Estradiol cypionate can be increased when combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13955</drugbank-id>
      <name>Estradiol dienanthate</name>
      <description>The metabolism of Estradiol dienanthate can be increased when combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13956</drugbank-id>
      <name>Estradiol valerate</name>
      <description>The metabolism of Estradiol valerate can be increased when combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14018</drugbank-id>
      <name>Bromotheophylline</name>
      <description>The metabolism of Bromotheophylline can be increased when combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14132</drugbank-id>
      <name>8-chlorotheophylline</name>
      <description>The metabolism of 8-chlorotheophylline can be increased when combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01115</drugbank-id>
      <name>Nifedipine</name>
      <description>The metabolism of Nifedipine can be increased when combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11757</drugbank-id>
      <name>Istradefylline</name>
      <description>The metabolism of Istradefylline can be increased when combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00972</drugbank-id>
      <name>Azelastine</name>
      <description>The metabolism of Azelastine can be increased when combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00625</drugbank-id>
      <name>Efavirenz</name>
      <description>The metabolism of Efavirenz can be increased when combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04889</drugbank-id>
      <name>Bicifadine</name>
      <description>The metabolism of Bicifadine can be increased when combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05708</drugbank-id>
      <name>GTS-21</name>
      <description>The metabolism of GTS-21 can be increased when combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01195</drugbank-id>
      <name>Flecainide</name>
      <description>The metabolism of Flecainide can be increased when combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00783</drugbank-id>
      <name>Estradiol</name>
      <description>The metabolism of Estradiol can be increased when combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00321</drugbank-id>
      <name>Amitriptyline</name>
      <description>The metabolism of Amitriptyline can be increased when combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01142</drugbank-id>
      <name>Doxepin</name>
      <description>The metabolism of Doxepin can be increased when combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00532</drugbank-id>
      <name>Mephenytoin</name>
      <description>The metabolism of Mephenytoin can be increased when combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00924</drugbank-id>
      <name>Cyclobenzaprine</name>
      <description>The metabolism of Cyclobenzaprine can be increased when combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11689</drugbank-id>
      <name>Selumetinib</name>
      <description>The metabolism of Selumetinib can be increased when combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00655</drugbank-id>
      <name>Estrone</name>
      <description>The metabolism of Estrone can be increased when combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00299</drugbank-id>
      <name>Penciclovir</name>
      <description>The metabolism of Penciclovir can be increased when combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00261</drugbank-id>
      <name>Anagrelide</name>
      <description>The metabolism of Anagrelide can be increased when combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00277</drugbank-id>
      <name>Theophylline</name>
      <description>The metabolism of Theophylline can be increased when combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00398</drugbank-id>
      <name>Sorafenib</name>
      <description>The metabolism of Sorafenib can be increased when combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00530</drugbank-id>
      <name>Erlotinib</name>
      <description>The metabolism of Erlotinib can be increased when combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00544</drugbank-id>
      <name>Fluorouracil</name>
      <description>The metabolism of Fluorouracil can be increased when combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00682</drugbank-id>
      <name>Warfarin</name>
      <description>The metabolism of Warfarin can be increased when combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00697</drugbank-id>
      <name>Tizanidine</name>
      <description>The metabolism of Tizanidine can be increased when combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00773</drugbank-id>
      <name>Etoposide</name>
      <description>The metabolism of Etoposide can be increased when combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00851</drugbank-id>
      <name>Dacarbazine</name>
      <description>The metabolism of Dacarbazine can be increased when combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01100</drugbank-id>
      <name>Pimozide</name>
      <description>The metabolism of Pimozide can be increased when combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01223</drugbank-id>
      <name>Aminophylline</name>
      <description>The metabolism of Aminophylline can be increased when combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01254</drugbank-id>
      <name>Dasatinib</name>
      <description>The metabolism of Dasatinib can be increased when combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01418</drugbank-id>
      <name>Acenocoumarol</name>
      <description>The metabolism of Acenocoumarol can be increased when combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06626</drugbank-id>
      <name>Axitinib</name>
      <description>The metabolism of Axitinib can be increased when combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06769</drugbank-id>
      <name>Bendamustine</name>
      <description>The metabolism of Bendamustine can be increased when combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08910</drugbank-id>
      <name>Pomalidomide</name>
      <description>The metabolism of Pomalidomide can be increased when combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09256</drugbank-id>
      <name>Tegafur</name>
      <description>The metabolism of Tegafur can be increased when combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13874</drugbank-id>
      <name>Enasidenib</name>
      <description>The metabolism of Enasidenib can be increased when combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00675</drugbank-id>
      <name>Tamoxifen</name>
      <description>The metabolism of Tamoxifen can be increased when combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00458</drugbank-id>
      <name>Imipramine</name>
      <description>The metabolism of Imipramine can be increased when combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00575</drugbank-id>
      <name>Clonidine</name>
      <description>The metabolism of Clonidine can be increased when combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01242</drugbank-id>
      <name>Clomipramine</name>
      <description>The metabolism of Clomipramine can be increased when combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00030</drugbank-id>
      <name>Insulin human</name>
      <description>The risk or severity of hypoglycemia can be increased when Insulin human is combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00046</drugbank-id>
      <name>Insulin lispro</name>
      <description>The risk or severity of hypoglycemia can be increased when Insulin lispro is combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00047</drugbank-id>
      <name>Insulin glargine</name>
      <description>The risk or severity of hypoglycemia can be increased when Insulin glargine is combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00197</drugbank-id>
      <name>Troglitazone</name>
      <description>The risk or severity of hypoglycemia can be increased when Insulin pork is combined with Troglitazone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00222</drugbank-id>
      <name>Glimepiride</name>
      <description>The risk or severity of hypoglycemia can be increased when Insulin pork is combined with Glimepiride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00280</drugbank-id>
      <name>Disopyramide</name>
      <description>The risk or severity of hypoglycemia can be increased when Insulin pork is combined with Disopyramide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00284</drugbank-id>
      <name>Acarbose</name>
      <description>The risk or severity of hypoglycemia can be increased when Insulin pork is combined with Acarbose.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00414</drugbank-id>
      <name>Acetohexamide</name>
      <description>The risk or severity of hypoglycemia can be increased when Insulin pork is combined with Acetohexamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00468</drugbank-id>
      <name>Quinine</name>
      <description>The risk or severity of hypoglycemia can be increased when Insulin pork is combined with Quinine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00491</drugbank-id>
      <name>Miglitol</name>
      <description>The risk or severity of hypoglycemia can be increased when Insulin pork is combined with Miglitol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00672</drugbank-id>
      <name>Chlorpropamide</name>
      <description>The risk or severity of hypoglycemia can be increased when Insulin pork is combined with Chlorpropamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00731</drugbank-id>
      <name>Nateglinide</name>
      <description>The risk or severity of hypoglycemia can be increased when Insulin pork is combined with Nateglinide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00834</drugbank-id>
      <name>Mifepristone</name>
      <description>The risk or severity of hypoglycemia can be increased when Insulin pork is combined with Mifepristone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00839</drugbank-id>
      <name>Tolazamide</name>
      <description>The risk or severity of hypoglycemia can be increased when Insulin pork is combined with Tolazamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00912</drugbank-id>
      <name>Repaglinide</name>
      <description>The risk or severity of hypoglycemia can be increased when Insulin pork is combined with Repaglinide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00914</drugbank-id>
      <name>Phenformin</name>
      <description>The risk or severity of hypoglycemia can be increased when Insulin pork is combined with Phenformin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01016</drugbank-id>
      <name>Glyburide</name>
      <description>The risk or severity of hypoglycemia can be increased when Insulin pork is combined with Glyburide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01067</drugbank-id>
      <name>Glipizide</name>
      <description>The risk or severity of hypoglycemia can be increased when Insulin pork is combined with Glipizide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01120</drugbank-id>
      <name>Gliclazide</name>
      <description>The risk or severity of hypoglycemia can be increased when Insulin pork is combined with Gliclazide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01124</drugbank-id>
      <name>Tolbutamide</name>
      <description>The risk or severity of hypoglycemia can be increased when Insulin pork is combined with Tolbutamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01200</drugbank-id>
      <name>Bromocriptine</name>
      <description>The risk or severity of hypoglycemia can be increased when Insulin pork is combined with Bromocriptine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01251</drugbank-id>
      <name>Gliquidone</name>
      <description>The risk or severity of hypoglycemia can be increased when Insulin pork is combined with Gliquidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01252</drugbank-id>
      <name>Mitiglinide</name>
      <description>The risk or severity of hypoglycemia can be increased when Insulin pork is combined with Mitiglinide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01268</drugbank-id>
      <name>Sunitinib</name>
      <description>The risk or severity of hypoglycemia can be increased when Insulin pork is combined with Sunitinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01277</drugbank-id>
      <name>Mecasermin</name>
      <description>The risk or severity of hypoglycemia can be increased when Insulin pork is combined with Mecasermin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01289</drugbank-id>
      <name>Glisoxepide</name>
      <description>The risk or severity of hypoglycemia can be increased when Insulin pork is combined with Glisoxepide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01306</drugbank-id>
      <name>Insulin aspart</name>
      <description>The risk or severity of hypoglycemia can be increased when Insulin pork is combined with Insulin aspart.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01307</drugbank-id>
      <name>Insulin detemir</name>
      <description>The risk or severity of hypoglycemia can be increased when Insulin pork is combined with Insulin detemir.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01309</drugbank-id>
      <name>Insulin glulisine</name>
      <description>The risk or severity of hypoglycemia can be increased when Insulin pork is combined with Insulin glulisine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01700</drugbank-id>
      <name>AICA ribonucleotide</name>
      <description>The risk or severity of hypoglycemia can be increased when Insulin pork is combined with AICA ribonucleotide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04830</drugbank-id>
      <name>Buformin</name>
      <description>The risk or severity of hypoglycemia can be increased when Insulin pork is combined with Buformin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04878</drugbank-id>
      <name>Voglibose</name>
      <description>The risk or severity of hypoglycemia can be increased when Insulin pork is combined with Voglibose.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05115</drugbank-id>
      <name>NN344</name>
      <description>The risk or severity of hypoglycemia can be increased when Insulin pork is combined with NN344.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05819</drugbank-id>
      <name>NBI-6024</name>
      <description>The risk or severity of hypoglycemia can be increased when Insulin pork is combined with NBI-6024.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08962</drugbank-id>
      <name>Glibornuride</name>
      <description>The risk or severity of hypoglycemia can be increased when Insulin pork is combined with Glibornuride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09022</drugbank-id>
      <name>Benfluorex</name>
      <description>The risk or severity of hypoglycemia can be increased when Insulin pork is combined with Benfluorex.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09198</drugbank-id>
      <name>Lobeglitazone</name>
      <description>The risk or severity of hypoglycemia can be increased when Insulin pork is combined with Lobeglitazone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09199</drugbank-id>
      <name>Netoglitazone</name>
      <description>The risk or severity of hypoglycemia can be increased when Insulin pork is combined with Netoglitazone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09200</drugbank-id>
      <name>Rivoglitazone</name>
      <description>The risk or severity of hypoglycemia can be increased when Insulin pork is combined with Rivoglitazone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09201</drugbank-id>
      <name>Ciglitazone</name>
      <description>The risk or severity of hypoglycemia can be increased when Insulin pork is combined with Ciglitazone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09456</drugbank-id>
      <name>Insulin beef</name>
      <description>The risk or severity of hypoglycemia can be increased when Insulin pork is combined with Insulin beef.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09564</drugbank-id>
      <name>Insulin degludec</name>
      <description>The risk or severity of hypoglycemia can be increased when Insulin pork is combined with Insulin degludec.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11567</drugbank-id>
      <name>Insulin peglispro</name>
      <description>The risk or severity of hypoglycemia can be increased when Insulin pork is combined with Insulin peglispro.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11568</drugbank-id>
      <name>Insulin tregopil</name>
      <description>The risk or severity of hypoglycemia can be increased when Insulin pork is combined with Insulin tregopil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11698</drugbank-id>
      <name>Ipragliflozin</name>
      <description>The risk or severity of hypoglycemia can be increased when Insulin pork is combined with Ipragliflozin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11780</drugbank-id>
      <name>Allicin</name>
      <description>The risk or severity of hypoglycemia can be increased when Insulin pork is combined with Allicin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11824</drugbank-id>
      <name>Tofogliflozin</name>
      <description>The risk or severity of hypoglycemia can be increased when Insulin pork is combined with Tofogliflozin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11898</drugbank-id>
      <name>2,4-thiazolidinedione</name>
      <description>The risk or severity of hypoglycemia can be increased when Insulin pork is combined with 2,4-thiazolidinedione.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12713</drugbank-id>
      <name>Sotagliflozin</name>
      <description>The risk or severity of hypoglycemia can be increased when Insulin pork is combined with Sotagliflozin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12781</drugbank-id>
      <name>Balaglitazone</name>
      <description>The risk or severity of hypoglycemia can be increased when Insulin pork is combined with Balaglitazone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12935</drugbank-id>
      <name>Remogliflozin etabonate</name>
      <description>The risk or severity of hypoglycemia can be increased when Insulin pork is combined with Remogliflozin etabonate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13406</drugbank-id>
      <name>Carbutamide</name>
      <description>The risk or severity of hypoglycemia can be increased when Insulin pork is combined with Carbutamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13446</drugbank-id>
      <name>Guar gum</name>
      <description>The risk or severity of hypoglycemia can be increased when Insulin pork is combined with Guar gum.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13675</drugbank-id>
      <name>Metahexamide</name>
      <description>The risk or severity of hypoglycemia can be increased when Insulin pork is combined with Metahexamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14035</drugbank-id>
      <name>Englitazone</name>
      <description>The risk or severity of hypoglycemia can be increased when Insulin pork is combined with Englitazone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15171</drugbank-id>
      <name>Tirzepatide</name>
      <description>The risk or severity of hypoglycemia can be increased when Insulin pork is combined with Tirzepatide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15217</drugbank-id>
      <name>Gastric inhibitory polypeptide</name>
      <description>The risk or severity of hypoglycemia can be increased when Insulin pork is combined with Gastric inhibitory polypeptide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09038</drugbank-id>
      <name>Empagliflozin</name>
      <description>The risk or severity of hypoglycemia can be increased when Insulin pork is combined with Empagliflozin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00270</drugbank-id>
      <name>Isradipine</name>
      <description>The risk or severity of hypoglycemia can be increased when Isradipine is combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00343</drugbank-id>
      <name>Diltiazem</name>
      <description>The risk or severity of hypoglycemia can be increased when Diltiazem is combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00347</drugbank-id>
      <name>Trimethadione</name>
      <description>The risk or severity of hypoglycemia can be increased when Trimethadione is combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00381</drugbank-id>
      <name>Amlodipine</name>
      <description>The risk or severity of hypoglycemia can be increased when Amlodipine is combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00393</drugbank-id>
      <name>Nimodipine</name>
      <description>The risk or severity of hypoglycemia can be increased when Nimodipine is combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00401</drugbank-id>
      <name>Nisoldipine</name>
      <description>The risk or severity of hypoglycemia can be increased when Nisoldipine is combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00528</drugbank-id>
      <name>Lercanidipine</name>
      <description>The risk or severity of hypoglycemia can be increased when Lercanidipine is combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00555</drugbank-id>
      <name>Lamotrigine</name>
      <description>The risk or severity of hypoglycemia can be increased when Lamotrigine is combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00593</drugbank-id>
      <name>Ethosuximide</name>
      <description>The risk or severity of hypoglycemia can be increased when Ethosuximide is combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00622</drugbank-id>
      <name>Nicardipine</name>
      <description>The risk or severity of hypoglycemia can be increased when Nicardipine is combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00653</drugbank-id>
      <name>Magnesium sulfate</name>
      <description>The risk or severity of hypoglycemia can be increased when Magnesium sulfate is combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00836</drugbank-id>
      <name>Loperamide</name>
      <description>The risk or severity of hypoglycemia can be increased when Loperamide is combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01054</drugbank-id>
      <name>Nitrendipine</name>
      <description>The risk or severity of hypoglycemia can be increased when Nitrendipine is combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01074</drugbank-id>
      <name>Perhexiline</name>
      <description>The risk or severity of hypoglycemia can be increased when Perhexiline is combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01244</drugbank-id>
      <name>Bepridil</name>
      <description>The risk or severity of hypoglycemia can be increased when Bepridil is combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01388</drugbank-id>
      <name>Mibefradil</name>
      <description>The risk or severity of hypoglycemia can be increased when Mibefradil is combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04743</drugbank-id>
      <name>Nimesulide</name>
      <description>The risk or severity of hypoglycemia can be increased when Nimesulide is combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04825</drugbank-id>
      <name>Prenylamine</name>
      <description>The risk or severity of hypoglycemia can be increased when Prenylamine is combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04838</drugbank-id>
      <name>Cyclandelate</name>
      <description>The risk or severity of hypoglycemia can be increased when Cyclandelate is combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04842</drugbank-id>
      <name>Fluspirilene</name>
      <description>The risk or severity of hypoglycemia can be increased when Fluspirilene is combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04920</drugbank-id>
      <name>Clevidipine</name>
      <description>The risk or severity of hypoglycemia can be increased when Clevidipine is combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05246</drugbank-id>
      <name>Methsuximide</name>
      <description>The risk or severity of hypoglycemia can be increased when Methsuximide is combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05885</drugbank-id>
      <name>Seletracetam</name>
      <description>The risk or severity of hypoglycemia can be increased when Seletracetam is combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06152</drugbank-id>
      <name>Nylidrin</name>
      <description>The risk or severity of hypoglycemia can be increased when Nylidrin is combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06283</drugbank-id>
      <name>Ziconotide</name>
      <description>The risk or severity of hypoglycemia can be increased when Ziconotide is combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06446</drugbank-id>
      <name>Dotarizine</name>
      <description>The risk or severity of hypoglycemia can be increased when Dotarizine is combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06694</drugbank-id>
      <name>Xylometazoline</name>
      <description>The risk or severity of hypoglycemia can be increased when Xylometazoline is combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06712</drugbank-id>
      <name>Nilvadipine</name>
      <description>The risk or severity of hypoglycemia can be increased when Nilvadipine is combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB07615</drugbank-id>
      <name>Tranilast</name>
      <description>The risk or severity of hypoglycemia can be increased when Tranilast is combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08838</drugbank-id>
      <name>Agmatine</name>
      <description>The risk or severity of hypoglycemia can be increased when Agmatine is combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08980</drugbank-id>
      <name>Fendiline</name>
      <description>The risk or severity of hypoglycemia can be increased when Fendiline is combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08992</drugbank-id>
      <name>Eperisone</name>
      <description>The risk or severity of hypoglycemia can be increased when Eperisone is combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09089</drugbank-id>
      <name>Trimebutine</name>
      <description>The risk or severity of hypoglycemia can be increased when Trimebutine is combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09090</drugbank-id>
      <name>Pinaverium</name>
      <description>The risk or severity of hypoglycemia can be increased when Pinaverium is combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09216</drugbank-id>
      <name>Tolfenamic acid</name>
      <description>The risk or severity of hypoglycemia can be increased when Tolfenamic acid is combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09227</drugbank-id>
      <name>Barnidipine</name>
      <description>The risk or severity of hypoglycemia can be increased when Barnidipine is combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09229</drugbank-id>
      <name>Aranidipine</name>
      <description>The risk or severity of hypoglycemia can be increased when Aranidipine is combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09230</drugbank-id>
      <name>Azelnidipine</name>
      <description>The risk or severity of hypoglycemia can be increased when Azelnidipine is combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09231</drugbank-id>
      <name>Benidipine</name>
      <description>The risk or severity of hypoglycemia can be increased when Benidipine is combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09232</drugbank-id>
      <name>Cilnidipine</name>
      <description>The risk or severity of hypoglycemia can be increased when Cilnidipine is combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09234</drugbank-id>
      <name>Darodipine</name>
      <description>The risk or severity of hypoglycemia can be increased when Darodipine is combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09235</drugbank-id>
      <name>Efonidipine</name>
      <description>The risk or severity of hypoglycemia can be increased when Efonidipine is combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09236</drugbank-id>
      <name>Lacidipine</name>
      <description>The risk or severity of hypoglycemia can be increased when Lacidipine is combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09238</drugbank-id>
      <name>Manidipine</name>
      <description>The risk or severity of hypoglycemia can be increased when Manidipine is combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09239</drugbank-id>
      <name>Niguldipine</name>
      <description>The risk or severity of hypoglycemia can be increased when Niguldipine is combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09240</drugbank-id>
      <name>Niludipine</name>
      <description>The risk or severity of hypoglycemia can be increased when Niludipine is combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11960</drugbank-id>
      <name>Carboxyamidotriazole</name>
      <description>The risk or severity of hypoglycemia can be increased when Carboxyamidotriazole is combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12092</drugbank-id>
      <name>Naftopidil</name>
      <description>The risk or severity of hypoglycemia can be increased when Naftopidil is combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12093</drugbank-id>
      <name>Tetrahydropalmatine</name>
      <description>The risk or severity of hypoglycemia can be increased when Tetrahydropalmatine is combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12131</drugbank-id>
      <name>Vinpocetine</name>
      <description>The risk or severity of hypoglycemia can be increased when Vinpocetine is combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12923</drugbank-id>
      <name>Gallopamil</name>
      <description>The risk or severity of hypoglycemia can be increased when Gallopamil is combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13488</drugbank-id>
      <name>Bencyclane</name>
      <description>The risk or severity of hypoglycemia can be increased when Bencyclane is combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13500</drugbank-id>
      <name>Otilonium</name>
      <description>The risk or severity of hypoglycemia can be increased when Otilonium is combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13725</drugbank-id>
      <name>Terodiline</name>
      <description>The risk or severity of hypoglycemia can be increased when Terodiline is combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13766</drugbank-id>
      <name>Lidoflazine</name>
      <description>The risk or severity of hypoglycemia can be increased when Lidoflazine is combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13791</drugbank-id>
      <name>Penfluridol</name>
      <description>The risk or severity of hypoglycemia can be increased when Penfluridol is combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13835</drugbank-id>
      <name>Caroverine</name>
      <description>The risk or severity of hypoglycemia can be increased when Caroverine is combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13950</drugbank-id>
      <name>WIN 55212-2</name>
      <description>The risk or severity of hypoglycemia can be increased when WIN 55212-2 is combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13961</drugbank-id>
      <name>Fish oil</name>
      <description>The risk or severity of hypoglycemia can be increased when Fish oil is combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14063</drugbank-id>
      <name>Dexverapamil</name>
      <description>The risk or severity of hypoglycemia can be increased when Dexverapamil is combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14064</drugbank-id>
      <name>Emopamil</name>
      <description>The risk or severity of hypoglycemia can be increased when Emopamil is combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14065</drugbank-id>
      <name>Lomerizine</name>
      <description>The risk or severity of hypoglycemia can be increased when Lomerizine is combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14066</drugbank-id>
      <name>Tetrandrine</name>
      <description>The risk or severity of hypoglycemia can be increased when Tetrandrine is combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14068</drugbank-id>
      <name>Dexniguldipine</name>
      <description>The risk or severity of hypoglycemia can be increased when Dexniguldipine is combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01023</drugbank-id>
      <name>Felodipine</name>
      <description>The risk or severity of hypoglycemia can be increased when Felodipine is combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01118</drugbank-id>
      <name>Amiodarone</name>
      <description>The risk or severity of hypoglycemia can be increased when Amiodarone is combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00191</drugbank-id>
      <name>Phentermine</name>
      <description>The therapeutic efficacy of Insulin pork can be increased when used in combination with Phentermine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00268</drugbank-id>
      <name>Ropinirole</name>
      <description>The metabolism of Ropinirole can be increased when combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13074</drugbank-id>
      <name>Macimorelin</name>
      <description>The therapeutic efficacy of Macimorelin can be decreased when used in combination with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00279</drugbank-id>
      <name>Liothyronine</name>
      <description>The therapeutic efficacy of Insulin pork can be decreased when used in combination with Liothyronine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00331</drugbank-id>
      <name>Metformin</name>
      <description>The risk or severity of adverse effects can be increased when Insulin pork is combined with Metformin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00542</drugbank-id>
      <name>Benazepril</name>
      <description>The risk or severity of hypoglycemia can be increased when Benazepril is combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13946</drugbank-id>
      <name>Testosterone undecanoate</name>
      <description>The risk or severity of adverse effects can be increased when Testosterone undecanoate is combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00945</drugbank-id>
      <name>Acetylsalicylic acid</name>
      <description>The risk or severity of hypoglycemia can be increased when Acetylsalicylic acid is combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00181</drugbank-id>
      <name>Baclofen</name>
      <description>The therapeutic efficacy of Insulin pork can be decreased when used in combination with Baclofen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00489</drugbank-id>
      <name>Sotalol</name>
      <description>The risk or severity of hypoglycemia can be increased when Sotalol is combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00196</drugbank-id>
      <name>Fluconazole</name>
      <description>The risk or severity of hypoglycemia can be increased when Insulin pork is combined with Fluconazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00040</drugbank-id>
      <name>Glucagon</name>
      <description>The therapeutic efficacy of Insulin pork can be decreased when used in combination with Glucagon.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00264</drugbank-id>
      <name>Metoprolol</name>
      <description>The therapeutic efficacy of Insulin pork can be increased when used in combination with Metoprolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00335</drugbank-id>
      <name>Atenolol</name>
      <description>The therapeutic efficacy of Insulin pork can be increased when used in combination with Atenolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00373</drugbank-id>
      <name>Timolol</name>
      <description>The therapeutic efficacy of Insulin pork can be increased when used in combination with Timolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00598</drugbank-id>
      <name>Labetalol</name>
      <description>The therapeutic efficacy of Insulin pork can be increased when used in combination with Labetalol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00612</drugbank-id>
      <name>Bisoprolol</name>
      <description>The therapeutic efficacy of Insulin pork can be increased when used in combination with Bisoprolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00866</drugbank-id>
      <name>Alprenolol</name>
      <description>The therapeutic efficacy of Insulin pork can be increased when used in combination with Alprenolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00960</drugbank-id>
      <name>Pindolol</name>
      <description>The therapeutic efficacy of Insulin pork can be increased when used in combination with Pindolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01193</drugbank-id>
      <name>Acebutolol</name>
      <description>The therapeutic efficacy of Insulin pork can be increased when used in combination with Acebutolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01203</drugbank-id>
      <name>Nadolol</name>
      <description>The therapeutic efficacy of Insulin pork can be increased when used in combination with Nadolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01295</drugbank-id>
      <name>Bevantolol</name>
      <description>The therapeutic efficacy of Insulin pork can be increased when used in combination with Bevantolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01297</drugbank-id>
      <name>Practolol</name>
      <description>The therapeutic efficacy of Insulin pork can be increased when used in combination with Practolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01359</drugbank-id>
      <name>Penbutolol</name>
      <description>The therapeutic efficacy of Insulin pork can be increased when used in combination with Penbutolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01580</drugbank-id>
      <name>Oxprenolol</name>
      <description>The therapeutic efficacy of Insulin pork can be increased when used in combination with Oxprenolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB03322</drugbank-id>
      <name>Dexpropranolol</name>
      <description>The therapeutic efficacy of Insulin pork can be increased when used in combination with Dexpropranolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04846</drugbank-id>
      <name>Celiprolol</name>
      <description>The therapeutic efficacy of Insulin pork can be increased when used in combination with Celiprolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04861</drugbank-id>
      <name>Nebivolol</name>
      <description>The therapeutic efficacy of Insulin pork can be increased when used in combination with Nebivolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06726</drugbank-id>
      <name>Bufuralol</name>
      <description>The therapeutic efficacy of Insulin pork can be increased when used in combination with Bufuralol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08807</drugbank-id>
      <name>Bopindolol</name>
      <description>The therapeutic efficacy of Insulin pork can be increased when used in combination with Bopindolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08808</drugbank-id>
      <name>Bupranolol</name>
      <description>The therapeutic efficacy of Insulin pork can be increased when used in combination with Bupranolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08952</drugbank-id>
      <name>Indenolol</name>
      <description>The therapeutic efficacy of Insulin pork can be increased when used in combination with Indenolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09204</drugbank-id>
      <name>Arotinolol</name>
      <description>The therapeutic efficacy of Insulin pork can be increased when used in combination with Arotinolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09351</drugbank-id>
      <name>Levobetaxolol</name>
      <description>The therapeutic efficacy of Insulin pork can be increased when used in combination with Levobetaxolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11770</drugbank-id>
      <name>Talinolol</name>
      <description>The therapeutic efficacy of Insulin pork can be increased when used in combination with Talinolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11785</drugbank-id>
      <name>Anisodamine</name>
      <description>The therapeutic efficacy of Insulin pork can be increased when used in combination with Anisodamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12752</drugbank-id>
      <name>Bucindolol</name>
      <description>The therapeutic efficacy of Insulin pork can be increased when used in combination with Bucindolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13443</drugbank-id>
      <name>Esatenolol</name>
      <description>The therapeutic efficacy of Insulin pork can be increased when used in combination with Esatenolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13508</drugbank-id>
      <name>Cloranolol</name>
      <description>The therapeutic efficacy of Insulin pork can be increased when used in combination with Cloranolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13530</drugbank-id>
      <name>Mepindolol</name>
      <description>The therapeutic efficacy of Insulin pork can be increased when used in combination with Mepindolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13757</drugbank-id>
      <name>Epanolol</name>
      <description>The therapeutic efficacy of Insulin pork can be increased when used in combination with Epanolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13775</drugbank-id>
      <name>Tertatolol</name>
      <description>The therapeutic efficacy of Insulin pork can be increased when used in combination with Tertatolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00195</drugbank-id>
      <name>Betaxolol</name>
      <description>The therapeutic efficacy of Betaxolol can be increased when used in combination with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00571</drugbank-id>
      <name>Propranolol</name>
      <description>The therapeutic efficacy of Propranolol can be increased when used in combination with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01136</drugbank-id>
      <name>Carvedilol</name>
      <description>The therapeutic efficacy of Carvedilol can be increased when used in combination with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01182</drugbank-id>
      <name>Propafenone</name>
      <description>The therapeutic efficacy of Propafenone can be increased when used in combination with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01611</drugbank-id>
      <name>Hydroxychloroquine</name>
      <description>The therapeutic efficacy of Insulin pork can be increased when used in combination with Hydroxychloroquine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01233</drugbank-id>
      <name>Metoclopramide</name>
      <description>The therapeutic efficacy of Metoclopramide can be increased when used in combination with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00394</drugbank-id>
      <name>Beclomethasone dipropionate</name>
      <description>The risk or severity of hyperglycemia can be increased when Beclomethasone dipropionate is combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00443</drugbank-id>
      <name>Betamethasone</name>
      <description>The risk or severity of hyperglycemia can be increased when Betamethasone is combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00620</drugbank-id>
      <name>Triamcinolone</name>
      <description>The risk or severity of hyperglycemia can be increased when Triamcinolone is combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00635</drugbank-id>
      <name>Prednisone</name>
      <description>The risk or severity of hyperglycemia can be increased when Prednisone is combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00687</drugbank-id>
      <name>Fludrocortisone</name>
      <description>The risk or severity of hyperglycemia can be increased when Fludrocortisone is combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00741</drugbank-id>
      <name>Hydrocortisone</name>
      <description>The risk or severity of hyperglycemia can be increased when Hydrocortisone is combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00764</drugbank-id>
      <name>Mometasone</name>
      <description>The risk or severity of hyperglycemia can be increased when Mometasone is combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00860</drugbank-id>
      <name>Prednisolone</name>
      <description>The risk or severity of hyperglycemia can be increased when Prednisolone is combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00959</drugbank-id>
      <name>Methylprednisolone</name>
      <description>The risk or severity of hyperglycemia can be increased when Methylprednisolone is combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01234</drugbank-id>
      <name>Dexamethasone</name>
      <description>The risk or severity of hyperglycemia can be increased when Dexamethasone is combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01285</drugbank-id>
      <name>Corticotropin</name>
      <description>The risk or severity of hyperglycemia can be increased when Corticotropin is combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01380</drugbank-id>
      <name>Cortisone acetate</name>
      <description>The risk or severity of hyperglycemia can be increased when Cortisone acetate is combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01384</drugbank-id>
      <name>Paramethasone</name>
      <description>The risk or severity of hyperglycemia can be increased when Paramethasone is combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01410</drugbank-id>
      <name>Ciclesonide</name>
      <description>The risk or severity of hyperglycemia can be increased when Ciclesonide is combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08906</drugbank-id>
      <name>Fluticasone furoate</name>
      <description>The risk or severity of hyperglycemia can be increased when Fluticasone furoate is combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08970</drugbank-id>
      <name>Fluprednidene</name>
      <description>The risk or severity of hyperglycemia can be increased when Fluprednidene is combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08971</drugbank-id>
      <name>Fluocortolone</name>
      <description>The risk or severity of hyperglycemia can be increased when Fluocortolone is combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09383</drugbank-id>
      <name>Meprednisone</name>
      <description>The risk or severity of hyperglycemia can be increased when Meprednisone is combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11487</drugbank-id>
      <name>Dexamethasone isonicotinate</name>
      <description>The risk or severity of hyperglycemia can be increased when Dexamethasone isonicotinate is combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11750</drugbank-id>
      <name>Clobetasol</name>
      <description>The risk or severity of hyperglycemia can be increased when Clobetasol is combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11921</drugbank-id>
      <name>Deflazacort</name>
      <description>The risk or severity of hyperglycemia can be increased when Deflazacort is combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13003</drugbank-id>
      <name>Cortivazol</name>
      <description>The risk or severity of hyperglycemia can be increased when Cortivazol is combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13208</drugbank-id>
      <name>Prednylidene</name>
      <description>The risk or severity of hyperglycemia can be increased when Prednylidene is combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13843</drugbank-id>
      <name>Cloprednol</name>
      <description>The risk or severity of hyperglycemia can be increased when Cloprednol is combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13867</drugbank-id>
      <name>Fluticasone</name>
      <description>The risk or severity of hyperglycemia can be increased when Fluticasone is combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14512</drugbank-id>
      <name>Mometasone furoate</name>
      <description>The risk or severity of hyperglycemia can be increased when Mometasone furoate is combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00180</drugbank-id>
      <name>Flunisolide</name>
      <description>The risk or severity of hyperglycemia can be increased when Flunisolide is combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01108</drugbank-id>
      <name>Trilostane</name>
      <description>The risk or severity of hyperglycemia can be increased when Trilostane is combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01222</drugbank-id>
      <name>Budesonide</name>
      <description>The risk or severity of hyperglycemia can be increased when Budesonide is combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04630</drugbank-id>
      <name>Aldosterone</name>
      <description>The risk or severity of hyperglycemia can be increased when Aldosterone is combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09378</drugbank-id>
      <name>Fluprednisolone</name>
      <description>The risk or severity of hyperglycemia can be increased when Fluprednisolone is combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11529</drugbank-id>
      <name>Melengestrol</name>
      <description>The risk or severity of hyperglycemia can be increased when Melengestrol is combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14681</drugbank-id>
      <name>Cortisone</name>
      <description>The risk or severity of hyperglycemia can be increased when Cortisone is combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00223</drugbank-id>
      <name>Diflorasone</name>
      <description>The risk or severity of hyperglycemia can be increased when Diflorasone is combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00240</drugbank-id>
      <name>Alclometasone</name>
      <description>The risk or severity of hyperglycemia can be increased when Alclometasone is combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00253</drugbank-id>
      <name>Medrysone</name>
      <description>The risk or severity of hyperglycemia can be increased when Medrysone is combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00288</drugbank-id>
      <name>Amcinonide</name>
      <description>The risk or severity of hyperglycemia can be increased when Amcinonide is combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00324</drugbank-id>
      <name>Fluorometholone</name>
      <description>The risk or severity of hyperglycemia can be increased when Fluorometholone is combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00547</drugbank-id>
      <name>Desoximetasone</name>
      <description>The risk or severity of hyperglycemia can be increased when Desoximetasone is combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00588</drugbank-id>
      <name>Fluticasone propionate</name>
      <description>The risk or severity of hyperglycemia can be increased when Fluticasone propionate is combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00591</drugbank-id>
      <name>Fluocinolone acetonide</name>
      <description>The risk or severity of hyperglycemia can be increased when Fluocinolone acetonide is combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00596</drugbank-id>
      <name>Ulobetasol</name>
      <description>The risk or severity of hyperglycemia can be increased when Ulobetasol is combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00663</drugbank-id>
      <name>Flumethasone</name>
      <description>The risk or severity of hyperglycemia can be increased when Flumethasone is combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00838</drugbank-id>
      <name>Clocortolone</name>
      <description>The risk or severity of hyperglycemia can be increased when Clocortolone is combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00846</drugbank-id>
      <name>Flurandrenolide</name>
      <description>The risk or severity of hyperglycemia can be increased when Flurandrenolide is combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00896</drugbank-id>
      <name>Rimexolone</name>
      <description>The risk or severity of hyperglycemia can be increased when Rimexolone is combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01013</drugbank-id>
      <name>Clobetasol propionate</name>
      <description>The risk or severity of hyperglycemia can be increased when Clobetasol propionate is combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01047</drugbank-id>
      <name>Fluocinonide</name>
      <description>The risk or severity of hyperglycemia can be increased when Fluocinonide is combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01130</drugbank-id>
      <name>Prednicarbate</name>
      <description>The risk or severity of hyperglycemia can be increased when Prednicarbate is combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01260</drugbank-id>
      <name>Desonide</name>
      <description>The risk or severity of hyperglycemia can be increased when Desonide is combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06781</drugbank-id>
      <name>Difluprednate</name>
      <description>The risk or severity of hyperglycemia can be increased when Difluprednate is combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06786</drugbank-id>
      <name>Halcinonide</name>
      <description>The risk or severity of hyperglycemia can be increased when Halcinonide is combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09091</drugbank-id>
      <name>Tixocortol</name>
      <description>The risk or severity of hyperglycemia can be increased when Tixocortol is combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09095</drugbank-id>
      <name>Difluocortolone</name>
      <description>The risk or severity of hyperglycemia can be increased when Difluocortolone is combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13158</drugbank-id>
      <name>Clobetasone</name>
      <description>The risk or severity of hyperglycemia can be increased when Clobetasone is combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13223</drugbank-id>
      <name>Fluocortin</name>
      <description>The risk or severity of hyperglycemia can be increased when Fluocortin is combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13491</drugbank-id>
      <name>Fluperolone</name>
      <description>The risk or severity of hyperglycemia can be increased when Fluperolone is combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13664</drugbank-id>
      <name>Formocortal</name>
      <description>The risk or severity of hyperglycemia can be increased when Formocortal is combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13728</drugbank-id>
      <name>Halometasone</name>
      <description>The risk or severity of hyperglycemia can be increased when Halometasone is combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13856</drugbank-id>
      <name>Fluclorolone</name>
      <description>The risk or severity of hyperglycemia can be increased when Fluclorolone is combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14538</drugbank-id>
      <name>Hydrocortisone aceponate</name>
      <description>The risk or severity of hyperglycemia can be increased when Hydrocortisone aceponate is combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14539</drugbank-id>
      <name>Hydrocortisone acetate</name>
      <description>The risk or severity of hyperglycemia can be increased when Hydrocortisone acetate is combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14540</drugbank-id>
      <name>Hydrocortisone butyrate</name>
      <description>The risk or severity of hyperglycemia can be increased when Hydrocortisone butyrate is combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14541</drugbank-id>
      <name>Hydrocortisone cypionate</name>
      <description>The risk or severity of hyperglycemia can be increased when Hydrocortisone cypionate is combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14543</drugbank-id>
      <name>Hydrocortisone probutate</name>
      <description>The risk or severity of hyperglycemia can be increased when Hydrocortisone probutate is combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14544</drugbank-id>
      <name>Hydrocortisone valerate</name>
      <description>The risk or severity of hyperglycemia can be increased when Hydrocortisone valerate is combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14545</drugbank-id>
      <name>Hydrocortisone succinate</name>
      <description>The risk or severity of hyperglycemia can be increased when Hydrocortisone succinate is combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00873</drugbank-id>
      <name>Loteprednol</name>
      <description>The risk or severity of hyperglycemia can be increased when Loteprednol is combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14631</drugbank-id>
      <name>Prednisolone phosphate</name>
      <description>The risk or severity of hyperglycemia can be increased when Prednisolone phosphate is combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14633</drugbank-id>
      <name>Prednisolone hemisuccinate</name>
      <description>The risk or severity of hyperglycemia can be increased when Prednisolone hemisuccinate is combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14634</drugbank-id>
      <name>Fluprednidene acetate</name>
      <description>The risk or severity of hyperglycemia can be increased when Fluprednidene acetate is combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14643</drugbank-id>
      <name>Methylprednisolone aceponate</name>
      <description>The risk or severity of hyperglycemia can be increased when Methylprednisolone aceponate is combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14644</drugbank-id>
      <name>Methylprednisolone hemisuccinate</name>
      <description>The risk or severity of hyperglycemia can be increased when Methylprednisolone hemisuccinate is combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14646</drugbank-id>
      <name>Prednisone acetate</name>
      <description>The risk or severity of hyperglycemia can be increased when Prednisone acetate is combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14652</drugbank-id>
      <name>Clocortolone acetate</name>
      <description>The risk or severity of hyperglycemia can be increased when Clocortolone acetate is combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14659</drugbank-id>
      <name>Melengestrol acetate</name>
      <description>The risk or severity of hyperglycemia can be increased when Melengestrol acetate is combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14669</drugbank-id>
      <name>Betamethasone phosphate</name>
      <description>The risk or severity of hyperglycemia can be increased when Betamethasone phosphate is combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15566</drugbank-id>
      <name>Prednisolone acetate</name>
      <description>The risk or severity of hyperglycemia can be increased when Prednisolone acetate is combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00451</drugbank-id>
      <name>Levothyroxine</name>
      <description>The therapeutic efficacy of Insulin pork can be decreased when used in combination with Levothyroxine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00024</drugbank-id>
      <name>Thyrotropin alfa</name>
      <description>Thyrotropin alfa may decrease the hypoglycemic activities of Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01583</drugbank-id>
      <name>Liotrix</name>
      <description>Liotrix may decrease the hypoglycemic activities of Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB03604</drugbank-id>
      <name>Tiratricol</name>
      <description>Tiratricol may decrease the hypoglycemic activities of Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09100</drugbank-id>
      <name>Thyroid, porcine</name>
      <description>Thyroid, porcine may decrease the hypoglycemic activities of Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00104</drugbank-id>
      <name>Octreotide</name>
      <description>The therapeutic efficacy of Insulin pork can be decreased when used in combination with Octreotide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15093</drugbank-id>
      <name>Somapacitan</name>
      <description>The therapeutic efficacy of Insulin pork can be decreased when used in combination with Somapacitan.</description>
    </drug-interaction>
  </drug-interactions>
  <sequences>
    <sequence format="FASTA">&gt;A chain
GIVEQCCTSICSLYQLENYCN</sequence>
    <sequence format="FASTA">&gt;B chain
FVNQHLCGSHLVEALYLVCGERGFFYTPKT</sequence>
  </sequences>
  <experimental-properties>
    <property>
      <kind>Water Solubility</kind>
      <value>Slightly soluble</value>
      <source/>
    </property>
    <property>
      <kind>Hydrophobicity</kind>
      <value>0.218</value>
      <source/>
    </property>
    <property>
      <kind>Isoelectric Point</kind>
      <value>5.39</value>
      <source/>
    </property>
    <property>
      <kind>Molecular Weight</kind>
      <value>5795.6</value>
      <source/>
    </property>
    <property>
      <kind>Molecular Formula</kind>
      <value>C257H387N65O76S6</value>
      <source/>
    </property>
  </experimental-properties>
  <external-identifiers>
    <external-identifier>
      <resource>Drugs Product Database (DPD)</resource>
      <identifier>7326</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PubChem Substance</resource>
      <identifier>46508925</identifier>
    </external-identifier>
    <external-identifier>
      <resource>GenBank</resource>
      <identifier>AY137503</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PharmGKB</resource>
      <identifier>PA164781053</identifier>
    </external-identifier>
    <external-identifier>
      <resource>UniProtKB</resource>
      <identifier>Q8HXV2</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Therapeutic Targets Database</resource>
      <identifier>DAP001089</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Wikipedia</resource>
      <identifier>Insulin</identifier>
    </external-identifier>
    <external-identifier>
      <resource>RxCUI</resource>
      <identifier>221109</identifier>
    </external-identifier>
  </external-identifiers>
  <external-links/>
  <pathways/>
  <reactions/>
  <snp-effects/>
  <snp-adverse-drug-reactions/>
  <targets>
    <target position="1">
      <id>BE0000033</id>
      <name>Insulin receptor</name>
      <organism>Humans</organism>
      <actions>
        <action>binder</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A1840</ref-id>
            <pubmed-id>12038982</pubmed-id>
            <citation>Chen LM, Yang XW, Tang JG: Acidic residues on the N-terminus of proinsulin C-Peptide are important for the folding of insulin precursor. J Biochem. 2002 Jun;131(6):855-9.</citation>
          </article>
          <article>
            <ref-id>A1839</ref-id>
            <pubmed-id>12970169</pubmed-id>
            <citation>Desbuquois B, Chauvet G, Kouach M, Authier F: Cell itinerary and metabolic fate of proinsulin in rat liver: in vivo and in vitro studies. Endocrinology. 2003 Dec;144(12):5308-21. Epub 2003 Sep 11.</citation>
          </article>
          <article>
            <ref-id>A9</ref-id>
            <pubmed-id>11752352</pubmed-id>
            <citation>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>yes</known-action>
      <polypeptide id="P06213" source="Swiss-Prot">
        <name>Insulin receptor</name>
        <general-function>Receptor signaling protein tyrosine kinase activity</general-function>
        <specific-function>Receptor tyrosine kinase which mediates the pleiotropic actions of insulin. Binding of insulin leads to phosphorylation of several intracellular substrates, including, insulin receptor substrates (IRS1, 2, 3, 4), SHC, GAB1, CBL and other signaling intermediates. Each of these phosphorylated proteins serve as docking proteins for other signaling proteins that contain Src-homology-2 domains (SH2 domain) that specifically recognize different phosphotyrosines residues, including the p85 regulatory subunit of PI3K and SHP2. Phosphorylation of IRSs proteins lead to the activation of two main signaling pathways: the PI3K-AKT/PKB pathway, which is responsible for most of the metabolic actions of insulin, and the Ras-MAPK pathway, which regulates expression of some genes and cooperates with the PI3K pathway to control cell growth and differentiation. Binding of the SH2 domains of PI3K to phosphotyrosines on IRS1 leads to the activation of PI3K and the generation of phosphatidylinositol-(3, 4, 5)-triphosphate (PIP3), a lipid second messenger, which activates several PIP3-dependent serine/threonine kinases, such as PDPK1 and subsequently AKT/PKB. The net effect of this pathway is to produce a translocation of the glucose transporter SLC2A4/GLUT4 from cytoplasmic vesicles to the cell membrane to facilitate glucose transport. Moreover, upon insulin stimulation, activated AKT/PKB is responsible for: anti-apoptotic effect of insulin by inducing phosphorylation of BAD; regulates the expression of gluconeogenic and lipogenic enzymes by controlling the activity of the winged helix or forkhead (FOX) class of transcription factors. Another pathway regulated by PI3K-AKT/PKB activation is mTORC1 signaling pathway which regulates cell growth and metabolism and integrates signals from insulin. AKT mediates insulin-stimulated protein synthesis by phosphorylating TSC2 thereby activating mTORC1 pathway. The Ras/RAF/MAP2K/MAPK pathway is mainly involved in mediating cell growth, survival and cellular differentiation of insulin. Phosphorylated IRS1 recruits GRB2/SOS complex, which triggers the activation of the Ras/RAF/MAP2K/MAPK pathway. In addition to binding insulin, the insulin receptor can bind insulin-like growth factors (IGFI and IGFII). Isoform Short has a higher affinity for IGFII binding. When present in a hybrid receptor with IGF1R, binds IGF1. PubMed:12138094 shows that hybrid receptors composed of IGF1R and INSR isoform Long are activated with a high affinity by IGF1, with low affinity by IGF2 and not significantly activated by insulin, and that hybrid receptors composed of IGF1R and INSR isoform Short are activated by IGF1, IGF2 and insulin. In contrast, PubMed:16831875 shows that hybrid receptors composed of IGF1R and INSR isoform Long and hybrid receptors composed of IGF1R and INSR isoform Short have similar binding characteristics, both bind IGF1 and have a low affinity for insulin.</specific-function>
        <gene-name>INSR</gene-name>
        <locus>19p13.3-p13.2</locus>
        <cellular-location>Cell membrane</cellular-location>
        <transmembrane-regions>957-979</transmembrane-regions>
        <signal-regions>1-27</signal-regions>
        <theoretical-pi>6.18</theoretical-pi>
        <molecular-weight>156331.465</molecular-weight>
        <chromosome-location>19</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:6091</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>INSR</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>M10051</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>307070</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>1800</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P06213</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>INSR_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>2.7.10.1</synonym>
          <synonym>IR</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0036940|Insulin receptor
MATGGRRGAAAAPLLVAVAALLLGAAGHLYPGEVCPGMDIRNNLTRLHELENCSVIEGHL
QILLMFKTRPEDFRDLSFPKLIMITDYLLLFRVYGLESLKDLFPNLTVIRGSRLFFNYAL
VIFEMVHLKELGLYNLMNITRGSVRIEKNNELCYLATIDWSRILDSVEDNYIVLNKDDNE
ECGDICPGTAKGKTNCPATVINGQFVERCWTHSHCQKVCPTICKSHGCTAEGLCCHSECL
GNCSQPDDPTKCVACRNFYLDGRCVETCPPPYYHFQDWRCVNFSFCQDLHHKCKNSRRQG
CHQYVIHNNKCIPECPSGYTMNSSNLLCTPCLGPCPKVCHLLEGEKTIDSVTSAQELRGC
TVINGSLIINIRGGNNLAAELEANLGLIEEISGYLKIRRSYALVSLSFFRKLRLIRGETL
EIGNYSFYALDNQNLRQLWDWSKHNLTITQGKLFFHYNPKLCLSEIHKMEEVSGTKGRQE
RNDIALKTNGDQASCENELLKFSYIRTSFDKILLRWEPYWPPDFRDLLGFMLFYKEAPYQ
NVTEFDGQDACGSNSWTVVDIDPPLRSNDPKSQNHPGWLMRGLKPWTQYAIFVKTLVTFS
DERRTYGAKSDIIYVQTDATNPSVPLDPISVSNSSSQIILKWKPPSDPNGNITHYLVFWE
RQAEDSELFELDYCLKGLKLPSRTWSPPFESEDSQKHNQSEYEDSAGECCSCPKTDSQIL
KELEESSFRKTFEDYLHNVVFVPRKTSSGTGAEDPRPSRKRRSLGDVGNVTVAVPTVAAF
PNTSSTSVPTSPEEHRPFEKVVNKESLVISGLRHFTGYRIELQACNQDTPEERCSVAAYV
SARTMPEAKADDIVGPVTHEIFENNVVHLMWQEPKEPNGLIVLYEVSYRRYGDEELHLCV
SRKHFALERGCRLRGLSPGNYSVRIRATSLAGNGSWTEPTYFYVTDYLDVPSNIAKIIIG
PLIFVFLFSVVIGSIYLFLRKRQPDGPLGPLYASSNPEYLSASDVFPCSVYVPDEWEVSR
EKITLLRELGQGSFGMVYEGNARDIIKGEAETRVAVKTVNESASLRERIEFLNEASVMKG
FTCHHVVRLLGVVSKGQPTLVVMELMAHGDLKSYLRSLRPEAENNPGRPPPTLQEMIQMA
AEIADGMAYLNAKKFVHRDLAARNCMVAHDFTVKIGDFGMTRDIYETDYYRKGGKGLLPV
RWMAPESLKDGVFTTSSDMWSFGVVLWEITSLAEQPYQGLSNEQVLKFVMDGGYLDQPDN
CPERVTDLMRMCWQFNPKMRPTFLEIVNLLKDDLHPSFPEVSFFHSEENKAPESEELEME
FEDMENVPLDRSSHCQREEAGGRDGGSSLGFKRSYEEHIPYTHMNGGKKNGRILTLPRSN
PS</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0020443|Insulin receptor (INSR)
ATGGCCACCGGGGGCCGGCGGGGGGCGGCGGCCGCGCCGCTGCTGGTGGCGGTGGCCGCG
CTGCTACTGGGCGCCGCGGGCCACCTGTACCCCGGAGAGGTGTGTCCCGGCATGGATATC
CGGAACAACCTCACTAGGTTGCATGAGCTGGAGAATTGCTCTGTCATCGAAGGACACTTG
CAGATACTCTTGATGTTCAAAACGAGGCCCGAAGATTTCCGAGACCTCAGTTTCCCCAAA
CTCATCATGATCACTGATTACTTGCTGCTCTTCCGGGTCTATGGGCTCGAGAGCCTGAAG
GACCTGTTCCCCAACCTCACGGTCATCCGGGGATCACGACTGTTCTTTAACTACGCGCTG
GTCATCTTCGAGATGGTTCACCTCAAGGAACTCGGCCTCTACAACCTGATGAACATCACC
CGGGGTTCTGTCCGCATCGAGAAGAACAATGAGCTCTGTTACTTGGCCACTATCGACTGG
TCCCGTATCCTGGATTCCGTGGAGGATAATTACATCGTGTTGAACAAAGATGACAACGAG
GAGTGTGGAGACATCTGTCCGGGTACCGCGAAGGGCAAGACCAACTGCCCCGCCACCGTC
ATCAACGGGCAGTTTGTCGAACGATGTTGGACTCATAGTCACTGCCAGAAAGTTTGCCCG
ACCATCTGTAAGTCACACGGCTGCACCGCCGAAGGCCTCTGTTGCCACAGCGAGTGCCTG
GGCAACTGTTCTCAGCCCGACGACCCCACCAAGTGCGTGGCCTGCCGCAACTTCTACCTG
GACGGCAGGTGTGTGGAGACCTGCCCGCCCCCGTACTACCACTTCCAGGACTGGCGCTGT
GTGAACTTCAGCTTCTGCCAGGACCTGCACCACAAATGCAAGAACTCGCGGAGGCAGGGC
TGCCACCAGTACGTCATTCACAACAACAAGTGCATCCCTGAGTGTCCCTCCGGGTACACG
ATGAATTCCAGCAACTTGCTGTGCACCCCATGCCTGGGTCCCTGTCCCAAGGTGTGCCAC
CTCCTAGAAGGCGAGAAGACCATCGACTCGGTGACGTCTGCCCAGGAGCTCCGAGGATGC
ACCGTCATCAACGGGAGTCTGATCATCAACATTCGAGGAGGCAACAATCTGGCAGCTGAG
CTAGAAGCCAACCTCGGCCTCATTGAAGAAATTTCAGGGTATCTAAAAATCCGCCGATCC
TACGCTCTGGTGTCACTTTCCTTCTTCCGGAAGTTACGTCTGATTCGAGGAGAGACCTTG
GAAATTGGGAACTACTCCTTCTATGCCTTGGACAACCAGAACCTAAGGCAGCTCTGGGAC
TGGAGCAAACACAACCTCACCATCACTCAGGGGAAACTCTTCTTCCACTATAACCCCAAA
CTCTGCTTGTCAGAAATCCACAAGATGGAAGAAGTTTCAGGAACCAAGGGGCGCCAGGAG
AGAAACGACATTGCCCTGAAGACCAATGGGGACCAGGCATCCTGTGAAAATGAGTTACTT
AAATTTTCTTACATTCGGACATCTTTTGACAAGATCTTGCTGAGATGGGAGCCGTACTGG
CCCCCCGACTTCCGAGACCTCTTGGGGTTCATGCTGTTCTACAAAGAGGCCCCTTATCAG
AATGTGACGGAGTTCGACGGGCAGGATGCGTGTGGTTCCAACAGTTGGACGGTGGTAGAC
ATTGACCCACCCCTGAGGTCCAACGACCCCAAATCACAGAACCACCCAGGGTGGCTGATG
CGGGGTCTCAAGCCCTGGACCCAGTATGCCATCTTTGTGAAGACCCTGGTCACCTTTTCG
GATGAACGCCGGACCTATGGGGCCAAGAGTGACATCATTTATGTCCAGACAGATGCCACC
AACCCCTCTGTGCCCCTGGATCCAATCTCAGTGTCTAACTCATCATCCCAGATTATTCTG
AAGTGGAAACCACCCTCCGACCCCAATGGCAACATCACCCACTACCTGGTTTTCTGGGAG
AGGCAGGCGGAAGACAGTGAGCTGTTCGAGCTGGATTATTGCCTCAAAGGGCTGAAGCTG
CCCTCGAGGACCTGGTCTCCACCATTCGAGTCTGAAGATTCTCAGAAGCACAACCAGAGT
GAGTATGAGGATTCGGCCGGCGAATGCTGCTCCTGTCCAAAGACAGACTCTCAGATCCTG
AAGGAGCTGGAGGAGTCCTCGTTTAGGAAGACGTTTGAGGATTACCTGCACAACGTGGTT
TTCGTCCCCAGAAAAACCTCTTCAGGCACTGGTGCCGAGGACCCTAGGCCATCTCGGAAA
CGCAGGTCCCTTGGCGATGTTGGGAATGTGACGGTGGCCGTGCCCACGGTGGCAGCTTTC
CCCAACACTTCCTCGACCAGCGTGCCCACGAGTCCGGAGGAGCACAGGCCTTTTGAGAAG
GTGGTGAACAAGGAGTCGCTGGTCATCTCCGGCTTGCGACACTTCACGGGCTATCGCATC
GAGCTGCAGGCTTGCAACCAGGACACCCCTGAGGAACGGTGCAGTGTGGCAGCCTACGTC
AGTGCGAGGACCATGCCTGAAGCCAAGGCTGATGACATTGTTGGCCCTGTGACGCATGAA
ATCTTTGAGAACAACGTCGTCCACTTGATGTGGCAGGAGCCGAAGGAGCCCAATGGTCTG
ATCGTGCTGTATGAAGTGAGTTATCGGCGATATGGTGATGAGGAGCTGCATCTCTGCGTC
TCCCGCAAGCACTTCGCTCTGGAACGGGGCTGCAGGCTGCGTGGGCTGTCACCGGGGAAC
TACAGCGTGCGAATCCGGGCCACCTCCCTTGCGGGCAACGGCTCTTGGACGGAACCCACC
TATTTCTACGTGACAGACTATTTAGACGTCCCGTCAAATATTGCAAAAATTATCATCGGC
CCCCTCATCTTTGTCTTTCTCTTCAGTGTTGTGATTGGAAGTATTTATCTATTCCTGAGA
AAGAGGCAGCCAGATGGGCCGCTGGGACCGCTTTACGCTTCTTCAAACCCTGAGTATCTC
AGTGCCAGTGATGTGTTTCCATGCTCTGTGTACGTGCCGGACGAGTGGGAGGTGTCTCGA
GAGAAGATCACCCTCCTTCGAGAGCTGGGGCAGGGCTCCTTCGGCATGGTGTATGAGGGC
AATGCCAGGGACATCATCAAGGGTGAGGCAGAGACCCGCGTGGCGGTGAAGACGGTCAAC
GAGTCAGCCAGTCTCCGAGAGCGGATTGAGTTCCTCAATGAGGCCTCGGTCATGAAGGGC
TTCACCTGCCATCACGTGGTGCGCCTCCTGGGAGTGGTGTCCAAGGGCCAGCCCACGCTG
GTGGTGATGGAGCTGATGGCTCACGGAGACCTGAAGAGCTACCTCCGTTCTCTGCGGCCA
GAGGCTGAGAATAATCCTGGCCGCCCTCCCCCTACCCTTCAAGAGATGATTCAGATGGCG
GCAGAGATTGCTGACGGGATGGCCTACCTGAACGCCAAGAAGTTTGTGCATCGGGACCTG
GCAGCGAGAAACTGCATGGTCGCCCATGATTTTACTGTCAAAATTGGAGACTTTGGAATG
ACCAGAGACATCTATGAAACGGATTACTACCGGAAAGGGGGCAAGGGTCTGCTCCCTGTA
CGGTGGATGGCACCGGAGTCCCTGAAGGATGGGGTCTTCACCACTTCTTCTGACATGTGG
TCCTTTGGCGTGGTCCTTTGGGAAATCACCAGCTTGGCAGAACAGCCTTACCAAGGCCTG
TCTAATGAACAGGTGTTGAAATTTGTCATGGATGGAGGGTATCTGGATCAACCCGACAAC
TGTCCAGAGAGAGTCACTGACCTCATGCGCATGTGCTGGCAATTCAACCCCAAGATGAGG
CCAACCTTCCTGGAGATTGTCAACCTGCTCAAGGACGACCTGCACCCCAGCTTTCCAGAG
GTGTCGTTCTTCCACAGCGAGGAGAACAAGGCTCCCGAGAGTGAGGAGCTGGAGATGGAG
TTTGAGGACATGGAGAATGTGCCCCTGGACCGTTCCTCGCACTGTCAGAGGGAGGAGGCG
GGGGGCCGGGATGGAGGGTCCTCGCTGGGTTTCAAGCGGAGCTACGAGGAACACATCCCT
TACACACACATGAACGGAGGCAAGAAAAACGGGCGGATTCTGACCTTGCCTCGGTCCAAT
CCTTCCTAA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF07714</identifier>
            <name>Pkinase_Tyr</name>
          </pfam>
          <pfam>
            <identifier>PF00041</identifier>
            <name>fn3</name>
          </pfam>
          <pfam>
            <identifier>PF00757</identifier>
            <name>Furin-like</name>
          </pfam>
          <pfam>
            <identifier>PF01030</identifier>
            <name>Recep_L_domain</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>caveola</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>endosome membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>extracellular exosome</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>insulin receptor complex</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>integral component of plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>intracellular membrane-bounded organelle</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>receptor complex</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>ATP binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>GTP binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>insulin binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>insulin receptor substrate binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>insulin-activated receptor activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>insulin-like growth factor I binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>insulin-like growth factor II binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>insulin-like growth factor receptor binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>phosphatidylinositol 3-kinase binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>protein tyrosine kinase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>PTB domain binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>receptor signaling protein tyrosine kinase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>activation of MAPK activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>activation of protein kinase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>activation of protein kinase B activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>adrenal gland development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>carbohydrate metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to growth factor stimulus</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to insulin stimulus</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>epidermis development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>exocrine pancreas development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>G-protein coupled receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>glucose homeostasis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>heart morphogenesis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>insulin receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>male gonad development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>male sex determination</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>peptidyl-tyrosine autophosphorylation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>peptidyl-tyrosine phosphorylation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of cell migration</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of cell proliferation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of developmental growth</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of DNA replication</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of glucose import</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of glycogen biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of glycolytic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of MAPK cascade</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of meiotic cell cycle</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of mitotic nuclear division</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of nitric oxide biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of protein kinase B signaling</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of protein phosphorylation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of respiratory burst</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of transcription, DNA-templated</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>protein autophosphorylation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>protein heterotetramerization</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of embryonic development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of female gonad development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of transcription, DNA-templated</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>signal transduction by protein phosphorylation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>transformation of host cell by virus</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
    <target position="2">
      <id>BE0000858</id>
      <name>Insulin-like growth factor 1 receptor</name>
      <organism>Humans</organism>
      <actions/>
      <references>
        <articles>
          <article>
            <ref-id>A1713</ref-id>
            <pubmed-id>17139284</pubmed-id>
            <citation>Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.</citation>
          </article>
          <article>
            <ref-id>A1715</ref-id>
            <pubmed-id>17016423</pubmed-id>
            <citation>Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.</citation>
          </article>
          <article>
            <ref-id>A13240</ref-id>
            <pubmed-id>9846170</pubmed-id>
            <citation>Fottner C, Engelhardt D, Weber MM: Regulation of steroidogenesis by insulin-like growth factors (IGFs) in adult human adrenocortical cells: IGF-I and, more potently, IGF-II preferentially enhance androgen biosynthesis through interaction with the IGF-I receptor and IGF-binding proteins. J Endocrinol. 1998 Sep;158(3):409-17.</citation>
          </article>
          <article>
            <ref-id>A13241</ref-id>
            <pubmed-id>9582514</pubmed-id>
            <citation>Zhang Q, Berggren PO, Hansson A, Tally M: Insulin-like growth factor-I-induced DNA synthesis in insulin-secreting cell line RINm5F is associated with phosphorylation of the insulin-like growth factor-I receptor and the insulin receptor substrate-2. J Endocrinol. 1998 Mar;156(3):573-81.</citation>
          </article>
          <article>
            <ref-id>A13242</ref-id>
            <pubmed-id>7476290</pubmed-id>
            <citation>Sowers JR, Jacobs DB, Simpson L, al-Homsi B, Grunberger G, Sokol R: Erythrocyte insulin and insulin-like growth factor-I receptor tyrosine kinase activity in hypertension in pregnancy. Metabolism. 1995 Oct;44(10):1308-13.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P08069" source="Swiss-Prot">
        <name>Insulin-like growth factor 1 receptor</name>
        <general-function>Protein tyrosine kinase activity</general-function>
        <specific-function>Receptor tyrosine kinase which mediates actions of insulin-like growth factor 1 (IGF1). Binds IGF1 with high affinity and IGF2 and insulin (INS) with a lower affinity. The activated IGF1R is involved in cell growth and survival control. IGF1R is crucial for tumor transformation and survival of malignant cell. Ligand binding activates the receptor kinase, leading to receptor autophosphorylation, and tyrosines phosphorylation of multiple substrates, that function as signaling adapter proteins including, the insulin-receptor substrates (IRS1/2), Shc and 14-3-3 proteins. Phosphorylation of IRSs proteins lead to the activation of two main signaling pathways: the PI3K-AKT/PKB pathway and the Ras-MAPK pathway. The result of activating the MAPK pathway is increased cellular proliferation, whereas activating the PI3K pathway inhibits apoptosis and stimulates protein synthesis. Phosphorylated IRS1 can activate the 85 kDa regulatory subunit of PI3K (PIK3R1), leading to activation of several downstream substrates, including protein AKT/PKB. AKT phosphorylation, in turn, enhances protein synthesis through mTOR activation and triggers the antiapoptotic effects of IGFIR through phosphorylation and inactivation of BAD. In parallel to PI3K-driven signaling, recruitment of Grb2/SOS by phosphorylated IRS1 or Shc leads to recruitment of Ras and activation of the ras-MAPK pathway. In addition to these two main signaling pathways IGF1R signals also through the Janus kinase/signal transducer and activator of transcription pathway (JAK/STAT). Phosphorylation of JAK proteins can lead to phosphorylation/activation of signal transducers and activators of transcription (STAT) proteins. In particular activation of STAT3, may be essential for the transforming activity of IGF1R. The JAK/STAT pathway activates gene transcription and may be responsible for the transforming activity. JNK kinases can also be activated by the IGF1R. IGF1 exerts inhibiting activities on JNK activation via phosphorylation and inhibition of MAP3K5/ASK1, which is able to directly associate with the IGF1R.When present in a hybrid receptor with INSR, binds IGF1. PubMed:12138094 shows that hybrid receptors composed of IGF1R and INSR isoform Long are activated with a high affinity by IGF1, with low affinity by IGF2 and not significantly activated by insulin, and that hybrid receptors composed of IGF1R and INSR isoform Short are activated by IGF1, IGF2 and insulin. In contrast, PubMed:16831875 shows that hybrid receptors composed of IGF1R and INSR isoform Long and hybrid receptors composed of IGF1R and INSR isoform Short have similar binding characteristics, both bind IGF1 and have a low affinity for insulin.</specific-function>
        <gene-name>IGF1R</gene-name>
        <locus>15q26.3</locus>
        <cellular-location>Cell membrane</cellular-location>
        <transmembrane-regions>936-959</transmembrane-regions>
        <signal-regions>1-30</signal-regions>
        <theoretical-pi>5.54</theoretical-pi>
        <molecular-weight>154791.73</molecular-weight>
        <chromosome-location>15</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:5465</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>IGF1R</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>X04434</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>804990</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>1801</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P08069</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>IGF1R_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>2.7.10.1</synonym>
          <synonym>IGF-I receptor</synonym>
          <synonym>Insulin-like growth factor I receptor</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0001710|Insulin-like growth factor 1 receptor
MKSGSGGGSPTSLWGLLFLSAALSLWPTSGEICGPGIDIRNDYQQLKRLENCTVIEGYLH
ILLISKAEDYRSYRFPKLTVITEYLLLFRVAGLESLGDLFPNLTVIRGWKLFYNYALVIF
EMTNLKDIGLYNLRNITRGAIRIEKNADLCYLSTVDWSLILDAVSNNYIVGNKPPKECGD
LCPGTMEEKPMCEKTTINNEYNYRCWTTNRCQKMCPSTCGKRACTENNECCHPECLGSCS
APDNDTACVACRHYYYAGVCVPACPPNTYRFEGWRCVDRDFCANILSAESSDSEGFVIHD
GECMQECPSGFIRNGSQSMYCIPCEGPCPKVCEEEKKTKTIDSVTSAQMLQGCTIFKGNL
LINIRRGNNIASELENFMGLIEVVTGYVKIRHSHALVSLSFLKNLRLILGEEQLEGNYSF
YVLDNQNLQQLWDWDHRNLTIKAGKMYFAFNPKLCVSEIYRMEEVTGTKGRQSKGDINTR
NNGERASCESDVLHFTSTTTSKNRIIITWHRYRPPDYRDLISFTVYYKEAPFKNVTEYDG
QDACGSNSWNMVDVDLPPNKDVEPGILLHGLKPWTQYAVYVKAVTLTMVENDHIRGAKSE
ILYIRTNASVPSIPLDVLSASNSSSQLIVKWNPPSLPNGNLSYYIVRWQRQPQDGYLYRH
NYCSKDKIPIRKYADGTIDIEEVTENPKTEVCGGEKGPCCACPKTEAEKQAEKEEAEYRK
VFENFLHNSIFVPRPERKRRDVMQVANTTMSSRSRNTTAADTYNITDPEELETEYPFFES
RVDNKERTVISNLRPFTLYRIDIHSCNHEAEKLGCSASNFVFARTMPAEGADDIPGPVTW
EPRPENSIFLKWPEPENPNGLILMYEIKYGSQVEDQRECVSRQEYRKYGGAKLNRLNPGN
YTARIQATSLSGNGSWTDPVFFYVQAKTGYENFIHLIIALPVAVLLIVGGLVIMLYVFHR
KRNNSRLGNGVLYASVNPEYFSAADVYVPDEWEVAREKITMSRELGQGSFGMVYEGVAKG
VVKDEPETRVAIKTVNEAASMRERIEFLNEASVMKEFNCHHVVRLLGVVSQGQPTLVIME
LMTRGDLKSYLRSLRPEMENNPVLAPPSLSKMIQMAGEIADGMAYLNANKFVHRDLAARN
CMVAEDFTVKIGDFGMTRDIYETDYYRKGGKGLLPVRWMSPESLKDGVFTTYSDVWSFGV
VLWEIATLAEQPYQGLSNEQVLRFVMEGGLLDKPDNCPDMLFELMRMCWQYNPKMRPSFL
EIISSIKEEMEPGFREVSFYYSEENKLPEPEELDLEPENMESVPLDPSASSSSLPLPDRH
SGHKAENGPGPGVLVLRASFDERQPYAHMNGGRKNERALPLPQSSTC</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0020490|Insulin-like growth factor 1 receptor (IGF1R)
ATGAAGTCTGGCTCCGGAGGAGGGTCCCCGACCTCGCTGTGGGGGCTCCTGTTTCTCTCC
GCCGCGCTCTCGCTCTGGCCGACGAGTGGAGAAATCTGCGGGCCAGGCATCGACATCCGC
AACGACTATCAGCAGCTGAAGCGCCTGGAGAACTGCACGGTGATCGAGGGCTACCTCCAC
ATCCTGCTCATCTCCAAGGCCGAGGACTACCGCAGCTACCGCTTCCCCAAGCTCACGGTC
ATTACCGAGTACTTGCTGCTGTTCCGAGTGGCTGGCCTCGAGAGCCTCGGAGACCTCTTC
CCCAACCTCACGGTCATCCGCGGCTGGAAACTCTTCTACAACTACGCCCTGGTCATCTTC
GAGATGACCAATCTCAAGGATATTGGGCTTTACAACCTGAGGAACATTACTCGGGGGGCC
ATCAGGATTGAGAAAAATGCTGACCTCTGTTACCTCTCCACTGTGGACTGGTCCCTGATC
CTGGATGCGGTGTCCAATAACTACATTGTGGGGAATAAGCCCCCAAAGGAATGTGGGGAC
CTGTGTCCAGGGACCATGGAGGAGAAGCCGATGTGTGAGAAGACCACCATCAACAATGAG
TACAACTACCGCTGCTGGACCACAAACCGCTGCCAGAAAATGTGCCCAAGCACGTGTGGG
AAGCGGGCGTGCACCGAGAACAATGAGTGCTGCCACCCCGAGTGCCTGGGCAGCTGCAGC
GCGCCTGACAACGACACGGCCTGTGTAGCTTGCCGCCACTACTACTATGCCGGTGTCTGT
GTGCCTGCCTGCCCGCCCAACACCTACAGGTTTGAGGGCTGGCGCTGTGTGGACCGTGAC
TTCTGCGCCAACATCCTCAGCGCCGAGAGCAGCGACTCCGAGGGGTTTGTGATCCACGAC
GGCGAGTGCATGCAGGAGTGCCCCTCGGGCTTCATCCGCAACGGCAGCCAGAGCATGTAC
TGCATCCCTTGTGAAGGTCCTTGCCCGAAGGTCTGTGAGGAAGAAAAGAAAACAAAGACC
ATTGATTCTGTTACTTCTGCTCAGATGCTCCAAGGATGCACCATCTTCAAGGGCAATTTG
CTCATTAACATCCGACGGGGGAATAACATTGCTTCAGAGCTGGAGAACTTCATGGGGCTC
ATCGAGGTGGTGACGGGCTACGTGAAGATCCGCCATTCTCATGCCTTGGTCTCCTTGTCC
TTCCTAAAAAACCTTCGCCTCATCCTAGGAGAGGAGCAGCTAGAAGGGAATTACTCCTTC
TACGTCCTCGACAACCAGAACTTGCAGCAACTGTGGGACTGGGACCACCGCAACCTGACC
ATCAAAGCAGGGAAAATGTACTTTGCTTTCAATCCCAAATTATGTGTTTCCGAAATTTAC
CGCATGGAGGAAGTGACGGGGACTAAAGGGCGCCAAAGCAAAGGGGACATAAACACCAGG
AACAACGGGGAGAGAGCCTCCTGTGAAAGTGACGTCCTGCATTTCACCTCCACCACCACG
TCGAAGAATCGCATCATCATAACCTGGCACCGGTACCGGCCCCCTGACTACAGGGATCTC
ATCAGCTTCACCGTTTACTACAAGGAAGCACCCTTTAAGAATGTCACAGAGTATGATGGG
CAGGATGCCTGCGGCTCCAACAGCTGGAACATGGTGGACGTGGACCTCCCGCCCAACAAG
GACGTGGAGCCCGGCATCTTACTACATGGGCTGAAGCCCTGGACTCAGTACGCCGTTTAC
GTCAAGGCTGTGACCCTCACCATGGTGGAGAACGACCATATCCGTGGGGCCAAGAGTGAG
ATCTTGTACATTCGCACCAATGCTTCAGTTCCTTCCATTCCCTTGGACGTTCTTTCAGCA
TCGAACTCCTCTTCTCAGTTAATCGTGAAGTGGAACCCTCCCTCTCTGCCCAACGGCAAC
CTGAGTTACTACATTGTGCGCTGGCAGCGGCAGCCTCAGGACGGCTACCTTTACCGGCAC
AATTACTGCTCCAAAGACAAAATCCCCATCAGGAAGTATGCCGACGGCACCATCGACATT
GAGGAGGTCACAGAGAACCCCAAGACTGAGGTGTGTGGTGGGGAGAAAGGGCCTTGCTGC
GCCTGCCCCAAAACTGAAGCCGAGAAGCAGGCCGAGAAGGAGGAGGCTGAATACCGCAAA
GTCTTTGAGAATTTCCTGCACAACTCCATCTTCGTGCCCAGACCTGAAAGGAAGCGGAGA
GATGTCATGCAAGTGGCCAACACCACCATGTCCAGCCGAAGCAGGAACACCACGGCCGCA
GACACCTACAACATCACCGACCCGGAAGAGCTGGAGACAGAGTACCCTTTCTTTGAGAGC
AGAGTGGATAACAAGGAGAGAACTGTCATTTCTAACCTTCGGCCTTTCACATTGTACCGC
ATCGATATCCACAGCTGCAACCACGAGGCTGAGAAGCTGGGCTGCAGCGCCTCCAACTTC
GTCTTTGCAAGGACTATGCCCGCAGAAGGAGCAGATGACATTCCTGGGCCAGTGACCTGG
GAGCCAAGGCCTGAAAACTCCATCTTTTTAAAGTGGCCGGAACCTGAGAATCCCAATGGA
TTGATTCTAATGTATGAAATAAAATACGGATCACAAGTTGAGGATCAGCGAGAATGTGTG
TCCAGACAGGAATACAGGAAGTATGGAGGGGCCAAGCTAAACCGGCTAAACCCGGGGAAC
TACACAGCCCGGATTCAGGCCACATCTCTCTCTGGGAATGGGTCGTGGACAGATCCTGTG
TTCTTCTATGTCCAGGCCAAAACAGGATATGAAAACTTCATCCATCTGATCATCGCTCTG
CCCGTCGCTGTCCTGTTGATCGTGGGAGGGTTGGTGATTATGCTGTACGTCTTCCATAGA
AAGAGAAATAACAGCAGGCTGGGGAATGGAGTGCTGTATGCCTCTGTGAACCCGGAGTAC
TTCAGCGCTGCTGATGTGTACGTTCCTGATGAGTGGGAGGTGGCTCGGGAGAAGATCACC
ATGAGCCGGGAACTTGGGCAGGGGTCGTTTGGGATGGTCTATGAAGGAGTTGCCAAGGGT
GTGGTGAAAGATGAACCTGAAACCAGAGTGGCCATTAAAACAGTGAACGAGGCCGCAAGC
ATGCGTGAGAGGATTGAGTTTCTCAACGAAGCTTCTGTGATGAAGGAGTTCAATTGTCAC
CATGTGGTGCGATTGCTGGGTGTGGTGTCCCAAGGCCAGCCAACACTGGTCATCATGGAA
CTGATGACACGGGGCGATCTCAAAAGTTATCTCCGGTCTCTGAGGCCAGAAATGGAGAAT
AATCCAGTCCTAGCACCTCCAAGCCTGAGCAAGATGATTCAGATGGCCGGAGAGATTGCA
GACGGCATGGCATACCTCAACGCCAATAAGTTCGTCCACAGAGACCTTGCTGCCCGGAAT
TGCATGGTAGCCGAAGATTTCACAGTCAAAATCGGAGATTTTGGTATGACGCGAGATATC
TATGAGACAGACTATTACCGGAAAGGAGGGAAAGGGCTGCTGCCCGTGCGCTGGATGTCT
CCTGAGTCCCTCAAGGATGGAGTCTTCACCACTTACTCGGACGTCTGGTCCTTCGGGGTC
GTCCTCTGGGAGATCGCCACACTGGCCGAGCAGCCCTACCAGGGCTTGTCCAACGAGCAA
GTCCTTCGCTTCGTCATGGAGGGCGGCCTTCTGGACAAGCCAGACAACTGTCCTGACATG
CTGTTTGAACTGATGCGCATGTGCTGGCAGTATAACCCCAAGATGAGGCCTTCCTTCCTG
GAGATCATCAGCAGCATCAAAGAGGAGATGGAGCCTGGCTTCCGGGAGGTCTCCTTCTAC
TACAGCGAGGAGAACAAGCTGCCCGAGCCGGAGGAGCTGGACCTGGAGCCAGAGAACATG
GAGAGCGTCCCCCTGGACCCCTCGGCCTCCTCGTCCTCCCTGCCACTGCCCGACAGACAC
TCAGGACACAAGGCCGAGAACGGCCCCGGCCCTGGGGTGCTGGTCCTCCGCGCCAGCTTC
GACGAGAGACAGCCTTACGCCCACATGAACGGGGGCCGCAAGAACGAGCGGGCCTTGCCG
CTGCCCCAGTCTTCGACCTGCTGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF07714</identifier>
            <name>Pkinase_Tyr</name>
          </pfam>
          <pfam>
            <identifier>PF00757</identifier>
            <name>Furin-like</name>
          </pfam>
          <pfam>
            <identifier>PF01030</identifier>
            <name>Recep_L_domain</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>caveola</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>integral component of plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>intracellular membrane-bounded organelle</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>neuron projection</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>receptor complex</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>ATP binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>identical protein binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>insulin binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>insulin receptor binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>insulin receptor substrate binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>insulin-like growth factor binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>insulin-like growth factor I binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>insulin-like growth factor-activated receptor activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>phosphatidylinositol 3-kinase binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>protein tyrosine kinase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>axonogenesis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>brain development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>epidermis development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>establishment of cell polarity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>exocrine pancreas development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>immune response</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>inactivation of MAPKK activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>insulin receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>insulin-like growth factor receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>male sex determination</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>mammary gland development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of apoptotic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of muscle cell apoptotic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of protein kinase B signaling</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of sequence-specific DNA binding transcription factor activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>peptidyl-tyrosine autophosphorylation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>phosphatidylinositol 3-kinase signaling</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>phosphatidylinositol-mediated signaling</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of cell migration</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of cell proliferation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of cytokinesis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of DNA replication</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of MAPK cascade</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of mitotic nuclear division</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of protein kinase B signaling</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of steroid hormone biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>prostate gland epithelium morphogenesis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>protein autophosphorylation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>protein heterooligomerization</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>protein tetramerization</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of JNK cascade</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to vitamin E</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>signal transduction</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
    <target position="3">
      <id>BE0001183</id>
      <name>Insulin-degrading enzyme</name>
      <organism>Humans</organism>
      <actions/>
      <references>
        <articles>
          <article>
            <ref-id>A1713</ref-id>
            <pubmed-id>17139284</pubmed-id>
            <citation>Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.</citation>
          </article>
          <article>
            <ref-id>A1715</ref-id>
            <pubmed-id>17016423</pubmed-id>
            <citation>Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.</citation>
          </article>
          <article>
            <ref-id>A13243</ref-id>
            <pubmed-id>8504733</pubmed-id>
            <citation>Harada S, Smith RM, Smith JA, Jarett L: Inhibition of insulin-degrading enzyme increases translocation of insulin to the nucleus in H35 rat hepatoma cells: evidence of a cytosolic pathway. Endocrinology. 1993 Jun;132(6):2293-8.</citation>
          </article>
          <article>
            <ref-id>A13244</ref-id>
            <pubmed-id>9643444</pubmed-id>
            <citation>Hsu MC, Bai JP: Investigation into the presence of insulin-degrading enzyme in cultured type II alveolar cells and the effects of enzyme inhibitors on pulmonary bioavailability of insulin in rats. J Pharm Pharmacol. 1998 May;50(5):507-14.</citation>
          </article>
          <article>
            <ref-id>A13245</ref-id>
            <pubmed-id>13560210</pubmed-id>
            <citation>MARIGO S, PANELLI G: [Insulinase and its inhibition by hypoglycemic sulfonamides; data on insulin sensitivity during tolbutamide therapy]. Arch Sci Med (Torino). 1958 Jun;105(6):587-609.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P14735" source="Swiss-Prot">
        <name>Insulin-degrading enzyme</name>
        <general-function>Zinc ion binding</general-function>
        <specific-function>Plays a role in the cellular breakdown of insulin, IAPP, glucagon, bradykinin, kallidin and other peptides, and thereby plays a role in intercellular peptide signaling. Degrades amyloid formed by APP and IAPP. May play a role in the degradation and clearance of naturally secreted amyloid beta-protein by neurons and microglia.(Microbial infection) The membrane-associated isoform acts as an entry receptor for varicella-zoster virus (VZV).</specific-function>
        <gene-name>IDE</gene-name>
        <locus>10q23-q25</locus>
        <cellular-location>Cytoplasm</cellular-location>
        <transmembrane-regions/>
        <signal-regions/>
        <theoretical-pi>6.74</theoretical-pi>
        <molecular-weight>117967.49</molecular-weight>
        <chromosome-location>10</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:5381</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>IDE</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>M21188</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>184556</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>2371</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P14735</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>IDE_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>3.4.24.56</synonym>
          <synonym>Abeta-degrading protease</synonym>
          <synonym>Insulin protease</synonym>
          <synonym>Insulinase</synonym>
          <synonym>Insulysin</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0037135|Insulin-degrading enzyme
MRYRLAWLLHPALPSTFRSVLGARLPPPERLCGFQKKTYSKMNNPAIKRIGNHITKSPED
KREYRGLELANGIKVLLISDPTTDKSSAALDVHIGSLSDPPNIAGLSHFCEHMLFLGTKK
YPKENEYSQFLSEHAGSSNAFTSGEHTNYYFDVSHEHLEGALDRFAQFFLCPLFDESCKD
REVNAVDSEHEKNVMNDAWRLFQLEKATGNPKHPFSKFGTGNKYTLETRPNQEGIDVRQE
LLKFHSAYYSSNLMAVCVLGRESLDDLTNLVVKLFSEVENKNVPLPEFPEHPFQEEHLKQ
LYKIVPIKDIRNLYVTFPIPDLQKYYKSNPGHYLGHLIGHEGPGSLLSELKSKGWVNTLV
GGQKEGARGFMFFIINVDLTEEGLLHVEDIILHMFQYIQKLRAEGPQEWVFQECKDLNAV
AFRFKDKERPRGYTSKIAGILHYYPLEEVLTAEYLLEEFRPDLIEMVLDKLRPENVRVAI
VSKSFEGKTDRTEEWYGTQYKQEAIPDEVIKKWQNADLNGKFKLPTKNEFIPTNFEILPL
EKEATPYPALIKDTAMSKLWFKQDDKFFLPKACLNFEFFSPFAYVDPLHCNMAYLYLELL
KDSLNEYAYAAELAGLSYDLQNTIYGMYLSVKGYNDKQPILLKKIIEKMATFEIDEKRFE
IIKEAYMRSLNNFRAEQPHQHAMYYLRLLMTEVAWTKDELKEALDDVTLPRLKAFIPQLL
SRLHIEALLHGNITKQAALGIMQMVEDTLIEHAHTKPLLPSQLVRYREVQLPDRGWFVYQ
QRNEVHNNCGIEIYYQTDMQSTSENMFLELFCQIISEPCFNTLRTKEQLGYIVFSGPRRA
NGIQGLRFIIQSEKPPHYLESRVEAFLITMEKSIEDMTEEAFQKHIQALAIRRLDKPKKL
SAECAKYWGEIISQQYNFDRDNTEVAYLKTLTKEDIIKFYKEMLAVDAPRRHKVSVHVLA
REMDSCPVVGEFPCQNDINLSQAPALPQPEVIQNMTEFKRGLPLFPLVKPHINFMAAKL</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0016342|Insulin-degrading enzyme (IDE)
ATGAGCAAACTTTGGTTCAAACAAGATGATAAGTTTTTTTTGCCGAAGGCTTGTCTCAAC
TTTGAATTTTTCAGCCCATTTGCTTATGTGGACCCCTTGCACTGTAACATGGCCTATTTG
TACCTTGAGCTCCTCAAAGACTCACTCAACGAGTATGCATATGCAGCAGAGCTAGCAGGC
TTGAGCTATGATCTCCAAAATACCATCTATGGGATGTATCTTTCAGTGAAAGGTTACAAT
GACAAGCAGCCAATTTTACTAAAGAAGATTATTGAGAAAATGGCTACCTTTGAGATTGAT
GAAAAAAGATTTGAAATTATCAAAGAAGCATATATGCGATCTCTTAACAATTTCCGGGCT
GAACAGCCTCACCAGCATGCCATGTACTACCTCCGCTTGCTGATGACTGAAGTGGCCTGG
ACTAAAGATGAGTTAAAAGAAGCTCTGGATGATGTAACCCTTCCTCGCCTTAAGGCCTTC
ATACCTCAGCTCCTGTCACGGCTGCACATTGAAGCCCTTCTCCATGGAAACATAACAAAG
CAGGCTGCATTAGGAATTATGCAGATGGTTGAAGACACCCTCATTGAACATGCTCATACC
AAACCTCTCCTTCCAAGTCAGCTGGTTCGGTATAGAGAAGTTCAGCTCCCTGACAGAGGA
TGGTTTGTTTATCAGCAGAGAAATGAAGTTCACAATAACTGTGGCATCGAGATATACTAC
CAAACAGACATGCAAAGCACCTCAGAGAATATGTTTCTGGAGCTCTTCTGTCAGATTATC
TCGGAACCTTGCTTCAACACCCTGCGCACCAAGGAGCAGTTGGGCTATATCGTCTTCAGC
GGGCCACGTCGAGCTAATGGCATACAGGGCTTGAGATTCATCATCCAGTCAGAAAAGCCA
CCTCACTACCTAGAAAGCAGAGTGGAAGCTTTCTTAATTACCATGGAAAAGTCCATAGAG
GACATGACAGAAGAGGCCTTCCAAAAACACATTCAGGCATTAGCAATTCGTCGACTAGAC
AAACCAAAGAAGCTATCTGCTGAGTGTGCTAAATACTGGGGAGAAATCATCTCCCAGCAA
TATAATTTTGACAGAGATAACACTGAGGTTGCATATTTAAAGACACTTACCAAGGAAGAT
ATCATCAAATTCTACAAGGAAATGTTGGCAGTAGATGCTCCAAGGAGACATAAGGTATCC
GTCCATGTTCTTGCCAGGGAAATGGATTCTTGTCCTGTTGTTGGAGAGTTCCCATGTCAA
AATGACATAAATTTGTCACAAGCACCAGCCTTGCCACAACCTGAAGTGATTCAGAACATG
ACCGAATTCAAGCGTGGTCTGCCACTGTTTCCCCTTGTGAAACCACATATTAACTTCATG
GCTGCAAAACTCTGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00675</identifier>
            <name>Peptidase_M16</name>
          </pfam>
          <pfam>
            <identifier>PF05193</identifier>
            <name>Peptidase_M16_C</name>
          </pfam>
          <pfam>
            <identifier>PF16187</identifier>
            <name>Peptidase_M16_M</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>cell surface</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>cytoplasm</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>cytosol</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>cytosolic proteasome complex</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>extracellular space</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>mitochondrion</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>nucleoplasm</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>nucleus</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>peroxisomal matrix</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>peroxisome</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>ATP binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>ATPase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>beta-amyloid binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>beta-endorphin binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>glycoprotein binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>insulin binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>metalloendopeptidase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>peptide binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>protein homodimerization activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>receptor binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>ubiquitin binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>virus receptor activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>zinc ion binding</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>beta-amyloid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>bradykinin catabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>determination of adult lifespan</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>hormone catabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>insulin catabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>insulin metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>insulin receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of proteolysis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of protein oligomerization</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>protein heterooligomerization</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>protein homooligomerization</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>protein homotetramerization</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>protein processing</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>proteolysis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>proteolysis involved in cellular protein catabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>ubiquitin homeostasis</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
    <target position="4">
      <id>BE0002122</id>
      <name>HLA class II histocompatibility antigen, DQ alpha 2 chain</name>
      <organism>Humans</organism>
      <actions/>
      <references>
        <articles>
          <article>
            <ref-id>A1713</ref-id>
            <pubmed-id>17139284</pubmed-id>
            <citation>Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.</citation>
          </article>
          <article>
            <ref-id>A1715</ref-id>
            <pubmed-id>17016423</pubmed-id>
            <citation>Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.</citation>
          </article>
          <article>
            <ref-id>A13231</ref-id>
            <pubmed-id>8200980</pubmed-id>
            <citation>Pugliese A, Bugawan T, Moromisato R, Awdeh ZL, Alper CA, Jackson RA, Erlich HA, Eisenbarth GS: Two subsets of HLA-DQA1 alleles mark phenotypic variation in levels of insulin autoantibodies in first degree relatives at risk for insulin-dependent diabetes. J Clin Invest. 1994 Jun;93(6):2447-52.</citation>
          </article>
          <article>
            <ref-id>A13232</ref-id>
            <pubmed-id>11006709</pubmed-id>
            <citation>Hermann R, Soltesz G: [Pathogenesis and types of neonatal diabetes]. Orv Hetil. 2000 Aug 20;141(34):1855-8.</citation>
          </article>
          <article>
            <ref-id>A13233</ref-id>
            <pubmed-id>9458118</pubmed-id>
            <citation>Donner H, Rau H, Braun J, Herwig J, Usadel KH, Badenhoop K: Highly polymorphic promoter regions of HLA DQA1 and DQB1 genes do not help to further define disease susceptibility in insulin-dependent diabetes mellitus. Tissue Antigens. 1997 Dec;50(6):642-5.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P01906" source="Swiss-Prot">
        <name>HLA class II histocompatibility antigen, DQ alpha 2 chain</name>
        <general-function>Mhc class ii receptor activity</general-function>
        <specific-function>Binds peptides derived from antigens that access the endocytic route of antigen presenting cells (APC) and presents them on the cell surface for recognition by the CD4 T-cells. The peptide binding cleft accommodates peptides of 10-30 residues. The peptides presented by MHC class II molecules are generated mostly by degradation of proteins that access the endocytic route, where they are processed by lysosomal proteases and other hydrolases. Exogenous antigens that have been endocytosed by the APC are thus readily available for presentation via MHC II molecules, and for this reason this antigen presentation pathway is usually referred to as exogenous. As membrane proteins on their way to degradation in lysosomes as part of their normal turn-over are also contained in the endosomal/lysosomal compartments, exogenous antigens must compete with those derived from endogenous components. Autophagy is also a source of endogenous peptides, autophagosomes constitutively fuse with MHC class II loading compartments. In addition to APCs, other cells of the gastrointestinal tract, such as epithelial cells, express MHC class II molecules and CD74 and act as APCs, which is an unusual trait of the GI tract. To produce a MHC class II molecule that presents an antigen, three MHC class II molecules (heterodimers of an alpha and a beta chain) associate with a CD74 trimer in the ER to form a heterononamer. Soon after the entry of this complex into the endosomal/lysosomal system where antigen processing occurs, CD74 undergoes a sequential degradation by various proteases, including CTSS and CTSL, leaving a small fragment termed CLIP (class-II-associated invariant chain peptide). The removal of CLIP is facilitated by HLA-DM via direct binding to the alpha-beta-CLIP complex so that CLIP is released. HLA-DM stabilizes MHC class II molecules until primary high affinity antigenic peptides are bound. The MHC II molecule bound to a peptide is then transported to the cell membrane surface. In B-cells, the interaction between HLA-DM and MHC class II molecules is regulated by HLA-DO. Primary dendritic cells (DCs) also to express HLA-DO. Lysosomal microenvironment has been implicated in the regulation of antigen loading into MHC II molecules, increased acidification produces increased proteolysis and efficient peptide loading.</specific-function>
        <gene-name>HLA-DQA2</gene-name>
        <locus>6p21.3</locus>
        <cellular-location>Cell membrane</cellular-location>
        <transmembrane-regions>218-240</transmembrane-regions>
        <signal-regions>1-23</signal-regions>
        <theoretical-pi>4.53</theoretical-pi>
        <molecular-weight>28032.82</molecular-weight>
        <chromosome-location>6</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:4943</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>HLA-DQA2</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>M29615</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>493166</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P01906</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>DQA2_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>DX alpha chain</synonym>
          <synonym>HLA class II histocompatibility antigen, DQ(6) alpha chain</synonym>
          <synonym>HLA-DQA1</synonym>
          <synonym>HLA-DXA</synonym>
          <synonym>MHC class II DQA2</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0011537|HLA class II histocompatibility antigen, DQ alpha 2 chain
MILNKALLLGALALTAVMSPCGGEDIVADHVASYGVNFYQSHGPSGQYTHEFDGDEEFYV
DLETKETVWQLPMFSKFISFDPQSALRNMAVGKHTLEFMMRQSNSTAATNEVPEVTVFSK
FPVTLGQPNTLICLVDNIFPPVVNITWLSNGHSVTEGVSETSFLSKSDHSFFKISYLTFL
PSADEIYDCKVEHWGLDEPLLKHWEPEIPAPMSELTETLVCALGLSVGLMGIVVGTVFII
QGLRSVGASRHQGLL</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0011538|HLA class II histocompatibility antigen, DQ alpha 2 chain (HLA-DQA2)
ATGATCCTAAACAAAGCTCTGCTGCTGGGGGCCCTCGCCCTGACTGCCGTGATGAGCCCC
TGTGGAGGTGAAGACATTGTGGCTGACCATGTTGCCTCCTATGGTGTGAACTTCTACCAG
TCTCACGGTCCCTCTGGCCAGTACACCCATGAATTTGATGGAGACGAGGAGTTCTATGTG
GACCTGGAGACGAAAGAGACTGTCTGGCAGTTGCCTATGTTTAGCAAATTTATAAGTTTT
GACCCGCAGAGTGCACTGAGAAATATGGCTGTGGGAAAACACACCTTGGAATTCATGATG
AGACAGTCCAACTCTACCGCTGCCACCAATGAGGTTCCTGAGGTCACAGTGTTTTCCAAG
TTTCCTGTGACGCTGGGTCAGCCCAACACCCTCATCTGTCTTGTGGACAACATCTTTCCT
CCTGTGGTCAACATCACCTGGCTGAGCAATGGGCACTCAGTCACAGAAGGTGTTTCTGAG
ACCAGCTTCCTCTCCAAGAGTGATCATTCCTTCTTCAAGATCAGTTACCTCACCTTCCTC
CCTTCTGCTGATGAGATTTATGACTGCAAGGTGGAGCACTGGGGCCTGGACGAGCCTCTT
CTGAAACACTGGGAGCCTGAGATTCCAGCCCCTATGTCAGAGCTCACAGAGACTTTGGTC
TGCGCCCTGGGGTTGTCTGTGGGCCTCATGGGCATTGTGGTGGGCACTGTCTTCATCATC
CAAGGCCTGCGTTCAGTTGGTGCTTCCAGACACCAAGGGCTCTTATGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF07654</identifier>
            <name>C1-set</name>
          </pfam>
          <pfam>
            <identifier>PF00993</identifier>
            <name>MHC_II_alpha</name>
          </pfam>
          <pfam>
            <identifier>PF16196</identifier>
            <name>C1-set_C</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>clathrin-coated endocytic vesicle membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>endocytic vesicle membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>endosome membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>ER to Golgi transport vesicle membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>Golgi membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>integral component of lumenal side of endoplasmic reticulum membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>integral component of plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>lysosomal membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>MHC class II protein complex</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>trans-Golgi network membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>transport vesicle membrane</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>MHC class II receptor activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>antigen processing and presentation of exogenous peptide antigen via MHC class II</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cytokine-mediated signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>immune response</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>interferon-gamma-mediated signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>T cell costimulation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>T cell receptor signaling pathway</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
    <target position="5">
      <id>BE0004466</id>
      <name>HLA class II histocompatibility antigen, DQ beta 1 chain</name>
      <organism>Humans</organism>
      <actions/>
      <references>
        <articles>
          <article>
            <ref-id>A1713</ref-id>
            <pubmed-id>17139284</pubmed-id>
            <citation>Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.</citation>
          </article>
          <article>
            <ref-id>A1715</ref-id>
            <pubmed-id>17016423</pubmed-id>
            <citation>Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.</citation>
          </article>
          <article>
            <ref-id>A13234</ref-id>
            <pubmed-id>1728861</pubmed-id>
            <citation>Mahran MZ, Ross DG, Sadeghi-Nejad A, Rabson AR: Use of the polymerase chain reaction mismatch technique to identify the HLA-DQw8 allele in patients with insulin-dependent diabetes mellitus. Am J Clin Pathol. 1992 Jan;97(1):29-33.</citation>
          </article>
          <article>
            <ref-id>A13235</ref-id>
            <pubmed-id>1612232</pubmed-id>
            <citation>Levy-Marchal C, Tichet J, Fajardy I, Gu XF, Dubois F, Czernichow P: Islet cell antibodies in normal French schoolchildren. Diabetologia. 1992 Jun;35(6):577-82.</citation>
          </article>
          <article>
            <ref-id>A1991</ref-id>
            <pubmed-id>10592235</pubmed-id>
            <citation>Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P01920" source="Swiss-Prot">
        <name>HLA class II histocompatibility antigen, DQ beta 1 chain</name>
        <general-function>Peptide antigen binding</general-function>
        <specific-function>Binds peptides derived from antigens that access the endocytic route of antigen presenting cells (APC) and presents them on the cell surface for recognition by the CD4 T-cells. The peptide binding cleft accommodates peptides of 10-30 residues. The peptides presented by MHC class II molecules are generated mostly by degradation of proteins that access the endocytic route, where they are processed by lysosomal proteases and other hydrolases. Exogenous antigens that have been endocytosed by the APC are thus readily available for presentation via MHC II molecules, and for this reason this antigen presentation pathway is usually referred to as exogenous. As membrane proteins on their way to degradation in lysosomes as part of their normal turn-over are also contained in the endosomal/lysosomal compartments, exogenous antigens must compete with those derived from endogenous components. Autophagy is also a source of endogenous peptides, autophagosomes constitutively fuse with MHC class II loading compartments. In addition to APCs, other cells of the gastrointestinal tract, such as epithelial cells, express MHC class II molecules and CD74 and act as APCs, which is an unusual trait of the GI tract. To produce a MHC class II molecule that presents an antigen, three MHC class II molecules (heterodimers of an alpha and a beta chain) associate with a CD74 trimer in the ER to form a heterononamer. Soon after the entry of this complex into the endosomal/lysosomal system where antigen processing occurs, CD74 undergoes a sequential degradation by various proteases, including CTSS and CTSL, leaving a small fragment termed CLIP (class-II-associated invariant chain peptide). The removal of CLIP is facilitated by HLA-DM via direct binding to the alpha-beta-CLIP complex so that CLIP is released. HLA-DM stabilizes MHC class II molecules until primary high affinity antigenic peptides are bound. The MHC II molecule bound to a peptide is then transported to the cell membrane surface. In B-cells, the interaction between HLA-DM and MHC class II molecules is regulated by HLA-DO. Primary dendritic cells (DCs) also to express HLA-DO. Lysosomal microenvironment has been implicated in the regulation of antigen loading into MHC II molecules, increased acidification produces increased proteolysis and efficient peptide loading.</specific-function>
        <gene-name>HLA-DQB1</gene-name>
        <locus/>
        <cellular-location>Cell membrane</cellular-location>
        <transmembrane-regions>231-251</transmembrane-regions>
        <signal-regions>1-32</signal-regions>
        <theoretical-pi/>
        <molecular-weight>29991.02</molecular-weight>
        <chromosome-location/>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:4944</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P01920</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>DQB1_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>HLA-DQB</synonym>
          <synonym>MHC class II antigen DQB1</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0009387|HLA class II histocompatibility antigen, DQ beta 1 chain
MSWKKALRIPGGLRAATVTLMLAMLSTPVAEGRDSPEDFVYQFKAMCYFTNGTERVRYVT
RYIYNREEYARFDSDVEVYRAVTPLGPPDAEYWNSQKEVLERTRAELDTVCRHNYQLELR
TTLQRRVEPTVTISPSRTEALNHHNLLVCSVTDFYPAQIKVRWFRNDQEETTGVVSTPLI
RNGDWTFQILVMLEMTPQHGDVYTCHVEHPSLQNPITVEWRAQSESAQSKMLSGIGGFVL
GLIFLGLGLIIHHRSQKGLLH</amino-acid-sequence>
        <gene-sequence format="FASTA"/>
        <pfams>
          <pfam>
            <identifier>PF07654</identifier>
            <name>C1-set</name>
          </pfam>
          <pfam>
            <identifier>PF00969</identifier>
            <name>MHC_II_beta</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>clathrin-coated endocytic vesicle membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>endocytic vesicle membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>endosome membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>ER to Golgi transport vesicle membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>Golgi membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>integral component of lumenal side of endoplasmic reticulum membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>lysosomal membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>MHC class II protein complex</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>trans-Golgi network membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>transport vesicle membrane</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>MHC class II receptor activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>peptide antigen binding</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>antigen processing and presentation of exogenous peptide antigen via MHC class II</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cytokine-mediated signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>humoral immune response mediated by circulating immunoglobulin</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>immune response</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>immunoglobulin production involved in immunoglobulin mediated immune response</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>interferon-gamma-mediated signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>T cell costimulation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>T cell receptor signaling pathway</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
    <target position="6">
      <id>BE0002123</id>
      <name>Retinoblastoma-associated protein</name>
      <organism>Humans</organism>
      <actions/>
      <references>
        <articles>
          <article>
            <ref-id>A1713</ref-id>
            <pubmed-id>17139284</pubmed-id>
            <citation>Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.</citation>
          </article>
          <article>
            <ref-id>A1715</ref-id>
            <pubmed-id>17016423</pubmed-id>
            <citation>Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.</citation>
          </article>
          <article>
            <ref-id>A13236</ref-id>
            <pubmed-id>1701386</pubmed-id>
            <citation>Biener Y, Zick Y: Basic polycations activate the insulin receptor kinase and a tightly associated serine kinase. Eur J Biochem. 1990 Nov 26;194(1):243-50.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P06400" source="Swiss-Prot">
        <name>Retinoblastoma-associated protein</name>
        <general-function>Ubiquitin protein ligase binding</general-function>
        <specific-function>Key regulator of entry into cell division that acts as a tumor suppressor. Promotes G0-G1 transition when phosphorylated by CDK3/cyclin-C. Acts as a transcription repressor of E2F1 target genes. The underphosphorylated, active form of RB1 interacts with E2F1 and represses its transcription activity, leading to cell cycle arrest. Directly involved in heterochromatin formation by maintaining overall chromatin structure and, in particular, that of constitutive heterochromatin by stabilizing histone methylation. Recruits and targets histone methyltransferases SUV39H1, SUV420H1 and SUV420H2, leading to epigenetic transcriptional repression. Controls histone H4 'Lys-20' trimethylation. Inhibits the intrinsic kinase activity of TAF1. Mediates transcriptional repression by SMARCA4/BRG1 by recruiting a histone deacetylase (HDAC) complex to the c-FOS promoter. In resting neurons, transcription of the c-FOS promoter is inhibited by BRG1-dependent recruitment of a phospho-RB1-HDAC1 repressor complex. Upon calcium influx, RB1 is dephosphorylated by calcineurin, which leads to release of the repressor complex (By similarity). In case of viral infections, interactions with SV40 large T antigen, HPV E7 protein or adenovirus E1A protein induce the disassembly of RB1-E2F1 complex thereby disrupting RB1's activity.</specific-function>
        <gene-name>RB1</gene-name>
        <locus>13q14.2</locus>
        <cellular-location>Nucleus</cellular-location>
        <transmembrane-regions/>
        <signal-regions/>
        <theoretical-pi>8.04</theoretical-pi>
        <molecular-weight>106158.335</molecular-weight>
        <chromosome-location>13</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:9884</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>RB1</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>M15400</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>190959</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P06400</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>RB_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>p105-Rb</synonym>
          <synonym>pp110</synonym>
          <synonym>pRb</synonym>
          <synonym>Rb</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0021315|Retinoblastoma-associated protein
MPPKTPRKTAATAAAAAAEPPAPPPPPPPEEDPEQDSGPEDLPLVRLEFEETEEPDFTAL
CQKLKIPDHVRERAWLTWEKVSSVDGVLGGYIQKKKELWGICIFIAAVDLDEMSFTFTEL
QKNIEISVHKFFNLLKEIDTSTKVDNAMSRLLKKYDVLFALFSKLERTCELIYLTQPSSS
ISTEINSALVLKVSWITFLLAKGEVLQMEDDLVISFQLMLCVLDYFIKLSPPMLLKEPYK
TAVIPINGSPRTPRRGQNRSARIAKQLENDTRIIEVLCKEHECNIDEVKNVYFKNFIPFM
NSLGLVTSNGLPEVENLSKRYEEIYLKNKDLDARLFLDHDKTLQTDSIDSFETQRTPRKS
NLDEEVNVIPPHTPVRTVMNTIQQLMMILNSASDQPSENLISYFNNCTVNPKESILKRVK
DIGYIFKEKFAKAVGQGCVEIGSQRYKLGVRLYYRVMESMLKSEEERLSIQNFSKLLNDN
IFHMSLLACALEVVMATYSRSTSQNLDSGTDLSFPWILNVLNLKAFDFYKVIESFIKAEG
NLTREMIKHLERCEHRIMESLAWLSDSPLFDLIKQSKDREGPTDHLESACPLNLPLQNNH
TAADMYLSPVRSPKKKGSTTRVNSTANAETQATSAFQTQKPLKSTSLSLFYKKVYRLAYL
RLNTLCERLLSEHPELEHIIWTLFQHTLQNEYELMRDRHLDQIMMCSMYGICKVKNIDLK
FKIIVTAYKDLPHAVQETFKRVLIKEEEYDSIIVFYNSVFMQRLKTNILQYASTRPPTLS
PIPHIPRSPYKFPSSPLRIPGGNIYISPLKSPYKISEGLPTPTKMTPRSRILVSIGESFG
TSEKFQKINQMVCNSDRVLKRSAEGSNPPKPLKKLRFDIEGSDEADGSKHLPGESKFQQK
LAEMTSTRTRMQKQKMNDSMDTSNKEEK</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0021316|Retinoblastoma-associated protein (RB1)
ATGCCGCCCAAAACCCCCCGAAAAACGGCCGCCACCGCCGCCGCTGCCGCCGCGGAACCC
CCGGCACCGCCGCCGCCGCCCCCTCCTGAGGAGGACCCAGAGCAGGACAGCGGCCCGGAG
GACCTGCCTCTCGTCAGGCTTGAGTTTGAAGAAACAGAAGAACCTGATTTTACTGCATTA
TGTCAGAAATTAAAGATACCAGATCATGTCAGAGAGAGAGCTTGGTTAACTTGGGAGAAA
GTTTCATCTGTGGATGGAGTATTGGGAGGTTATATTCAAAAGAAAAAGGAACTGTGGGGA
ATCTGTATCTTTATTGCAGCAGTTGACCTAGATGAGATGTCGTTCACTTTTACTGAGCTA
CAGAAAAACATAGAAATCAGTGTCCATAAATTCTTTAACTTACTAAAAGAAATTGATACC
AGTACCAAAGTTGATAATGCTATGTCAAGACTGTTGAAGAAGTATGATGTATTGTTTGCA
CTCTTCAGCAAATTGGAAAGGACATGTGAACTTATATATTTGACACAACCCAGCAGTTCG
ATATCTACTGAAATAAATTCTGCATTGGTGCTAAAAGTTTCTTGGATCACATTTTTATTA
GCTAAAGGGGAAGTATTACAAATGGAAGATGATCTGGTGATTTCATTTCAGTTAATGCTA
TGTGTCCTTGACTATTTTATTAAACTCTCACCTCCCATGTTGCTCAAAGAACCATATAAA
ACAGCTGTTATACCCATTAATGGTTCACCTCGAACACCCAGGCGAGGTCAGAACAGGAGT
GCACGGATAGCAAAACAACTAGAAAATGATACAAGAATTATTGAAGTTCTCTGTAAAGAA
CATGAATGTAATATAGATGAGGTGAAAAATGTTTATTTCAAAAATTTTATACCTTTTATG
AATTCTCTTGGACTTGTAACATCTAATGGACTTCCAGAGGTTGAAAATCTTTCTAAACGA
TACGAAGAAATTTATCTTAAAAATAAAGATCTAGATGCAAGATTATTTTTGGATCATGAT
AAAACTCTTCAGACTGATTCTATAGACAGTTTTGAAACACAGAGAACACCACGAAAAAGT
AACCTTGATGAAGAGGTGAATGTAATTCCTCCACACACTCCAGTTAGGACTGTTATGAAC
ACTATCCAACAATTAATGATGATTTTAAATTCAGCAAGTGATCAACCTTCAGAAAATCTG
ATTTCCTATTTTAACAACTGCACAGTGAATCCAAAAGAAAGTATACTGAAAAGAGTGAAG
GATATAGGATACATCTTTAAAGAGAAATTTGCTAAAGCTGTGGGACAGGGTTGTGTCGAA
ATTGGATCACAGCGATACAAACTTGGAGTTCGCTTGTATTACCGAGTAATGGAATCCATG
CTTAAATCAGAAGAAGAACGATTATCCATTCAAAATTTTAGCAAACTTCTGAATGACAAC
ATTTTTCATATGTCTTTATTGGCGTGCGCTCTTGAGGTTGTAATGGCCACATATAGCAGA
AGTACATCTCAGAATCTTGATTCTGGAACAGATTTGTCTTTCCCATGGATTCTGAATGTG
CTTAATTTAAAAGCCTTTGATTTTTACAAAGTGATCGAAAGTTTTATCAAAGCAGAAGGC
AACTTGACAAGAGAAATGATAAAACATTTAGAACGATGTGAACATCGAATCATGGAATCC
CTTGCATGGCTCTCAGATTCACCTTTATTTGATCTTATTAAACAATCAAAGGACCGAGAA
GGACCAACTGATCACCTTGAATCTGCTTGTCCTCTTAATCTTCCTCTCCAGAATAATCAC
ACTGCAGCAGATATGTATCTTTCTCCTGTAAGATCTCCAAAGAAAAAAGGTTCAACTACG
CGTGTAAATTCTACTGCAAATGCAGAGACACAAGCAACCTCAGCCTTCCAGACCCAGAAG
CCATTGAAATCTACCTCTCTTTCACTGTTTTATAAAAAAGTGTATCGGCTAGCCTATCTC
CGGCTAAATACACTTTGTGAACGCCTTCTGTCTGAGCACCCAGAATTAGAACATATCATC
TGGACCCTTTTCCAGCACACCCTGCAGAATGAGTATGAACTCATGAGAGACAGGCATTTG
GACCAAATTATGATGTGTTCCATGTATGGCATATGCAAAGTGAAGAATATAGACCTTAAA
TTCAAAATCATTGTAACAGCATACAAGGATCTTCCTCATGCTGTTCAGGAGACATTCAAA
CGTGTTTTGATCAAAGAAGAGGAGTATGATTCTATTATAGTATTCTATAACTCGGTCTTC
ATGCAGAGACTGAAAACAAATATTTTGCAGTATGCTTCCACCAGGCCCCCTACCTTGTCA
CCAATACCTCACATTCCTCGAAGCCCTTACAAGTTTCCTAGTTCACCCTTACGGATTCCT
GGAGGGAACATCTATATTTCACCCCTGAAGAGTCCATATAAAATTTCAGAAGGTCTGCCA
ACACCAACAAAAATGACTCCAAGATCAAGAATCTTAGTATCAATTGGTGAATCATTCGGG
ACTTCTGAGAAGTTCCAGAAAATAAATCAGATGGTATGTAACAGCGACCGTGTGCTCAAA
AGAAGTGCTGAAGGAAGCAACCCTCCTAAACCACTGAAAAAACTACGCTTTGATATTGAA
GGATCAGATGAAGCAGATGGAAGTAAACATCTCCCAGGAGAGTCCAAATTTCAGCAGAAA
CTGGCAGAAATGACTTCTACTCGAACACGAATGCAAAAGCAGAAAATGAATGATAGCATG
GATACCTCAAACAAGGAAGAGAAATGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF01858</identifier>
            <name>RB_A</name>
          </pfam>
          <pfam>
            <identifier>PF01857</identifier>
            <name>RB_B</name>
          </pfam>
          <pfam>
            <identifier>PF08934</identifier>
            <name>Rb_C</name>
          </pfam>
          <pfam>
            <identifier>PF11934</identifier>
            <name>DUF3452</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>chromatin</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>nucleoplasm</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>nucleus</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>PML body</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>Rb-E2F complex</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>spindle</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>SWI/SNF complex</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>androgen receptor binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>core promoter binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>DNA binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>identical protein binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>kinase binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>phosphoprotein binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>transcription coactivator activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>transcription factor activity, sequence-specific DNA binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>transcription factor binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>ubiquitin protein ligase binding</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>androgen receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cell cycle arrest</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cell cycle checkpoint</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cell division</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cell morphogenesis involved in neuron differentiation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to xenobiotic stimulus</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>chromatin remodeling</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>digestive tract development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>enucleate erythrocyte differentiation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>G1/S transition of mitotic cell cycle</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>glial cell apoptotic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>hepatocyte apoptotic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>maintenance of mitotic sister chromatid cohesion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>mitotic cell cycle</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>mitotic cell cycle checkpoint</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>myoblast differentiation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of epithelial cell proliferation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of G1/S transition of mitotic cell cycle</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of protein kinase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of sequence-specific DNA binding transcription factor activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of smoothened signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of transcription from RNA polymerase II promoter during mitosis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of transcription involved in G1/S transition of mitotic cell cycle</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of transcription, DNA-templated</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>neuron apoptotic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>neuron maturation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>neuron projection development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of macrophage differentiation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of mitotic metaphase/anaphase transition</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of transcription from RNA polymerase II promoter</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of transcription, DNA-templated</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>protein localization to chromosome, centromeric region</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>Ras protein signal transduction</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of centromere complex assembly</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of cohesin localization to chromatin</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of lipid kinase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of mitotic cell cycle</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of transcription involved in G1/S transition of mitotic cell cycle</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>sister chromatid biorientation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>skeletal muscle cell differentiation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>striated muscle cell differentiation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>transcription, DNA-templated</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>viral process</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
    <target position="7">
      <id>BE0000941</id>
      <name>Cathepsin D</name>
      <organism>Humans</organism>
      <actions/>
      <references>
        <articles>
          <article>
            <ref-id>A1713</ref-id>
            <pubmed-id>17139284</pubmed-id>
            <citation>Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.</citation>
          </article>
          <article>
            <ref-id>A1715</ref-id>
            <pubmed-id>17016423</pubmed-id>
            <citation>Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.</citation>
          </article>
          <article>
            <ref-id>A13237</ref-id>
            <pubmed-id>11779865</pubmed-id>
            <citation>Authier F, Metioui M, Fabrega S, Kouach M, Briand G: Endosomal proteolysis of internalized insulin at the C-terminal region of the B chain by cathepsin D. J Biol Chem. 2002 Mar 15;277(11):9437-46. Epub 2002 Jan 4.</citation>
          </article>
          <article>
            <ref-id>A13238</ref-id>
            <pubmed-id>10229502</pubmed-id>
            <citation>Ogino S, Cohen ML, Abdul-Karim FW: Atypical teratoid/rhabdoid tumor of the CNS: cytopathology and immunohistochemistry of insulin-like growth factor-II, insulin-like growth factor receptor type 1, cathepsin D, and Ki-67. Mod Pathol. 1999 Apr;12(4):379-85.</citation>
          </article>
          <article>
            <ref-id>A13239</ref-id>
            <pubmed-id>9130467</pubmed-id>
            <citation>Nunn SE, Peehl DM, Cohen P: Acid-activated insulin-like growth factor binding protein protease activity of cathepsin D in normal and malignant prostatic epithelial cells and seminal plasma. J Cell Physiol. 1997 May;171(2):196-204.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P07339" source="Swiss-Prot">
        <name>Cathepsin D</name>
        <general-function>Aspartic-type endopeptidase activity</general-function>
        <specific-function>Acid protease active in intracellular protein breakdown. Involved in the pathogenesis of several diseases such as breast cancer and possibly Alzheimer disease.</specific-function>
        <gene-name>CTSD</gene-name>
        <locus>11p15.5</locus>
        <cellular-location>Lysosome</cellular-location>
        <transmembrane-regions/>
        <signal-regions>1-18</signal-regions>
        <theoretical-pi>6.5</theoretical-pi>
        <molecular-weight>44551.845</molecular-weight>
        <chromosome-location>11</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:2529</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>CTSD</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>M11233</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>181180</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>2345</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P07339</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>CATD_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>3.4.23.5</synonym>
          <synonym>CPSD</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0016260|Cathepsin D
MQPSSLLPLALCLLAAPASALVRIPLHKFTSIRRTMSEVGGSVEDLIAKGPVSKYSQAVP
AVTEGPIPEVLKNYMDAQYYGEIGIGTPPQCFTVVFDTGSSNLWVPSIHCKLLDIACWIH
HKYNSDKSSTYVKNGTSFDIHYGSGSLSGYLSQDTVSVPCQSASSASALGGVKVERQVFG
EATKQPGITFIAAKFDGILGMAYPRISVNNVLPVFDNLMQQKLVDQNIFSFYLSRDPDAQ
PGGELMLGGTDSKYYKGSLSYLNVTRKAYWQVHLDQVEVASGLTLCKEGCEAIVDTGTSL
MVGPVDEVRELQKAIGAVPLIQGEYMIPCEKVSTLPAITLKLGGKGYKLSPEDYTLKVSQ
AGKTLCLSGFMGMDIPPPSGPLWILGDVFIGRYYTVFDRDNNRVGFAEAARL</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0016261|Cathepsin D (CTSD)
ATGCAGCCCTCCAGCCTTCTGCCGCTCGCCCTCTGCCTGCTGGCTGCACCCGCCTCCGCG
CTCGTCAGGATCCCGCTGCACAAGTTCACGTCCATCCGCCGGACCATGTCGGAGGTTGGG
GGCTCTGTGGAGGACCTGATTGCCAAAGGCCCCGTCTCAAAGTACTCCCAGGCGGTGCCA
GCCGTGACCGAGGGGCCCATTCCCGAGGTGCTCAAGAACTACATGGACGCCCAGTACTAC
GGGGAGATTGGCATCGGGACGCCCCCCCAGTGCTTCACAGTCGTCTTCGACACGGGCTCC
TCCAACCTGTGGGTCCCCTCCATCCACTGCAAACTGCTGGACATCGCTTGCTGGATCCAC
CACAAGTACAACAGCGACAAGTCCAGCACCTACGTGAAGAATGGTACCTCGTTTGACATC
CACTATGGCTCGGGCAGCCTCTCCGGGTACCTGAGCCAGGACACTGTGTCGGTGCCCTGC
CAGTCAGCGTCGTCAGCCTCTGCCCTGGGCGGTGTCAAAGTGGAGAGGCAGGTCTTTGGG
GAGGCCACCAAGCAGCCAGGCATCACCTTCATCGCAGCCAAGTTCGATGGCATCCTGGGC
ATGGCCTACCCCCGCATCTCCGTCAACAACGTGCTGCCCGTCTTCGACAACCTGATGCAG
CAGAAGCTGGTGGACCAGAACATCTTCTCCTTCTACCTGAGCAGGGACCCAGATGCGCAG
CCTGGGGGTGAGCTGATGCTGGGTGGCACAGACTCCAAGTATTACAAGGGTTCTCTGTCC
TACCTGAATGTCACCCGCAAGGCCTACTGGCAGGTCCACCTGGACCAGGTGGAGGTGGCC
AGCGGGCTGACCCTGTGCAAGGAGGGCTGTGAGGCCATTGTGGACACAGGCACTTCCCTC
ATGGTGGGCCCGGTGGATGAGGTGCGCGAGCTGCAGAAGGCCATCGGGGCCGTGCCGCTG
ATTCAGGGCGAGTACATGATCCCCTGTGAGAAGGTGTCCACCCTGCCCGCGATCACACTG
AAGCTGGGAGGCAAAGGCTACAAGCTGTCCCCAGAGGACTACACGCTCAAGGTGTCGCAG
GCCGGGAAGACCCTCTGCCTGAGCGGCTTCATGGGCATGGACATCCCGCCACCCAGCGGG
CCACTCTGGATCCTGGGCGACGTCTTCATCGGCCGCTACTACACTGTGTTTGACCGTGAC
AACAACAGGGTGGGCTTCGCCGAGGCTGCCCGCCTCTAG</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF07966</identifier>
            <name>A1_Propeptide</name>
          </pfam>
          <pfam>
            <identifier>PF00026</identifier>
            <name>Asp</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>extracellular exosome</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>extracellular region</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>extracellular space</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>lysosomal lumen</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>lysosome</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>melanosome</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>membrane raft</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>aspartic-type endopeptidase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>antigen processing and presentation of exogenous peptide antigen via MHC class II</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>autophagy</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>collagen catabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>extracellular matrix disassembly</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>extracellular matrix organization</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>protein catabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>proteolysis</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
    <target position="8">
      <id>BE0001123</id>
      <name>Carboxypeptidase E</name>
      <organism>Humans</organism>
      <actions/>
      <references>
        <articles>
          <article>
            <ref-id>A1713</ref-id>
            <pubmed-id>17139284</pubmed-id>
            <citation>Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.</citation>
          </article>
          <article>
            <ref-id>A1715</ref-id>
            <pubmed-id>17016423</pubmed-id>
            <citation>Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.</citation>
          </article>
          <article>
            <ref-id>A13249</ref-id>
            <pubmed-id>12588113</pubmed-id>
            <citation>Polastri L, Galbiati F, Folli F, Davalli AM: Effects of carboxypeptidase E overexpression on insulin mRNA levels, regulated insulin secretion, and proinsulin processing of pituitary GH3 cells transfected with a furin-cleavable human proinsulin cDNA. Cell Transplant. 2002;11(8):803-11.</citation>
          </article>
          <article>
            <ref-id>A13250</ref-id>
            <pubmed-id>2481446</pubmed-id>
            <citation>Guest PC, Pipeleers D, Rossier J, Rhodes CJ, Hutton JC: Co-secretion of carboxypeptidase H and insulin from isolated rat islets of Langerhans. Biochem J. 1989 Dec 1;264(2):503-8.</citation>
          </article>
          <article>
            <ref-id>A13251</ref-id>
            <pubmed-id>9452465</pubmed-id>
            <citation>Furuta M, Carroll R, Martin S, Swift HH, Ravazzola M, Orci L, Steiner DF: Incomplete processing of proinsulin to insulin accompanied by elevation of Des-31,32 proinsulin intermediates in islets of mice lacking active PC2. J Biol Chem. 1998 Feb 6;273(6):3431-7.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P16870" source="Swiss-Prot">
        <name>Carboxypeptidase E</name>
        <general-function>Zinc ion binding</general-function>
        <specific-function>Removes residual C-terminal Arg or Lys remaining after initial endoprotease cleavage during prohormone processing. Processes proinsulin.</specific-function>
        <gene-name>CPE</gene-name>
        <locus>4q32.3</locus>
        <cellular-location>Cytoplasmic vesicle</cellular-location>
        <transmembrane-regions/>
        <signal-regions>1-25</signal-regions>
        <theoretical-pi>4.78</theoretical-pi>
        <molecular-weight>53150.185</molecular-weight>
        <chromosome-location>4</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:2303</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>CPE</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>X51405</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>29667</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P16870</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>CBPE_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>3.4.17.10</synonym>
          <synonym>Carboxypeptidase H</synonym>
          <synonym>CPE</synonym>
          <synonym>CPH</synonym>
          <synonym>Enkephalin convertase</synonym>
          <synonym>Prohormone-processing carboxypeptidase</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0002234|Carboxypeptidase E
MAGRGGSALLALCGALAACGWLLGAEAQEPGAPAAGMRRRRRLQQEDGISFEYHRYPELR
EALVSVWLQCTAISRIYTVGRSFEGRELLVIELSDNPGVHEPGEPEFKYIGNMHGNEAVG
RELLIFLAQYLCNEYQKGNETIVNLIHSTRIHIMPSLNPDGFEKAASQPGELKDWFVGRS
NAQGIDLNRNFPDLDRIVYVNEKEGGPNNHLLKNMKKIVDQNTKLAPETKAVIHWIMDIP
FVLSANLHGGDLVANYPYDETRSGSAHEYSSSPDDAIFQSLARAYSSFNPAMSDPNRPPC
RKNDDDSSFVDGTTNGGAWYSVPGGMQDFNYLSSNCFEITVELSCEKFPPEETLKTYWED
NKNSLISYLEQIHRGVKGFVRDLQGNPIANATISVEGIDHDVTSAKDGDYWRLLIPGNYK
LTASAPGYLAITKKVAVPYSPAAGVDFELESFSERKEEEKEELMEWWKMMSETLNF</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0016324|Carboxypeptidase E (CPE)
ATGGCCGGGCGAGGGGGCAGCGCGCTGCTGGCTCTGTGCGGGGCACTGGCTGCCTGCGGG
TGGCTCCTGGGCGCCGAAGCCCAGGAGCCCGGGGCGCCCGCGGCGGGCATGAGGCGGCGC
CGGCGGCTGCAGCAAGAGGACGGCATCTCCTTCGAGTACCACCGCTACCCCGAGCTGCGC
GAGGCGCTCGTGTCCGTGTGGCTGCAGTGCACCGCCATCAGCAGGATTTACACGGTGGGG
CGCAGCTTCGAGGGCCGGGAGCTCCTGGTCATCGAGCTGTCCGACAACCCTGGCGTCCAT
GAGCCTGGTGAGCCTGAATTTAAATACATTGGGAATATGCATGGGAATGAGGCTGTTGGA
CGAGAACTGCTCATTTTCTTGGCCCAGTACCTATGCAACGAATACCAGAAGGGGAACGAG
ACAATTGTCAACCTGATCCACAGTACCCGCATTCACATCATGCCTTCCCTGAACCCAGAT
GGCTTTGAGAAGGCAGCGTCTCAGCCTGGTGAACTCAAGGACTGGTTTGTGGGTCGAAGC
AATGCCCAGGGAATAGATCTGAACCGGAACTTTCCAGACCTGGATAGGATAGTGTACGTG
AATGAGAAAGAAGGTGGTCCAAATAATCATCTGTTGAAAAATATGAAGAAAATTGTGGAT
CAAAACACAAAGCTTGCTCCTGAGACCAAGGCTGTCATTCATTGGATTATGGATATTCCT
TTTGTGCTTTCTGCCAATCTCCATGGAGGAGACCTTGTGGCCAATTATCCATATGATGAG
ACGCGGAGTGGTAGTGCTCACGAATACAGCTCCTCCCCAGATGACGCCATTTTCCAAAGC
TTGGCCCGGGCATACTCTTCTTTCAACCCGGCCATGTCTGACCCCAATCGGCCACCATGT
CGCAAGAATGATGATGACAGCAGCTTTGTAGATGGAACCACCAACGGTGGTGCTTGGTAC
AGCGTACCTGGAGGGATGCAAGACTTCAATTACCTTAGCAGCAACTGTTTTGAGATCACC
GTGGAGCTTAGCTGTGAGAAGTTCCCACCTGAAGAGACTCTGAAGACCTACTGGGAGGAT
AACAAAAACTCCCTCATTAGCTACCTTGAGCAGATACACCGAGGAGTTAAAGGATTTGTC
CGAGACCTTCAAGGTAACCCAATTGCGAATGCCACCATCTCCGTGGAAGGAATAGACCAC
GATGTTACATCCGCAAAGGATGGTGATTACTGGAGATTGCTTATACCTGGAAACTATAAA
CTTACAGCCTCAGCTCCAGGCTATCTGGCAATAACAAAGAAAGTGGCAGTTCCTTACAGC
CCTGCTGCTGGGGTTGATTTTGAACTGGAGTCATTTTCTGAAAGGAAAGAAGAGGAGAAG
GAAGAATTGATGGAATGGTGGAAAATGATGTCAGAAACTTTAAATTTTTAA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00246</identifier>
            <name>Peptidase_M14</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>extracellular exosome</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>extracellular space</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>Golgi apparatus</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>neuronal cell body</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>nucleus</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>secretory granule</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>secretory granule membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>synaptic membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>transport vesicle membrane</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>carboxypeptidase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>cell adhesion molecule binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>metallocarboxypeptidase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>neurexin family protein binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>serine-type carboxypeptidase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>zinc ion binding</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cardiac left ventricle morphogenesis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular protein metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular protein modification process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>insulin processing</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>neuropeptide signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>protein localization to membrane</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>Wnt signaling pathway</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
    <target position="9">
      <id>BE0002124</id>
      <name>Neuroendocrine convertase 2</name>
      <organism>Humans</organism>
      <actions/>
      <references>
        <articles>
          <article>
            <ref-id>A1713</ref-id>
            <pubmed-id>17139284</pubmed-id>
            <citation>Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.</citation>
          </article>
          <article>
            <ref-id>A1715</ref-id>
            <pubmed-id>17016423</pubmed-id>
            <citation>Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.</citation>
          </article>
          <article>
            <ref-id>A13246</ref-id>
            <pubmed-id>17221210</pubmed-id>
            <citation>Zertal-Zidani S, Bounacer A, Scharfmann R: Regulation of pancreatic endocrine cell differentiation by sulphated proteoglycans. Diabetologia. 2007 Mar;50(3):585-95. Epub 2007 Jan 13.</citation>
          </article>
          <article>
            <ref-id>A13247</ref-id>
            <pubmed-id>9662053</pubmed-id>
            <citation>Utsunomiya N, Ohagi S, Sanke T, Tatsuta H, Hanabusa T, Nanjo K: Organization of the human carboxypeptidase E gene and molecular scanning for mutations in Japanese subjects with NIDDM or obesity. Diabetologia. 1998 Jun;41(6):701-5.</citation>
          </article>
          <article>
            <ref-id>A13248</ref-id>
            <pubmed-id>8666140</pubmed-id>
            <citation>Ohagi S, Sakaguchi H, Sanke T, Tatsuta H, Hanabusa T, Nanjo K: Human prohormone convertase 3 gene: exon-intron organization and molecular scanning for mutations in Japanese subjects with NIDDM. Diabetes. 1996 Jul;45(7):897-901.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P16519" source="Swiss-Prot">
        <name>Neuroendocrine convertase 2</name>
        <general-function>Serine-type endopeptidase activity</general-function>
        <specific-function>Involved in the processing of hormone and other protein precursors at sites comprised of pairs of basic amino acid residues. Responsible for the release of glucagon from proglucagon in pancreatic A cells.</specific-function>
        <gene-name>PCSK2</gene-name>
        <locus>20p11.2</locus>
        <cellular-location>Cytoplasmic vesicle</cellular-location>
        <transmembrane-regions/>
        <signal-regions>1-25</signal-regions>
        <theoretical-pi>6.47</theoretical-pi>
        <molecular-weight>70564.735</molecular-weight>
        <chromosome-location>20</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:8744</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>PCSK2</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>J05252</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>189652</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>2383</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P16519</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>NEC2_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>3.4.21.94</synonym>
          <synonym>KEX2-like endoprotease 2</synonym>
          <synonym>NEC 2</synonym>
          <synonym>NEC2</synonym>
          <synonym>PC2</synonym>
          <synonym>Prohormone convertase 2</synonym>
          <synonym>Proprotein convertase 2</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0004166|Neuroendocrine convertase 2
MKGGCVSQWKAAAGFLFCVMVFASAERPVFTNHFLVELHKGGEDKARQVAAEHGFGVRKL
PFAEGLYHFYHNGLAKAKRRRSLHHKQQLERDPRVKMALQQEGFDRKKRGYRDINEIDIN
MNDPLFTKQWYLINTGQADGTPGLDLNVAEAWELGYTGKGVTIGIMDDGIDYLHPDLASN
YNAEASYDFSSNDPYPYPRYTDDWFNSHGTRCAGEVSAAANNNICGVGVAYNSKVAGIRM
LDQPFMTDIIEASSISHMPQLIDIYSASWGPTDNGKTVDGPRELTLQAMADGVNKGRGGK
GSIYVWASGDGGSYDDCNCDGYASSMWTISINSAINDGRTALYDESCSSTLASTFSNGRK
RNPEAGVATTDLYGNCTLRHSGTSAAAPEAAGVFALALEANLGLTWRDMQHLTVLTSKRN
QLHDEVHQWRRNGVGLEFNHLFGYGVLDAGAMVKMAKDWKTVPERFHCVGGSVQDPEKIP
STGKLVLTLTTDACEGKENFVRYLEHVQAVITVNATRRGDLNINMTSPMGTKSILLSRRP
RDDDSKVGFDKWPFMTTHTWGEDARGTWTLELGFVGSAPQKGVLKEWTLMLHGTQSAPYI
DQVVRDYQSKLAMSKKEELEEELDEAVERSLKSILNKN</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0011539|Neuroendocrine convertase 2 (PCSK2)
ATGGTTTTTGCATCTGCTGAGCGACCGGTCTTCACGAATCATTTTCTTGTGGAGTTGCAT
AAAGGGGGAGAGGACAAAGCTCGCCAAGTTGCAGCAGAACACGGCTTTGGAGTCCGAAAG
CTTCCCTTTGCTGAAGGTCTGTACCACTTTTATCACAATGGCCTTGCAAAGGCCAAGAGA
AGACGCAGCCTACACCACAAGCAGCAGCTGGAGAGAGACCCCAGGGTAAAGATGGCTTTG
CAGCAGGAAGGATTTGACCGAAAAAAGCGAGGTTACAGAGACATCAATGAGATCGACATC
AACATGAACGATCCTCTTTTTACAAAGCAGTGGTATCTGATCAATACTGGGCAAGCTGAT
GGCACTCCTGGCCTTGATTTGAATGTGGCTGAAGCCTGGGAGCTGGGATACACAGGGAAA
GGTGTTACCATTGGAATTATGGATGATGGGATTGACTATCTCCACCCGGACCTGGCCTCC
AACTATAATGCCGAAGCAAGTTACGACTTCAGCAGCAACGACCCCTATCCTTACCCTCGG
TACACAGATGACTGGTTTAACAGCCACGGGACCCGATGTGCAGGAGAAGTTTCTGCTGCC
GCCAACAACAATATCTGTGGAGTTGGAGTAGCATACAACTCCAAGGTTGCAGGCATCCGG
ATGCTGGACCAGCCATTCATGACAGACATCATCGAGGCCTCCTCCATCAGTCATATGCCA
CAGCTGATTGACATCTACAGCGCCAGCTGGGGCCCCACAGACAACGGCAAGACAGTGGAT
GGGCCCCGGGAGCTCACGCTGCAGGCCATGGCCGATGGCGTGAACAAGGGCCGCGGCGGC
AAAGGCAGCATCTACGTGTGGGCCTCCGGGGACGGCGGCAGCTATGACGACTGCAACTGC
GACGGCTACGCCTCCAGCATGTGGACCATCTCCATCAACTCAGCCATCAACGACGGCAGG
ACTGCCCTGTACGACGAGAGCTGCTCTTCCACCTTGGCTTCCACCTTCAGCAACGGGAGG
AAAAGGAACCCCGAGGCCGGTGTGGCAACCACAGATTTGTACGGCAACTGCACTCTGAGG
CATTCTGGGACATCTGCAGCTGCCCCCGAGGCAGCTGGTGTGTTTGCACTGGCTCTGGAG
GCTAACCTGGGTCTGACCTGGCGGGACATGCAGCATCTGACTGTGCTCACCTCCAAACGG
AACCAGCTTCACGACGAGGTCCATCAGTGGCGGCGCAATGGGGTCGGCCTGGAATTTAAT
CACCTCTTTGGCTACGGGGTCCTTGATGCAGGTGCCATGGTGAAAATGGCTAAAGACTGG
AAAACCGTGCCTGAGAGATTCCACTGTGTGGGAGGCTCCGTGCAGGACCCTGAGAAAATA
CCATCCACTGGCAAGTTGGTGCTGACACTCACAACCGACGCCTGTGAGGGGAAGGAAAAT
TTTGTCCGCTACCTGGAGCATGTCCAGGCTGTCATCACGGTCAACGCAACCAGAAGAGGA
GACCTGAACATCAACATGACTTCCCCTATGGGCACCAAGTCCATTTTGCTGAGCCGGCGT
CCAAGGGATGACGACTCCAAGGTGGGCTTTGACAAGTGGCCTTTCATGACCACTCACACG
TGGGGGGAAGACGCCCGAGGCACCTGGACCCTGGAGCTGGGATTTGTCGGCAGCGCCCCG
CAGAAGGGGGTGCTGAAGGAGTGGACCCTGATGCTGCATGGCACTCAGAGTGCCCCGTAC
ATCGACCAGGTGGTGCGGGATTACCAGTCCAAGTTGGCCATGTCCAAGAAAGAGGAGCTG
GAGGAAGAGCTGGACGAAGCCGTGGAGAGAAGCCTGAAAAGCATCCTTAACAAGAACTAG
</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00082</identifier>
            <name>Peptidase_S8</name>
          </pfam>
          <pfam>
            <identifier>PF01483</identifier>
            <name>P_proprotein</name>
          </pfam>
          <pfam>
            <identifier>PF16470</identifier>
            <name>S8_pro-domain</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>dendrite</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>extracellular space</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>perikaryon</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>secretory granule lumen</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>transport vesicle</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>serine-type endopeptidase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular protein metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>enkephalin processing</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>insulin processing</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>islet amyloid polypeptide processing</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>nervous system development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>protein autoprocessing</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>proteolysis</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
    <target position="10">
      <id>BE0002125</id>
      <name>Neuroendocrine convertase 1</name>
      <organism>Humans</organism>
      <actions/>
      <references>
        <articles>
          <article>
            <ref-id>A1713</ref-id>
            <pubmed-id>17139284</pubmed-id>
            <citation>Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.</citation>
          </article>
          <article>
            <ref-id>A1715</ref-id>
            <pubmed-id>17016423</pubmed-id>
            <citation>Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.</citation>
          </article>
          <article>
            <ref-id>A13252</ref-id>
            <pubmed-id>1435788</pubmed-id>
            <citation>Marriott D, Gillece-Castro B, Gorman CM: Prohormone convertase-1 will process prorelaxin, a member of the insulin family of hormones. Mol Endocrinol. 1992 Sep;6(9):1441-50.</citation>
          </article>
          <article>
            <ref-id>A13253</ref-id>
            <pubmed-id>12136131</pubmed-id>
            <citation>Zhu X, Orci L, Carroll R, Norrbom C, Ravazzola M, Steiner DF: Severe block in processing of proinsulin to insulin accompanied by elevation of des-64,65 proinsulin intermediates in islets of mice lacking prohormone convertase 1/3. Proc Natl Acad Sci U S A. 2002 Aug 6;99(16):10299-304. Epub 2002 Jul 22.</citation>
          </article>
          <article>
            <ref-id>A13254</ref-id>
            <pubmed-id>17097861</pubmed-id>
            <citation>Kuwahata M, Tomoe Y, Harada N, Amano S, Segawa H, Tatsumi S, Ito M, Oka T, Miyamoto K: Characterization of the molecular mechanisms involved in the increased insulin secretion in rats with acute liver failure. Biochim Biophys Acta. 2007 Jan;1772(1):60-5. Epub 2006 Oct 4.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P29120" source="Swiss-Prot">
        <name>Neuroendocrine convertase 1</name>
        <general-function>Serine-type endopeptidase activity</general-function>
        <specific-function>Involved in the processing of hormone and other protein precursors at sites comprised of pairs of basic amino acid residues. Substrates include POMC, renin, enkephalin, dynorphin, somatostatin, insulin and AGRP.</specific-function>
        <gene-name>PCSK1</gene-name>
        <locus>5q15-q21</locus>
        <cellular-location>Cytoplasmic vesicle</cellular-location>
        <transmembrane-regions/>
        <signal-regions>1-27</signal-regions>
        <theoretical-pi>5.84</theoretical-pi>
        <molecular-weight>84150.92</molecular-weight>
        <chromosome-location>5</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:8743</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>PCSK1</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>X64810</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>35318</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>2382</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P29120</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>NEC1_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>3.4.21.93</synonym>
          <synonym>NEC 1</synonym>
          <synonym>NEC1</synonym>
          <synonym>PC1</synonym>
          <synonym>Prohormone convertase 1</synonym>
          <synonym>Proprotein convertase 1</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0004168|Neuroendocrine convertase 1
MERRAWSLQCTAFVLFCAWCALNSAKAKRQFVNEWAAEIPGGPEAASAIAEELGYDLLGQ
IGSLENHYLFKHKNHPRRSRRSAFHITKRLSDDDRVIWAEQQYEKERSKRSALRDSALNL
FNDPMWNQQWYLQDTRMTAALPKLDLHVIPVWQKGITGKGVVITVLDDGLEWNHTDIYAN
YDPEASYDFNDNDHDPFPRYDPTNENKHGTRCAGEIAMQANNHKCGVGVAYNSKVGGIRM
LDGIVTDAIEASSIGFNPGHVDIYSASWGPNDDGKTVEGPGRLAQKAFEYGVKQGRQGKG
SIFVWASGNGGRQGDNCDCDGYTDSIYTISISSASQQGLSPWYAEKCSSTLATSYSSGDY
TDQRITSADLHNDCTETHTGTSASAPLAAGIFALALEANPNLTWRDMQHLVVWTSEYDPL
ANNPGWKKNGAGLMVNSRFGFGLLNAKALVDLADPRTWRSVPEKKECVVKDNDFEPRALK
ANGEVIIEIPTRACEGQENAIKSLEHVQFEATIEYSRRGDLHVTLTSAAGTSTVLLAERE
RDTSPNGFKNWDFMSVHTWGENPIGTWTLRITDMSGRIQNEGRIVNWKLILHGTSSQPEH
MKQPRVYTSYNTVQNDRRGVEKMVDPGEEQPTQENPKENTLVSKSPSSSSVGGRRDELEE
GAPSQAMLRLLQSAFSKNSPPKQSPKKSPSAKLNIPYENFYEALEKLNKPSQLKDSEDSL
YNDYVDVFYNTKPYKHRDDRLLQALVDILNEEN</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0016688|Neuroendocrine convertase 1 (PCSK1)
ATGGAGCGAAGAGCCTGGAGTCTGCAGTGCACTGCTTTCGTCCTCTTTTGCGCTTGGTGT
GCACTGAACAGTGCAAAAGCGAAAAGGCAATTTGTCAATGAATGGGCAGCGGAGATCCCC
GGGGGCCCGGAAGCAGCCTCGGCCATCGCCGAGGAGCTGGGCTATGACCTTTTGGGTCAG
ATTGGTTCACTTGAAAATCACTACTTATTCAAACATAAAAACCACCCCAGAAGGTCTCGA
AGGAGTGCCTTTCATATCACTAAGAGATTATCTGATGATGATCGTGTGATATGGGCTGAA
CAACAGTATGAAAAAGAAAGAAGTAAACGTTCAGCTCTAAGGGACTCAGCACTAAATCTC
TTCAATGATCCCATGTGGAATCAGCAATGGTACTTGCAAGATACCAGGATGACGGCAGCC
CTGCCCAAGCTGGACCTTCATGTGATACCTGTTTGGCAAAAAGGCATTACGGGCAAAGGA
GTTGTTATCACCGTACTGGATGATGGTTTGGAGTGGAATCACACGGACATTTATGCCAAC
TATGATCCAGAGGCTAGCTATGATTTTAATGATAATGACCATGATCCATTTCCCCGATAT
GATCCCACAAACGAGAACAAACACGGGACCAGATGTGCAGGAGAAATTGCCATGCAAGCA
AATAATCACAAATGCGGGGTTGGAGTTGCATACAATTCCAAAGTTGGAGGCATAAGAATG
CTGGATGGCATTGTGACGGATGCTATTGAGGCCAGTTCAATTGGATTCAATCCTGGACAC
GTGGATATTTACAGTGCAAGCTGGGGCCCTAATGATGATGGGAAAACTGTGGAGGGGCCT
GGCCGGCTAGCCCAGAAGGCTTTTGAATATGGTGTCAAACAGGGGAGACAGGGGAAGGGG
TCCATCTTCGTCTGGGCTTCGGGAAACGGGGGGCGTCAGGGAGATAATTGTGACTGTGAT
GGCTACACAGACAGCATCTACACCATCTCCATCAGCAGTGCCTCCCAGCAAGGCCTATCC
CCCTGGTACGCTGAGAAGTGCTCCTCCACACTGGCCACCTCTTACAGCAGCGGAGATTAC
ACCGACCAGAGAATCACGAGCGCTGACCTGCACAATGACTGCACGGAGACGCACACAGGC
ACCTCGGCCTCTGCACCTCTGGCTGCTGGCATCTTCGCTCTGGCCCTGGAAGCAAACCCA
AATCTCACCTGGCGAGATATGCAGCACCTGGTTGTCTGGACCTCTGAGTATGACCCGCTG
GCCAATAACCCTGGATGGAAAAAGAATGGAGCAGGCTTGATGGTGAATAGTCGATTTGGA
TTTGGCTTGCTAAATGCCAAAGCTCTGGTGGATTTAGCTGACCCCAGGACCTGGAGGAGC
GTGCCTGAGAAGAAAGAGTGTGTTGTAAAGGACAATGACTTTGAGCCCAGAGCCCTGAAA
GCTAATGGAGAAGTTATCATTGAAATTCCAACAAGAGCTTGTGAAGGACAAGAAAATGCT
ATCAAGTCCCTGGAGCATGTACAATTTGAAGCAACAATTGAATATTCCCGAAGAGGAGAC
CTTCATGTCACACTTACTTCTGCTGCTGGAACTAGCACTGTGCTCTTGGCTGAAAGAGAA
CGGGATACATCTCCTAATGGCTTTAAGAATTGGGACTTCATGTCTGTTCACACATGGGGA
GAGAACCCTATAGGTACTTGGACTTTGAGAATTACAGACATGTCTGGAAGAATTCAAAAT
GAAGGAAGAATTGTGAACTGGAAGCTGATTTTGCACGGGACCTCTTCTCAGCCAGAGCAT
ATGAAGCAGCCTCGTGTGTACACGTCCTACAACACTGTTCAGAATGACAGAAGAGGGGTG
GAGAAGATGGTGGATCCAGGGGAGGAGCAGCCCACACAAGAGAACCCTAAGGAGAACACC
CTGGTGTCCAAAAGCCCCAGCAGCAGCAGCGTAGGGGGCCGGAGGGATGAGTTGGAGGAG
GGAGCCCCTTCCCAGGCCATGCTGCGACTCCTGCAAAGTGCTTTCAGTAAAAACTCACCG
CCAAAGCAATCACCAAAGAAGTCCCCAAGTGCAAAGCTCAACATCCCTTATGAAAACTTC
TACGAAGCCCTGGAAAAGCTGAACAAACCTTCCCAGCTTAAAGACTCTGAAGACAGTCTG
TATAATGACTATGTTGATGTTTTTTATAACACTAAACCTTACAAGCACAGAGACGACCGG
CTGCTTCAAGCTCTGGTGGACATTCTGAATGAGGAAAATTAA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00082</identifier>
            <name>Peptidase_S8</name>
          </pfam>
          <pfam>
            <identifier>PF01483</identifier>
            <name>P_proprotein</name>
          </pfam>
          <pfam>
            <identifier>PF16470</identifier>
            <name>S8_pro-domain</name>
          </pfam>
          <pfam>
            <identifier>PF12177</identifier>
            <name>Proho_convert</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>extracellular space</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>Golgi apparatus</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>secretory granule lumen</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>transport vesicle</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>serine-type endopeptidase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cell-cell signaling</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular protein metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>peptide biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>peptide hormone processing</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>proteolysis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of insulin secretion</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
    <target position="11">
      <id>BE0001147</id>
      <name>Protein NOV homolog</name>
      <organism>Humans</organism>
      <actions/>
      <references>
        <articles>
          <article>
            <ref-id>A1713</ref-id>
            <pubmed-id>17139284</pubmed-id>
            <citation>Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.</citation>
          </article>
          <article>
            <ref-id>A1715</ref-id>
            <pubmed-id>17016423</pubmed-id>
            <citation>Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.</citation>
          </article>
          <article>
            <ref-id>A13255</ref-id>
            <pubmed-id>10084601</pubmed-id>
            <citation>Burren CP, Wilson EM, Hwa V, Oh Y, Rosenfeld RG: Binding properties and distribution of insulin-like growth factor binding protein-related protein 3 (IGFBP-rP3/NovH), an additional member of the IGFBP Superfamily. J Clin Endocrinol Metab. 1999 Mar;84(3):1096-103.</citation>
          </article>
          <article>
            <ref-id>A13256</ref-id>
            <pubmed-id>12149257</pubmed-id>
            <citation>Lafont J, Laurent M, Thibout H, Lallemand F, Le Bouc Y, Atfi A, Martinerie C: The expression of novH in adrenocortical cells is down-regulated by TGFbeta 1 through c-Jun in a Smad-independent manner. J Biol Chem. 2002 Oct 25;277(43):41220-9. Epub 2002 Jul 30.</citation>
          </article>
          <article>
            <ref-id>A13257</ref-id>
            <pubmed-id>8622864</pubmed-id>
            <citation>Martinerie C, Chevalier G, Rauscher FJ 3rd, Perbal B: Regulation of nov by WT1: a potential role for nov in nephrogenesis. Oncogene. 1996 Apr 4;12(7):1479-92.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P48745" source="Swiss-Prot">
        <name>Protein NOV homolog</name>
        <general-function>Notch binding</general-function>
        <specific-function>Immediate-early protein playing a role in various cellular processes including proliferation, adhesion, migration, differentiation and survival (PubMed:15181016, PubMed:15611078, PubMed:12695522, PubMed:21344378, PubMed:12050162). Acts by binding to integrins or membrane receptors such as NOTCH1 (PubMed:12695522, PubMed:21344378, PubMed:15611078). Essential regulator of hematopoietic stem and progenitor cell function (PubMed:17463287). Inhibits myogenic differentiation through the activation of Notch-signaling pathway (PubMed:12050162). Inhibits vascular smooth muscle cells proliferation by increasing expression of cell-cycle regulators such as CDKN2B or CDKN1A independently of TGFB1 signaling (PubMed:20139355). Ligand of integrins ITGAV:ITGB3 and ITGA5:ITGB1, acts directly upon endothelial cells to stimulate pro-angiogenic activities and induces angiogenesis. In endothelial cells, supports cell adhesion, induces directed cell migration (chemotaxis) and promotes cell survival (PubMed:12695522). Plays also a role in cutaneous wound healing acting as integrin receptor ligand. Supports skin fibroblast adhesion through ITGA5:ITGB1 and ITGA6:ITGB1 and induces fibroblast chemotaxis through ITGAV:ITGB5. Seems to enhance bFGF-induced DNA synthesis in fibroblasts (PubMed:15611078). Involved in bone regeneration as a negative regulator (By similarity). Enhances the articular chondrocytic phenotype, whereas it repressed the one representing endochondral ossification (PubMed:21871891). Impairs pancreatic beta-cell function, inhibits beta-cell proliferation and insulin secretion (By similarity). Plays a role as negative regulator of endothelial pro-inflammatory activation reducing monocyte adhesion, its anti-inflammatory effects occur secondary to the inhibition of NF-kappaB signaling pathway (PubMed:21063504). Contributes to the control and coordination of inflammatory processes in atherosclerosis (By similarity). Attenuates inflammatory pain through regulation of IL1B- and TNF-induced MMP9, MMP2 and CCL2 expression. Inhibits MMP9 expression through ITGB1 engagement (PubMed:21871891).</specific-function>
        <gene-name>NOV</gene-name>
        <locus>8q24.1</locus>
        <cellular-location>Secreted</cellular-location>
        <transmembrane-regions/>
        <signal-regions>1-31</signal-regions>
        <theoretical-pi>7.74</theoretical-pi>
        <molecular-weight>39161.82</molecular-weight>
        <chromosome-location>8</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:7885</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>NOV</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>X78351</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>825696</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P48745</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>NOV_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>CCN family member 3</synonym>
          <synonym>CCN3</synonym>
          <synonym>IBP-9</synonym>
          <synonym>IGF-binding protein 9</synonym>
          <synonym>IGFBP-9</synonym>
          <synonym>IGFBP9</synonym>
          <synonym>Insulin-like growth factor-binding protein 9</synonym>
          <synonym>Nephroblastoma-overexpressed gene protein homolog</synonym>
          <synonym>NOVH</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0019069|Protein NOV homolog
MQSVQSTSFCLRKQCLCLTFLLLHLLGQVAATQRCPPQCPGRCPATPPTCAPGVRAVLDG
CSCCLVCARQRGESCSDLEPCDESSGLYCDRSADPSNQTGICTAVEGDNCVFDGVIYRSG
EKFQPSCKFQCTCRDGQIGCVPRCQLDVLLPEPNCPAPRKVEVPGECCEKWICGPDEEDS
LGGLTLAAYRPEATLGVEVSDSSVNCIEQTTEWTACSKSCGMGFSTRVTNRNRQCEMLKQ
TRLCMVRPCEQEPEQPTDKKGKKCLRTKKSLKAIHLQFKNCTSLHTYKPRFCGVCSDGRC
CTPHNTKTIQAEFQCSPGQIVKKPVMVIGTCTCHTNCPKNNEAFLQELELKTTRGKM</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0019070|Protein NOV homolog (NOV)
ATGCAGAGTGTGCAGAGCACGAGCTTTTGTCTCCGAAAGCAGTGCCTTTGCCTGACCTTC
CTGCTTCTCCATCTCCTGGGACAGGTCGCTGCGACTCAGCGCTGCCCTCCCCAGTGCCCG
GGCCGGTGCCCTGCGACGCCGCCGACCTGCGCCCCCGGGGTGCGCGCGGTGCTGGACGGC
TGCTCATGCTGTCTGGTGTGTGCCCGCCAGCGTGGCGAGAGCTGCTCAGATCTGGAGCCA
TGCGACGAGAGCAGTGGCCTCTACTGTGATCGCAGCGCGGACCCCAGCAACCAGACTGGC
ATCTGCACGGCGGTAGAGGGAGATAACTGTGTGTTCGATGGGGTCATCTACCGCAGTGGA
GAGAAATTTCAGCCAAGCTGCAAATTCCAGTGCACCTGCAGAGATGGGCAGATTGGCTGT
GTGCCCCGCTGTCAGCTGGATGTGCTACTGCCTGAGCCTAACTGCCCAGCTCCAAGAAAA
GTTGAGGTGCCTGGAGAGTGCTGTGAAAAGTGGATCTGTGGCCCAGATGAGGAGGATTCA
CTGGGAGGCCTTACCCTTGCAGCTTACAGGCCAGAAGCCACCCTAGGAGTAGAAGTCTCT
GACTCAAGTGTCAACTGCATTGAACAGACCACAGAGTGGACAGCATGCTCCAAGAGCTGT
GGTATGGGGTTCTCCACCCGGGTCACCAATAGGAACCGTCAATGTGAGATGCTGAAACAG
ACTCGGCTCTGCATGGTGCGGCCCTGTGAACAAGAGCCAGAGCAGCCAACAGATAAGAAA
GGAAAAAAGTGTCTCCGCACCAAGAAGTCACTCAAAGCCATCCACCTGCAGTTCAAGAAC
TGCACCAGCCTGCACACCTACAAGCCCAGGTTCTGTGGGGTCTGCAGTGATGGCCGCTGC
TGCACTCCCCACAATACCAAAACCATCCAGGCAGAGTTTCAGTGCTCCCCAGGGCAAATA
GTCAAGAAGCCAGTGATGGTCATTGGGACCTGCACCTGTCACACCAACTGTCCTAAGAAC
AATGAGGCCTTCCTCCAGGAGCTGGAGCTGAAGACTACCAGAGGGAAAATGTAA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00093</identifier>
            <name>VWC</name>
          </pfam>
          <pfam>
            <identifier>PF00219</identifier>
            <name>IGFBP</name>
          </pfam>
          <pfam>
            <identifier>PF00007</identifier>
            <name>Cys_knot</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>axon</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>cytoplasm</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>dendrite</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>extracellular region</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>gap junction</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>intracellular membrane-bounded organelle</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>neuronal cell body</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>proteinaceous extracellular matrix</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>heparin binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>integrin binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>Notch binding</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>angiogenesis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>bone regeneration</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cell adhesion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cell adhesion mediated by integrin</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cell chemotaxis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cell-cell signaling</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>chondrocyte differentiation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>endothelial cell chemotaxis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>endothelial cell-cell adhesion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>fibroblast migration</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>hematopoietic stem cell homeostasis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of cell death</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of cell growth</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of chondrocyte proliferation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of inflammatory response</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of insulin secretion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of monocyte chemotaxis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of myotube differentiation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of NF-kappaB import into nucleus</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of sensory perception of pain</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of SMAD protein import into nucleus</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of Notch signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of gene expression</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>signal transduction</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>smooth muscle cell migration</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>smooth muscle cell proliferation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>type B pancreatic cell proliferation</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
    <target position="12">
      <id>BE0000942</id>
      <name>Low-density lipoprotein receptor-related protein 2</name>
      <organism>Humans</organism>
      <actions/>
      <references>
        <articles>
          <article>
            <ref-id>A1713</ref-id>
            <pubmed-id>17139284</pubmed-id>
            <citation>Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.</citation>
          </article>
          <article>
            <ref-id>A1715</ref-id>
            <pubmed-id>17016423</pubmed-id>
            <citation>Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.</citation>
          </article>
          <article>
            <ref-id>A13258</ref-id>
            <pubmed-id>9773776</pubmed-id>
            <citation>Orlando RA, Rader K, Authier F, Yamazaki H, Posner BI, Bergeron JJ, Farquhar MG: Megalin is an endocytic receptor for insulin. J Am Soc Nephrol. 1998 Oct;9(10):1759-66.</citation>
          </article>
          <article>
            <ref-id>A13259</ref-id>
            <pubmed-id>9051350</pubmed-id>
            <citation>Christensen EI, Birn H: Hormone, growth factor, and vitamin handling by proximal tubule cells. Curr Opin Nephrol Hypertens. 1997 Jan;6(1):20-7.</citation>
          </article>
          <article>
            <ref-id>A13260</ref-id>
            <pubmed-id>17018843</pubmed-id>
            <citation>Fuster DG, Bobulescu IA, Zhang J, Wade J, Moe OW: Characterization of the regulation of renal Na+/H+ exchanger NHE3 by insulin. Am J Physiol Renal Physiol. 2007 Feb;292(2):F577-85. Epub 2006 Oct 3.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P98164" source="Swiss-Prot">
        <name>Low-density lipoprotein receptor-related protein 2</name>
        <general-function>Calcium ion binding</general-function>
        <specific-function>Acts together with cubilin to mediate HDL endocytosis (By similarity). May participate in regulation of parathyroid-hormone and para-thyroid-hormone-related protein release.</specific-function>
        <gene-name>LRP2</gene-name>
        <locus>2q24-q31</locus>
        <cellular-location>Membrane</cellular-location>
        <transmembrane-regions>4424-4446</transmembrane-regions>
        <signal-regions>1-25</signal-regions>
        <theoretical-pi>4.68</theoretical-pi>
        <molecular-weight>521952.77</molecular-weight>
        <chromosome-location>2</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:6694</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>LRP2</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>U33837</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>1809240</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P98164</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>LRP2_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>Glycoprotein 330</synonym>
          <synonym>gp330</synonym>
          <synonym>LRP-2</synonym>
          <synonym>Megalin</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0010661|Low-density lipoprotein receptor-related protein 2
MDRGPAAVACTLLLALVACLAPASGQECDSAHFRCGSGHCIPADWRCDGTKDCSDDADEI
GCAVVTCQQGYFKCQSEGQCIPNSWVCDQDQDCDDGSDERQDCSQSTCSSHQITCSNGQC
IPSEYRCDHVRDCPDGADENDCQYPTCEQLTCDNGACYNTSQKCDWKVDCRDSSDEINCT
EICLHNEFSCGNGECIPRAYVCDHDNDCQDGSDEHACNYPTCGGYQFTCPSGRCIYQNWV
CDGEDDCKDNGDEDGCESGPHDVHKCSPREWSCPESGRCISIYKVCDGILDCPGREDENN
TSTGKYCSMTLCSALNCQYQCHETPYGGACFCPPGYIINHNDSRTCVEFDDCQIWGICDQ
KCESRPGRHLCHCEEGYILERGQYCKANDSFGEASIIFSNGRDLLIGDIHGRSFRILVES
QNRGVAVGVAFHYHLQRVFWTDTVQNKVFSVDINGLNIQEVLNVSVETPENLAVDWVNNK
IYLVETKVNRIDMVNLDGSYRVTLITENLGHPRGIAVDPTVGYLFFSDWESLSGEPKLER
AFMDGSNRKDLVKTKLGWPAGVTLDMISKRVYWVDSRFDYIETVTYDGIQRKTVVHGGSL
IPHPFGVSLFEGQVFFTDWTKMAVLKANKFTETNPQVYYQASLRPYGVTVYHSLRQPYAT
NPCKDNNGGCEQVCVLSHRTDNDGLGFRCKCTFGFQLDTDERHCIAVQNFLIFSSQVAIR
GIPFTLSTQEDVMVPVSGNPSFFVGIDFDAQDSTIFFSDMSKHMIFKQKIDGTGREILAA
NRVENVESLAFDWISKNLYWTDSHYKSISVMRLADKTRRTVVQYLNNPRSVVVHPFAGYL
FFTDWFRPAKIMRAWSDGSHLLPVINTTLGWPNGLAIDWAASRLYWVDAYFDKIEHSTFD
GLDRRRLGHIEQMTHPFGLAIFGEHLFFTDWRLGAIIRVRKADGGEMTVIRSGIAYILHL
KSYDVNIQTGSNACNQPTHPNGDCSHFCFPVPNFQRVCGCPYGMRLASNHLTCEGDPTNE
PPTEQCGLFSFPCKNGRCVPNYYLCDGVDDCHDNSDEQLCGTLNNTCSSSAFTCGHGECI
PAHWRCDKRNDCVDGSDEHNCPTHAPASCLDTQYTCDNHQCISKNWVCDTDNDCGDGSDE
KNCNSTETCQPSQFNCPNHRCIDLSFVCDGDKDCVDGSDEVGCVLNCTASQFKCASGDKC
IGVTNRCDGVFDCSDNSDEAGCPTRPPGMCHSDEFQCQEDGICIPNFWECDGHPDCLYGS
DEHNACVPKTCPSSYFHCDNGNCIHRAWLCDRDNDCGDMSDEKDCPTQPFRCPSWQWQCL
GHNICVNLSVVCDGIFDCPNGTDESPLCNGNSCSDFNGGCTHECVQEPFGAKCLCPLGFL
LANDSKTCEDIDECDILGSCSQHCYNMRGSFRCSCDTGYMLESDGRTCKVTASESLLLLV
ASQNKIIADSVTSQVHNIYSLVENGSYIVAVDFDSISGRIFWSDATQGKTWSAFQNGTDR
RVVFDSSIILTETIAIDWVGRNLYWTDYALETIEVSKIDGSHRTVLISKNLTNPRGLALD
PRMNEHLLFWSDWGHHPRIERASMDGSMRTVIVQDKIFWPCGLTIDYPNRLLYFMDSYLD
YMDFCDYNGHHRRQVIASDLIIRHPYALTLFEDSVYWTDRATRRVMRANKWHGGNQSVVM
YNIQWPLGIVAVHPSKQPNSVNPCAFSRCSHLCLLSSQGPHFYSCVCPSGWSLSPDLLNC
LRDDQPFLITVRQHIIFGISLNPEVKSNDAMVPIAGIQNGLDVEFDDAEQYIYWVENPGE
IHRVKTDGTNRTVFASISMVGPSMNLALDWISRNLYSTNPRTQSIEVLTLHGDIRYRKTL
IANDGTALGVGFPIGITVDPARGKLYWSDQGTDSGVPAKIASANMDGTSVKTLFTGNLEH
LECVTLDIEEQKLYWAVTGRGVIERGNVDGTDRMILVHQLSHPWGIAVHDSFLYYTDEQY
EVIERVDKATGANKIVLRDNVPNLRGLQVYHRRNAAESSNGCSNNMNACQQICLPVPGGL
FSCACATGFKLNPDNRSCSPYNSFIVVSMLSAIRGFSLELSDHSETMVPVAGQGRNALHV
DVDVSSGFIYWCDFSSSVASDNAIRRIKPDGSSLMNIVTHGIGENGVRGIAVDWVAGNLY
FTNAFVSETLIEVLRINTTYRRVLLKVTVDMPRHIVVDPKNRYLFWADYGQRPKIERSFL
DCTNRTVLVSEGIVTPRGLAVDRSDGYVYWVDDSLDIIARIRINGENSEVIRYGSRYPTP
YGITVFENSIIWVDRNLKKIFQASKEPENTEPPTVIRDNINWLRDVTIFDKQVQPRSPAE
VNNNPCLENNGGCSHLCFALPGLHTPKCDCAFGTLQSDGKNCAISTENFLIFALSNSLRS
LHLDPENHSPPFQTINVERTVMSLDYDSVSDRIYFTQNLASGVGQISYATLSSGIHTPTV
IASGIGTADGIAFDWITRRIYYSDYLNQMINSMAEDGSNRTVIARVPKPRAIVLDPCQGY
LYWADWDTHAKIERATLGGNFRVPIVNSSLVMPSGLTLDYEEDLLYWVDASLQRIERSTL
TGVDREVIVNAAVHAFGLTLYGQYIYWTDLYTQRIYRANKYDGSGQIAMTTNLLSQPRGI
NTVVKNQKQQCNNPCEQFNGGCSHICAPGPNGAECQCPHEGNWYLANNRKHCIVDNGERC
GASSFTCSNGRCISEEWKCDNDNDCGDGSDEMESVCALHTCSPTAFTCANGRCVQYSYRC
DYYNDCGDGSDEAGCLFRDCNATTEFMCNNRRCIPREFICNGVDNCHDNNTSDEKNCPDR
TCQSGYTKCHNSNICIPRVYLCDGDNDCGDNSDENPTYCTTHTCSSSEFQCASGRCIPQH
WYCDQETDCFDASDEPASCGHSERTCLADEFKCDGGRCIPSEWICDGDNDCGDMSDEDKR
HQCQNQNCSDSEFLCVNDRPPDRRCIPQSWVCDGDVDCTDGYDENQNCTRRTCSENEFTC
GYGLCIPKIFRCDRHNDCGDYSDERGCLYQTCQQNQFTCQNGRCISKTFVCDEDNDCGDG
SDELMHLCHTPEPTCPPHEFKCDNGRCIEMMKLCNHLDDCLDNSDEKGCGINECHDPSIS
GCDHNCTDTLTSFYCSCRPGYKLMSDKRTCVDIDECTEMPFVCSQKCENVIGSYICKCAP
GYLREPDGKTCRQNSNIEPYLIFSNRYYLRNLTIDGYFYSLILEGLDNVVALDFDRVEKR
LYWIDTQRQVIERMFLNKTNKETIINHRLPAAESLAVDWVSRKLYWLDARLDGLFVSDLN
GGHRRMLAQHCVDANNTFCFDNPRGLALHPQYGYLYWADWGHRAYIGRVGMDGTNKSVII
STKLEWPNGITIDYTNDLLYWADAHLGYIEYSDLEGHHRHTVYDGALPHPFAITIFEDTI
YWTDWNTRTVEKGNKYDGSNRQTLVNTTHRPFDIHVYHPYRQPIVSNPCGTNNGGCSHLC
LIKPGGKGFTCECPDDFRTLQLSGSTYCMPMCSSTQFLCANNEKCIPIWWKCDGQKDCSD
GSDELALCPQRFCRLGQFQCSDGNCTSPQTLCNAHQNCPDGSDEDRLLCENHHCDSNEWQ
CANKRCIPESWQCDTFNDCEDNSDEDSSHCASRTCRPGQFRCANGRCIPQAWKCDVDNDC
GDHSDEPIEECMSSAHLCDNFTEFSCKTNYRCIPKWAVCNGVDDCRDNSDEQGCEERTCH
PVGDFRCKNHHCIPLRWQCDGQNDCGDNSDEENCAPRECTESEFRCVNQQCIPSRWICDH
YNDCGDNSDERDCEMRTCHPEYFQCTSGHCVHSELKCDGSADCLDASDEADCPTRFPDGA
YCQATMFECKNHVCIPPYWKCDGDDDCGDGSDEELHLCLDVPCNSPNRFRCDNNRCIYSH
EVCNGVDDCGDGTDETEEHCRKPTPKPCTEYEYKCGNGHCIPHDNVCDDADDCGDWSDEL
GCNKGKERTCAENICEQNCTQLNEGGFICSCTAGFETNVFDRTSCLDINECEQFGTCPQH
CRNTKGSYECVCADGFTSMSDRPGKRCAAEGSSPLLLLPDNVRIRKYNLSSERFSEYLQD
EEYIQAVDYDWDPKDIGLSVVYYTVRGEGSRFGAIKRAYIPNFESGRNNLVQEVDLKLKY
VMQPDGIAVDWVGRHIYWSDVKNKRIEVAKLDGRYRKWLISTDLDQPAAIAVNPKLGLMF
WTDWGKEPKIESAWMNGEDRNILVFEDLGWPTGLSIDYLNNDRIYWSDFKEDVIETIKYD
GTDRRVIAKEAMNPYSLDIFEDQLYWISKEKGEVWKQNKFGQGKKEKTLVVNPWLTQVRI
FHQLRYNKSVPNLCKQICSHLCLLRPGGYSCACPQGSSFIEGSTTECDAAIELPINLPPP
CRCMHGGNCYFDETDLPKCKCPSGYTGKYCEMAFSKGISPGTTAVAVLLTILLIVVIGAL
AIAGFFHYRRTGSLLPALPKLPSLSSLVKPSENGNGVTFRSGADLNMDIGVSGFGPETAI
DRSMAMSEDFVMEMGKQPIIFENPMYSARDSAVKVVQPIQVTVSENVDNKNYGSPINPSE
IVPETNPTSPAADGTQVTKWNLFKRKSKQTTNFENPIYAQMENEQKESVAATPPPSPSLP
AKPKPPSRRDPTPTYSATEDTFKDTANLVKEDSEV</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0010662|Low-density lipoprotein receptor-related protein 2 (LRP2)
ATGGATCGCGGGCCGGCAGCAGTGGCGTGCACGCTGCTCCTGGCTCTCGTCGCCTGCCTA
GCGCCGGCCAGTGGCCAAGAATGTGACAGTGCGCATTTTCGCTGTGGAAGTGGGCATTGC
ATCCCTGCAGACTGGAGGTGTGATGGGACCAAAGACTGTTCAGATGACGCGGATGAAATT
GGCTGCGCTGTTGTGACCTGCCAGCAGGGCTATTTCAAGTGCCAGAGTGAGGGACAATGC
ATCCCCAACTCCTGGGTGTGTGACCAAGATCAAGACTGTGATGATGGCTCAGATGAACGT
CAAGATTGCTCACAAAGTACATGCTCAAGTCATCAGATAACATGCTCCAATGGTCAGTGT
ATCCCAAGTGAATACAGGTGCGACCACGTCAGAGACTGCCCCGATGGAGCTGATGAGAAT
GACTGCCAGTACCCAACATGTGAGCAGCTTACTTGTGACAATGGGGCCTGCTATAACACC
AGTCAGAAGTGTGATTGGAAAGTTGATTGCAGGGACTCCTCAGATGAAATCAACTGCACT
GAGATATGCTTGCACAATGAGTTTTCATGTGGCAATGGAGAGTGTATCCCTCGTGCTTAT
GTCTGTGACCATGACAATGATTGCCAAGACGGCAGTGACGAACATGCTTGCAACTATCCG
ACCTGCGGTGGTTACCAGTTCACTTGCCCCAGTGGCCGATGCATTTATCAAAACTGGGTT
TGTGATGGAGAAGATGACTGTAAAGATAATGGAGATGAAGATGGATGTGAAAGCGGTCCT
CATGATGTTCATAAATGTTCCCCAAGAGAATGGTCTTGCCCAGAGTCGGGACGATGCATC
TCCATTTATAAAGTTTGTGATGGGATTTTAGATTGCCCAGGAAGAGAAGATGAAAACAAC
ACTAGTACCGGAAAATACTGTAGTATGACTCTGTGCTCTGCCTTGAACTGCCAGTACCAG
TGCCATGAGACGCCGTATGGAGGAGCGTGTTTTTGTCCCCCAGGTTATATCATCAACCAC
AATGACAGCCGTACCTGTGTTGAGTTTGATGATTGCCAGATATGGGGAATTTGTGACCAG
AAGTGTGAAAGCCGACCTGGCCGTCACCTGTGCCACTGTGAAGAAGGGTATATCTTGGAG
CGTGGACAGTATTGCAAAGCTAATGATTCCTTTGGCGAGGCCTCCATTATCTTCTCCAAT
GGTCGGGATTTGTTAATTGGTGATATTCATGGAAGGAGCTTCCGGATCCTAGTGGAGTCT
CAGAATCGTGGAGTGGCCGTGGGTGTGGCTTTCCACTATCACCTGCAAAGAGTTTTTTGG
ACAGACACCGTGCAAAATAAGGTTTTTTCAGTTGACATTAATGGTTTAAATATCCAAGAG
GTTCTCAATGTTTCTGTTGAAACCCCAGAGAACCTGGCTGTGGACTGGGTTAATAATAAA
ATCTATCTAGTGGAAACCAAGGTCAACCGCATAGATATGGTAAATTTGGATGGAAGCTAT
CGGGTTACCCTTATAACTGAAAACTTGGGGCATCCTAGAGGAATTGCCGTGGACCCAACT
GTTGGTTATTTATTTTTCTCAGATTGGGAGAGCCTTTCTGGGGAACCTAAGCTGGAAAGG
GCATTCATGGATGGCAGCAACCGTAAAGACTTGGTGAAAACAAAGCTGGGATGGCCTGCT
GGGGTAACTCTGGATATGATATCGAAGCGTGTTTACTGGGTTGACTCTCGGTTTGATTAC
ATTGAAACTGTAACTTATGATGGAATTCAAAGGAAGACTGTAGTTCATGGAGGCTCCCTC
ATTCCTCATCCCTTTGGAGTAAGCTTATTTGAAGGTCAGGTGTTCTTTACAGATTGGACA
AAGATGGCCGTGCTGAAGGCAAACAAGTTCACAGAGACCAACCCACAAGTGTACTACCAG
GCTTCCCTGAGGCCCTATGGAGTGACTGTTTACCATTCCCTCAGACAGCCCTATGCTACC
AATCCGTGTAAAGATAACAATGGGGGCTGTGAGCAGGTCTGTGTCCTCAGCCACAGAACA
GATAATGATGGTTTGGGTTTCCGTTGCAAGTGCACATTCGGCTTCCAACTGGATACAGAT
GAGCGCCACTGCATTGCTGTTCAGAATTTCCTCATTTTTTCATCCCAAGTTGCTATTCGT
GGGATCCCGTTCACCTTGTCTACCCAGGAAGATGTCATGGTTCCAGTTTCGGGGAATCCT
TCTTTCTTTGTCGGGATTGATTTTGACGCCCAGGACAGCACTATCTTTTTTTCAGATATG
TCAAAACACATGATTTTTAAGCAAAAGATTGATGGCACAGGAAGAGAAATTCTCGCAGCT
AACAGGGTGGAAAATGTTGAAAGTTTGGCTTTTGATTGGATTTCAAAGAATCTCTATTGG
ACAGACTCTCATTACAAGAGTATCAGTGTCATGAGGCTAGCTGATAAAACGAGACGCACA
GTAGTTCAGTATTTAAATAACCCACGGTCGGTGGTAGTTCATCCTTTTGCCGGGTATCTA
TTCTTCACTGATTGGTTCCGTCCTGCTAAAATTATGAGAGCATGGAGTGACGGATCTCAC
CTCTTGCCTGTAATAAACACTACTCTTGGATGGCCCAATGGCTTGGCCATCGATTGGGCT
GCTTCACGATTGTACTGGGTAGATGCCTATTTTGATAAAATTGAGCACAGCACCTTTGAT
GGTTTAGACAGAAGAAGACTGGGCCATATAGAGCAGATGACACATCCGTTTGGACTTGCC
ATCTTTGGAGAGCATTTATTTTTTACTGACTGGAGACTGGGTGCCATTATTCGAGTCAGG
AAAGCAGATGGTGGAGAAATGACAGTTATCCGAAGTGGCATTGCTTACATACTGCATTTG
AAATCGTATGATGTCAACATCCAGACTGGTTCTAACGCCTGTAATCAACCCACGCATCCT
AACGGTGACTGCAGCCACTTCTGCTTCCCGGTGCCAAATTTCCAGCGAGTGTGTGGGTGC
CCTTATGGAATGAGGCTGGCTTCCAATCACTTGACATGCGAGGGGGACCCAACCAATGAA
CCACCCACAGAGCAGTGTGGCTTATTTTCCTTCCCCTGTAAAAATGGCAGATGTGTGCCC
AATTACTATCTCTGTGATGGAGTCGATGATTGTCATGATAACAGTGATGAGCAACTATGT
GGCACACTTAATAATACCTGTTCATCTTCGGCGTTCACCTGTGGCCATGGGGAGTGCATT
CCTGCACACTGGCGCTGTGACAAACGCAACGACTGTGTGGATGGCAGTGATGAGCACAAC
TGCCCCACCCACGCACCTGCTTCCTGCCTTGACACCCAATACACCTGTGATAATCACCAG
TGTATCTCAAAGAACTGGGTCTGTGACACAGACAATGATTGTGGGGATGGATCTGATGAA
AAGAACTGCAATTCGACAGAGACATGCCAACCTAGTCAGTTTAATTGCCCCAATCATCGA
TGTATTGACCTATCGTTTGTCTGTGATGGTGACAAGGATTGTGTTGATGGATCTGATGAG
GTTGGTTGTGTATTAAACTGTACTGCTTCTCAATTCAAGTGTGCCAGTGGGGATAAATGT
ATTGGCGTCACAAATCGTTGTGATGGTGTTTTTGATTGCAGTGACAACTCGGATGAAGCA
GGCTGTCCAACCAGGCCTCCTGGTATGTGCCACTCAGATGAATTTCAGTGCCAAGAAGAT
GGTATCTGCATCCCGAACTTCTGGGAATGTGATGGGCATCCAGACTGCCTCTATGGATCT
GATGAGCACAATGCCTGTGTCCCCAAGACTTGCCCTTCATCATATTTCCACTGTGACAAC
GGAAACTGCATCCACAGGGCATGGCTCTGTGATCGGGACAATGACTGCGGGGATATGAGT
GATGAGAAGGACTGCCCTACTCAGCCCTTTCGCTGTCCTAGTTGGCAATGGCAGTGTCTT
GGCCATAACATCTGTGTGAATCTGAGTGTAGTGTGTGATGGCATCTTTGACTGCCCCAAT
GGGACAGATGAGTCCCCACTTTGCAATGGGAACAGCTGCTCAGATTTCAATGGTGGTTGT
ACTCACGAGTGTGTTCAAGAGCCCTTTGGGGCTAAATGCCTATGTCCATTGGGATTCTTA
CTTGCCAATGATTCTAAGACCTGTGAAGACATAGATGAATGTGATATTCTAGGCTCTTGT
AGCCAGCACTGTTACAATATGAGAGGTTCTTTCCGGTGCTCGTGTGATACAGGCTACATG
TTAGAAAGTGATGGGAGGACTTGCAAAGTTACAGCATCTGAGAGTCTGCTGTTACTTGTG
GCAAGTCAGAACAAAATTATTGCCGACAGTGTCACCTCCCAGGTCCACAATATCTATTCA
TTGGTCGAGAATGGTTCTTACATTGTAGCTGTTGATTTTGATTCAATTAGTGGTCGTATC
TTTTGGTCTGATGCAACTCAGGGTAAAACCTGGAGTGCGTTTCAAAATGGAACGGACAGA
AGAGTGGTATTTGACAGTAGCATCATCTTGACTGAAACTATTGCAATAGATTGGGTAGGT
CGTAATCTTTACTGGACAGACTATGCTCTGGAAACAATTGAAGTCTCCAAAATTGATGGG
AGCCACAGGACTGTGCTGATTAGTAAAAACCTAACAAATCCAAGAGGACTAGCATTAGAT
CCCAGAATGAATGAGCATCTACTGTTCTGGTCTGACTGGGGCCACCACCCTCGCATCGAG
CGAGCCAGCATGGACGGCAGCATGCGCACTGTCATTGTCCAGGACAAGATCTTCTGGCCC
TGCGGCTTAACTATTGACTACCCCAACAGACTGCTCTACTTCATGGACTCCTATCTTGAT
TACATGGACTTTTGTGATTATAATGGACACCATCGGAGACAGGTGATAGCCAGTGATTTG
ATTATACGGCACCCCTATGCCCTAACTCTCTTTGAAGACTCTGTGTACTGGACTGACCGT
GCTACTCGTCGGGTTATGCGAGCCAACAAGTGGCATGGAGGGAACCAGTCAGTTGTAATG
TATAATATTCAATGGCCCCTTGGGATTGTTGCGGTTCATCCTTCGAAACAACCAAATTCC
GTGAATCCATGTGCCTTTTCCCGCTGCAGCCATCTCTGCCTGCTTTCCTCACAGGGGCCT
CATTTTTACTCCTGTGTTTGTCCTTCAGGATGGAGTCTGTCTCCTGATCTCCTGAATTGC
TTGAGAGATGATCAACCTTTCTTAATAACTGTAAGGCAACATATAATTTTTGGAATCTCC
CTTAATCCTGAGGTGAAGAGCAATGATGCTATGGTCCCCATAGCAGGGATACAGAATGGT
TTAGATGTTGAATTTGATGATGCTGAGCAATACATCTATTGGGTTGAAAATCCAGGTGAA
ATTCACAGAGTGAAGACAGATGGCACCAACAGGACAGTATTTGCTTCTATATCTATGGTG
GGGCCTTCTATGAACCTGGCCTTAGATTGGATTTCAAGAAACCTTTATTCTACCAATCCT
AGAACTCAGTCAATCGAGGTTTTGACACTCCACGGAGATATCAGATACAGAAAAACATTG
ATTGCCAATGATGGGACAGCTCTTGGAGTTGGCTTTCCAATTGGCATAACTGTTGATCCT
GCTCGTGGGAAGCTGTACTGGTCAGACCAAGGAACTGACAGTGGGGTTCCTGCCAAGATC
GCCAGTGCTAACATGGATGGCACATCTGTGAAAACTCTCTTTACTGGGAACCTCGAACAC
CTGGAGTGTGTCACTCTTGACATCGAAGAGCAGAAACTCTACTGGGCAGTCACTGGAAGA
GGAGTGATTGAAAGAGGAAACGTGGATGGAACAGATCGAATGATCCTGGTACACCAGCTT
TCCCACCCCTGGGGAATTGCAGTCCATGATTCTTTCCTTTATTATACTGATGAACAGTAT
GAGGTCATTGAAAGAGTTGATAAGGCCACTGGGGCCAACAAAATAGTCTTGAGAGATAAT
GTTCCAAATCTGAGGGGTCTTCAAGTTTATCACAGACGCAATGCCGCCGAATCCTCAAAT
GGCTGTAGCAACAACATGAATGCCTGTCAGCAGATTTGCCTGCCTGTACCAGGAGGATTG
TTTTCCTGCGCCTGTGCCACTGGATTTAAACTCAATCCTGATAATCGGTCCTGCTCTCCA
TATAACTCTTTCATTGTTGTTTCAATGCTGTCTGCAATCAGAGGCTTTAGCTTGGAATTG
TCAGATCATTCAGAAACCATGGTGCCGGTGGCAGGCCAAGGACGAAACGCACTGCATGTG
GATGTGGATGTGTCCTCTGGCTTTATTTATTGGTGTGATTTTAGCAGCTCAGTGGCATCT
GATAATGCGATCCGTAGAATTAAACCAGATGGATCTTCTCTGATGAACATTGTGACACAT
GGAATAGGAGAAAATGGAGTCCGGGGTATTGCAGTGGATTGGGTAGCAGGAAATCTTTAT
TTCACCAATGCCTTTGTTTCTGAAACACTGATAGAAGTTCTGCGGATCAATACTACTTAC
CGCCGTGTTCTTCTTAAAGTCACAGTGGACATGCCTAGGCATATTGTTGTAGATCCCAAG
AACAGATACCTCTTCTGGGCTGACTATGGGCAGAGACCAAAGATTGAGCGTTCTTTCCTT
GACTGTACCAATCGAACAGTGCTTGTGTCAGAGGGCATTGTCACACCACGGGGCTTGGCA
GTGGACCGAAGTGATGGCTACGTTTATTGGGTTGATGATTCTTTAGATATAATTGCAAGG
ATTCGTATCAATGGAGAGAACTCTGAAGTGATTCGTTATGGCAGTCGTTACCCAACTCCT
TATGGCATCACTGTTTTTGAAAATTCTATCATATGGGTAGATAGGAATTTGAAAAAGATC
TTCCAAGCCAGCAAGGAACCAGAGAACACAGAGCCACCCACAGTGATAAGAGACAATATC
AACTGGCTAAGAGATGTGACCATCTTTGACAAGCAAGTCCAGCCCCGGTCACCAGCAGAG
GTCAACAACAACCCTTGCTTGGAAAACAATGGTGGGTGCTCTCATCTCTGCTTTGCTCTG
CCTGGATTGCACACCCCAAAATGTGACTGTGCCTTTGGGACCCTGCAAAGTGATGGCAAG
AATTGTGCCATTTCAACAGAAAATTTCCTCATCTTTGCCTTGTCTAATTCCTTGAGAAGC
TTACACTTGGACCCTGAAAACCATAGCCCACCTTTCCAAACAATAAATGTGGAAAGAACT
GTCATGTCTCTAGACTATGACAGTGTAAGTGATAGAATCTACTTCACACAAAATTTAGCC
TCTGGAGTTGGACAGATTTCCTATGCCACCCTGTCTTCAGGGATCCATACTCCAACTGTC
ATTGCTTCAGGTATAGGGACTGCTGATGGCATTGCCTTTGACTGGATTACTAGAAGAATT
TATTACAGTGACTACCTCAACCAGATGATTAATTCCATGGCTGAAGATGGGTCTAACCGC
ACTGTGATAGCCCGCGTTCCAAAACCAAGAGCAATTGTGTTAGATCCCTGCCAAGGGTAC
CTGTACTGGGCTGACTGGGATACACATGCCAAAATCGAGAGAGCCACATTGGGAGGAAAC
TTCCGCGTACCCATTGTGAACAGCAGTCTGGTCATGCCCAGTGGGCTGACTCTGGACTAT
GAAGAGGACCTTCTCTACTGGGTGGATGCTAGTCTGCAGAGGATTGAACGCAGCACTCTG
ACGGGCGTGGATCGTGAAGTCATTGTCAATGCAGCCGTTCATGCTTTTGGCTTGACTCTC
TATGGCCAGTATATTTACTGGACTGACTTGTACACACAAAGAATTTACCGAGCTAACAAA
TATGACGGGTCAGGTCAGATTGCAATGACCACAAATTTGCTCTCCCAGCCCAGGGGAATC
AACACTGTTGTGAAGAACCAGAAACAACAGTGTAACAATCCTTGTGAACAGTTTAATGGG
GGCTGCAGCCATATCTGTGCACCAGGTCCAAATGGTGCCGAGTGCCAGTGTCCACATGAG
GGCAACTGGTATTTGGCCAACAACAGGAAGCACTGCATTGTGGACAATGGTGAACGATGT
GGTGCATCTTCCTTCACCTGCTCCAATGGGCGCTGCATCTCGGAAGAGTGGAAGTGTGAT
AATGACAACGACTGTGGGGATGGCAGTGATGAGATGGAAAGTGTCTGTGCACTTCACACC
TGCTCACCGACAGCCTTCACCTGTGCCAATGGGCGATGTGTCCAATACTCTTACCGCTGT
GATTACTACAATGACTGTGGTGATGGCAGTGATGAGGCAGGGTGCCTGTTCAGGGACTGC
AATGCCACCACGGAGTTTATGTGCAATAACAGAAGGTGCATACCTCGTGAGTTTATCTGC
AATGGTGTAGACAACTGCCATGATAATAACACTTCAGATGAGAAAAATTGCCCTGATCGC
ACTTGCCAGTCTGGATACACAAAATGTCATAATTCAAATATTTGTATTCCTCGCGTTTAT
TTGTGTGACGGAGACAATGACTGTGGAGATAACAGTGATGAAAACCCTACTTATTGCACC
ACTCACACGTGCAGCAGCAGTGAGTTCCAATGCGCATCTGGGCGCTGTATTCCTCAACAT
TGGTATTGTGATCAAGAAACAGATTGTTTTGATGCCTCTGATGAACCTGCCTCTTGTGGT
CACTCTGAGCGAACATGCCTAGCTGATGAGTTCAAGTGTGATGGTGGGAGGTGCATCCCA
AGCGAATGGATCTGTGACGGTGATAATGACTGTGGGGATATGAGTGACGAGGATAAAAGG
CACCAGTGTCAGAATCAAAACTGCTCGGATTCCGAGTTTCTCTGTGTAAATGACAGACCT
CCGGACAGGAGGTGCATTCCCCAGTCTTGGGTCTGTGATGGCGATGTGGATTGTACTGAC
GGCTACGATGAGAATCAGAATTGCACCAGGAGAACTTGCTCTGAAAATGAATTCACCTGT
GGTTACGGACTGTGTATCCCAAAGATATTCAGGTGTGACCGGCACAATGACTGTGGTGAC
TATAGCGACGAGAGGGGCTGCTTATACCAGACTTGCCAACAGAATCAGTTTACCTGTCAG
AACGGGCGCTGCATTAGTAAAACCTTCGTCTGTGATGAGGATAATGACTGTGGAGACGGA
TCTGATGAGCTGATGCACCTGTGCCACACCCCAGAACCCACGTGTCCACCTCACGAGTTC
AAGTGTGACAATGGGCGCTGCATCGAGATGATGAAACTCTGCAACCACCTAGATGACTGT
TTGGACAACAGCGATGAGAAAGGCTGTGGCATTAATGAATGCCATGACCCTTCAATCAGT
GGCTGCGATCACAACTGCACAGACACCTTAACCAGTTTCTATTGTTCCTGTCGTCCTGGT
TACAAGCTCATGTCTGACAAGCGGACTTGTGTTGATATTGATGAATGCACAGAGATGCCT
TTTGTCTGTAGCCAGAAGTGTGAGAATGTAATAGGCTCCTACATCTGTAAGTGTGCCCCA
GGCTACCTCCGAGAACCAGATGGAAAGACCTGCCGGCAAAACAGTAACATCGAACCCTAT
CTCATTTTTAGCAACCGTTACTATTTGAGAAATTTAACTATAGATGGCTATTTTTACTCC
CTCATCTTGGAAGGACTGGACAATGTTGTGGCATTAGATTTTGACCGAGTAGAGAAGAGA
TTGTATTGGATTGATACACAGAGGCAAGTCATTGAGAGAATGTTTCTGAATAAGACAAAC
AAGGAGACAATCATAAACCACAGACTACCAGCTGCAGAAAGTCTGGCTGTAGACTGGGTT
TCCAGAAAGCTCTACTGGTTGGATGCCCGCCTGGATGGCCTCTTTGTCTCTGACCTCAAT
GGTGGACACCGCCGCATGCTGGCCCAGCACTGTGTGGATGCCAACAACACCTTCTGCTTT
GATAATCCCAGAGGACTTGCCCTTCACCCTCAATATGGGTACCTCTACTGGGCAGACTGG
GGTCACCGCGCATACATTGGGAGAGTAGGCATGGATGGAACCAACAAGTCTGTGATAATC
TCCACCAAGTTAGAGTGGCCTAATGGCATCACCATTGATTACACCAATGATCTACTCTAC
TGGGCAGATGCCCACCTGGGTTACATAGAGTACTCTGATTTGGAGGGCCACCATCGACAC
ACGGTGTATGATGGGGCACTGCCTCACCCTTTCGCTATTACCATTTTTGAAGACACTATT
TATTGGACAGATTGGAATACAAGGACAGTGGAAAAGGGAAACAAATATGATGGATCAAAT
AGACAGACACTGGTGAACACAACACACAGACCATTTGACATCCATGTGTACCATCCATAT
AGGCAGCCCATTGTGAGCAATCCCTGTGGTACCAACAATGGTGGCTGTTCTCATCTCTGC
CTCATCAAGCCAGGAGGAAAAGGGTTCACTTGCGAGTGTCCAGATGACTTCCGCACCCTT
CAGCTGAGTGGCAGCACCTACTGCATGCCCATGTGCTCCAGCACCCAGTTCCTGTGCGCT
AACAATGAAAAGTGCATTCCTATCTGGTGGAAATGTGATGGACAGAAAGACTGCTCAGAT
GGCTCTGATGAACTGGCCCTTTGCCCGCAGCGCTTCTGCCGACTGGGACAGTTCCAGTGC
AGTGACGGCAACTGCACCAGCCCGCAGACTTTATGCAATGCTCACCAAAATTGCCCTGAT
GGGTCTGATGAAGACCGTCTTCTTTGTGAGAATCACCACTGTGACTCCAATGAATGGCAG
TGCGCCAACAAACGTTGCATCCCAGAATCCTGGCAGTGTGACACATTTAACGACTGTGAG
GATAACTCAGATGAAGACAGTTCCCACTGTGCCAGCAGGACCTGCCGGCCGGGCCAGTTT
CGGTGTGCTAATGGCCGCTGCATCCCGCAGGCCTGGAAGTGTGATGTGGATAATGATTGT
GGAGACCACTCGGATGAGCCCATTGAAGAATGCATGAGCTCTGCCCATCTCTGTGACAAC
TTCACAGAATTCAGCTGCAAAACAAATTACCGCTGCATCCCAAAGTGGGCCGTGTGCAAT
GGTGTAGATGACTGCAGGGACAACAGTGATGAGCAAGGCTGTGAGGAGAGGACATGCCAT
CCTGTGGGGGATTTCCGCTGTAAAAATCACCACTGCATCCCTCTTCGTTGGCAGTGTGAT
GGGCAAAATGACTGTGGAGATAACTCAGATGAGGAAAACTGTGCTCCCCGGGAGTGCACA
GAGAGCGAGTTTCGATGTGTCAATCAGCAGTGCATTCCCTCGCGATGGATCTGTGACCAT
TACAACGACTGTGGGGACAACTCAGATGAACGGGACTGTGAGATGAGGACCTGCCATCCT
GAATATTTTCAGTGTACAAGTGGACATTGTGTACACAGTGAACTGAAATGCGATGGATCC
GCTGACTGTTTGGATGCGTCTGATGAAGCTGATTGTCCCACACGCTTTCCTGATGGTGCA
TACTGCCAGGCTACTATGTTCGAATGCAAAAACCATGTTTGTATCCCGCCATATTGGAAA
TGTGATGGCGATGATGACTGTGGCGATGGTTCAGATGAAGAACTTCACCTGTGCTTGGAT
GTTCCCTGTAATTCACCAAACCGTTTCCGGTGTGACAACAATCGCTGCATTTATAGTCAT
GAGGTGTGCAATGGTGTGGATGACTGTGGAGATGGAACTGATGAGACAGAGGAGCACTGT
AGAAAACCGACCCCTAAACCTTGTACAGAATATGAATATAAGTGTGGCAATGGGCATTGC
ATTCCACATGACAATGTGTGTGATGATGCCGATGACTGTGGTGACTGGTCCGATGAACTG
GGTTGCAATAAAGGAAAAGAAAGAACATGTGCTGAAAATATATGCGAGCAAAATTGTACC
CAATTAAATGAAGGAGGATTTATCTGCTCCTGTACAGCTGGGTTCGAAACCAATGTTTTT
GACAGAACCTCCTGTCTAGATATCAATGAATGTGAACAATTTGGGACTTGTCCCCAGCAC
TGCAGAAATACCAAAGGAAGTTATGAGTGTGTCTGTGCTGATGGCTTCACGTCTATGAGT
GACCGCCCTGGAAAACGATGTGCAGCTGAGGGTAGCTCTCCTTTGTTGCTACTGCCTGAC
AATGTCCGAATTCGAAAATATAATCTCTCATCTGAGAGGTTCTCAGAGTATCTTCAAGAT
GAGGAATATATCCAAGCTGTTGATTATGATTGGGATCCCAAGGACATAGGCCTCAGTGTT
GTGTATTACACTGTGCGAGGGGAGGGCTCTAGGTTTGGTGCTATCAAACGTGCCTACATC
CCCAACTTTGAATCCGGCCGCAATAATCTTGTGCAGGAAGTTGACCTGAAACTGAAATAC
GTAATGCAGCCAGATGGAATAGCAGTGGACTGGGTTGGAAGGCATATTTACTGGTCAGAT
GTCAAGAATAAACGCATTGAGGTGGCTAAACTTGATGGAAGGTACAGAAAGTGGCTGATT
TCCACTGACCTGGACCAACCAGCTGCTATTGCTGTGAATCCCAAACTAGGGCTTATGTTC
TGGACTGACTGGGGAAAGGAACCTAAAATCGAGTCTGCCTGGATGAATGGAGAGGACCGC
AACATCCTGGTTTTCGAGGACCTTGGTTGGCCAACTGGCCTTTCTATCGATTATTTGAAC
AATGACCGAATCTACTGGAGTGACTTCAAGGAGGACGTTATTGAAACCATAAAATATGAT
GGGACTGATAGGAGAGTCATTGCAAAGGAAGCAATGAACCCTTACAGCCTGGACATCTTT
GAAGACCAGTTATACTGGATATCTAAGGAAAAGGGAGAAGTATGGAAACAAAATAAATTT
GGGCAAGGAAAGAAAGAGAAAACGCTGGTAGTGAACCCTTGGCTCACTCAAGTTCGAATC
TTTCATCAACTCAGATACAATAAGTCAGTGCCCAACCTTTGCAAACAGATCTGCAGCCAC
CTCTGCCTTCTGAGACCTGGAGGATACAGCTGTGCCTGTCCCCAAGGCTCCAGCTTTATA
GAGGGGAGCACCACTGAGTGTGATGCAGCCATCGAACTGCCTATCAACCTGCCCCCCCCA
TGCAGGTGCATGCACGGAGGAAATTGCTATTTTGATGAGACTGACCTCCCCAAATGCAAG
TGTCCTAGCGGCTACACCGGAAAATATTGTGAAATGGCGTTTTCAAAAGGCATCTCTCCA
GGAACAACCGCAGTAGCTGTGCTGTTGACAATCCTCTTGATCGTCGTAATTGGAGCTCTG
GCAATTGCAGGATTCTTCCACTATAGAAGGACCGGCTCCCTTTTGCCTGCTCTGCCCAAG
CTGCCAAGCTTAAGCAGTCTCGTCAAGCCCTCTGAAAATGGGAATGGGGTGACCTTCAGA
TCAGGGGCAGATCTTAACATGGATATTGGAGTGTCTGGTTTTGGACCTGAGACTGCTATT
GACAGGTCAATGGCAATGAGTGAAGACTTTGTCATGGAAATGGGGAAGCAGCCCATAATA
TTTGAAAACCCAATGTACTCAGCCAGAGACAGTGCTGTCAAAGTGGTTCAGCCAATCCAG
GTGACTGTATCTGAAAATGTGGATAATAAGAATTATGGAAGTCCCATAAACCCTTCTGAG
ATAGTTCCAGAGACAAACCCAACTTCACCAGCTGCTGATGGAACTCAGGTGACAAAATGG
AATCTCTTCAAACGAAAATCTAAACAAACTACCAACTTTGAAAATCCAATCTATGCACAG
ATGGAGAACGAGCAAAAGGAAAGTGTTGCTGCGACACCACCTCCATCACCTTCGCTCCCT
GCTAAGCCTAAGCCTCCTTCGAGAAGAGACCCAACTCCAACCTATTCTGCAACAGAAGAC
ACTTTTAAAGACACCGCAAATCTTGTTAAAGAAGACTCTGAAGTATAG</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF07645</identifier>
            <name>EGF_CA</name>
          </pfam>
          <pfam>
            <identifier>PF00057</identifier>
            <name>Ldl_recept_a</name>
          </pfam>
          <pfam>
            <identifier>PF00058</identifier>
            <name>Ldl_recept_b</name>
          </pfam>
          <pfam>
            <identifier>PF12662</identifier>
            <name>cEGF</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>apical plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>brush border membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>coated pit</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>endocytic vesicle</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>endoplasmic reticulum</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>endosome</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>extracellular exosome</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>Golgi apparatus</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>integral component of membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>lysosomal membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>lysosome</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>receptor complex</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>calcium ion binding</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cell proliferation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>endocytosis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>forebrain development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>lipid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>phototransduction, visible light</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>protein glycosylation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>receptor-mediated endocytosis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>retinoid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>small molecule metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>steroid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>vitamin D metabolic process</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
    <target position="13">
      <id>BE0002126</id>
      <name>Insulin-like growth factor-binding protein 7</name>
      <organism>Humans</organism>
      <actions/>
      <references>
        <articles>
          <article>
            <ref-id>A1713</ref-id>
            <pubmed-id>17139284</pubmed-id>
            <citation>Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.</citation>
          </article>
          <article>
            <ref-id>A1715</ref-id>
            <pubmed-id>17016423</pubmed-id>
            <citation>Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.</citation>
          </article>
          <article>
            <ref-id>A13261</ref-id>
            <pubmed-id>11089538</pubmed-id>
            <citation>Lopez-Bermejo A, Buckway CK, Devi GR, Hwa V, Plymate SR, Oh Y, Rosenfeld RG: Characterization of insulin-like growth factor-binding protein-related proteins (IGFBP-rPs) 1, 2, and 3 in human prostate epithelial cells: potential roles for IGFBP-rP1 and 2 in senescence of the prostatic epithelium. Endocrinology. 2000 Nov;141(11):4072-80.</citation>
          </article>
          <article>
            <ref-id>A13262</ref-id>
            <pubmed-id>17475416</pubmed-id>
            <citation>Radulescu RT: One for all and all for one: RB defends the cell while IDE, PTEN and IGFBP-7 antagonize insulin and IGFs to protect RB. Med Hypotheses. 2007;69(5):1018-20. Epub 2007 May 1.</citation>
          </article>
          <article>
            <ref-id>A13263</ref-id>
            <pubmed-id>10383131</pubmed-id>
            <citation>Degeorges A, Wang F, Frierson HF Jr, Seth A, Chung LW, Sikes RA: Human prostate cancer expresses the low affinity insulin-like growth factor binding protein IGFBP-rP1. Cancer Res. 1999 Jun 15;59(12):2787-90.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="Q16270" source="Swiss-Prot">
        <name>Insulin-like growth factor-binding protein 7</name>
        <general-function/>
        <specific-function>Binds IGF-I and IGF-II with a relatively low affinity. Stimulates prostacyclin (PGI2) production. Stimulates cell adhesion.</specific-function>
        <gene-name>IGFBP7</gene-name>
        <locus>4q12</locus>
        <cellular-location>Secreted</cellular-location>
        <transmembrane-regions/>
        <signal-regions>1-26</signal-regions>
        <theoretical-pi>7.94</theoretical-pi>
        <molecular-weight>29130.055</molecular-weight>
        <chromosome-location>4</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:5476</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>IGFBP7</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>L19182</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>307151</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>Q16270</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>IBP7_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>IBP-7</synonym>
          <synonym>IGFBP-rP1</synonym>
          <synonym>MAC25</synonym>
          <synonym>MAC25 protein</synonym>
          <synonym>PGI2-stimulating factor</synonym>
          <synonym>Prostacyclin-stimulating factor</synonym>
          <synonym>PSF</synonym>
          <synonym>TAF</synonym>
          <synonym>Tumor-derived adhesion factor</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0004170|Insulin-like growth factor-binding protein 7
MERPSLRALLLGAAGLLLLLLPLSSSSSSDTCGPCEPASCPPLPPLGCLLGETRDACGCC
PMCARGEGEPCGGGGAGRGYCAPGMECVKSRKRRKGKAGAAAGGPGVSGVCVCKSRYPVC
GSDGTTYPSGCQLRAASQRAESRGEKAITQVSKGTCEQGPSIVTPPKDIWNVTGAQVYLS
CEVIGIPTPVLIWNKVKRGHYGVQRTELLPGDRDNLAIQTRGGPEKHEVTGWVLVSPLSK
EDAGEYECHASNSQGQASASAKITVVDALHEIPVKKGEGAEL</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0011540|Insulin-like growth factor-binding protein 7 (IGFBP7)
ATGGAGCGGCCGTCGCTGCGCGCCCTGCTCCTCGGCGCCGCTGGGCTGCTGCTCCTGCTC
CTGCCCCTCTCCTCTTCCTCCTCTTCGGACACCTGCGGCCCCTGCGAGCCGGCCTCCTGC
CCGCCCCTGCCCCCGCTGGGCTGCCTGCTGGGCGAGACCCGCGACGCGTGCGGCTGCTGC
CCTATGTGCGCCCGCGGCGAGGGCGAGCCGTGCGGGGGTGGCGGCGCCGGCAGGGGGTAC
TGCGCGCCGGGCATGGAGTGCGTGAAGAGCCGCAAGAGGCGGAAGGGTAAAGCCGGGGCA
GCAGCCGGCGGTCCGGGTGTAAGCGGCGTGTGCGTGTGCAAGAGCCGCTACCCGGTGTGC
GGCAGCGACGGCACCACCTACCCGAGCGGCTGCCAGCTGCGCGCCGCCAGCCAGAGGGCC
GAGAGCCGCGGGGAGAAGGCCATCACCCAGGTCAGCAAGGGCACCTGCGAGCAAGGTCCT
TCCATAGTGACGCCCCCCAAGGACATCTGGAATGTCACTGGTGCCCAGGTGTACTTGAGC
TGTGAGGTCATCGGAATCCCGACACCTGTCCTCATCTGGAACAAGGTAAAAAGGGGTCAC
TATGGAGTTCAAAGGACAGAACTCCTGCCTGGTGACCGGGACAACCTGGCCATTCAGACC
CGGGGTGGCCCAGAAAAGCATGAAGTAACTGGCTGGGTGCTGGTATCTCCTCTAAGTAAG
GAAGATGCTGGAGAATATGAGTGCCATGCATCCAATTCCCAAGGACAGGCTTCAGCATCA
GCAAAAATTACAGTGGTTGATGCCTTACATGAAATACCAGTGAAAAAAGGTACACAATAA
</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF07679</identifier>
            <name>I-set</name>
          </pfam>
          <pfam>
            <identifier>PF00219</identifier>
            <name>IGFBP</name>
          </pfam>
          <pfam>
            <identifier>PF07648</identifier>
            <name>Kazal_2</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>extracellular exosome</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>extracellular region</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>extracellular space</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cell adhesion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of cell proliferation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of cell growth</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
    <target position="14">
      <id>BE0002127</id>
      <name>Synaptotagmin-like protein 4</name>
      <organism>Humans</organism>
      <actions/>
      <references>
        <articles>
          <article>
            <ref-id>A1713</ref-id>
            <pubmed-id>17139284</pubmed-id>
            <citation>Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.</citation>
          </article>
          <article>
            <ref-id>A1715</ref-id>
            <pubmed-id>17016423</pubmed-id>
            <citation>Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.</citation>
          </article>
          <article>
            <ref-id>A13264</ref-id>
            <pubmed-id>16216924</pubmed-id>
            <citation>Gomi H, Mizutani S, Kasai K, Itohara S, Izumi T: Granuphilin molecularly docks insulin granules to the fusion machinery. J Cell Biol. 2005 Oct 10;171(1):99-109.</citation>
          </article>
          <article>
            <ref-id>A13265</ref-id>
            <pubmed-id>16831872</pubmed-id>
            <citation>Plaisance V, Abderrahmani A, Perret-Menoud V, Jacquemin P, Lemaigre F, Regazzi R: MicroRNA-9 controls the expression of Granuphilin/Slp4 and the secretory response of insulin-producing cells. J Biol Chem. 2006 Sep 15;281(37):26932-42. Epub 2006 Jul 10.</citation>
          </article>
          <article>
            <ref-id>A13266</ref-id>
            <pubmed-id>15028737</pubmed-id>
            <citation>Torii S, Takeuchi T, Nagamatsu S, Izumi T: Rab27 effector granuphilin promotes the plasma membrane targeting of insulin granules via interaction with syntaxin 1a. J Biol Chem. 2004 May 21;279(21):22532-8. Epub 2004 Mar 17.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="Q96C24" source="Swiss-Prot">
        <name>Synaptotagmin-like protein 4</name>
        <general-function>Zinc ion binding</general-function>
        <specific-function>Modulates exocytosis of dense-core granules and secretion of hormones in the pancreas and the pituitary. Interacts with vesicles containing negatively charged phospholipids in a Ca(2+)-independent manner (By similarity).</specific-function>
        <gene-name>SYTL4</gene-name>
        <locus>-</locus>
        <cellular-location>Membrane</cellular-location>
        <transmembrane-regions/>
        <signal-regions/>
        <theoretical-pi>9.42</theoretical-pi>
        <molecular-weight>76022.99</molecular-weight>
        <chromosome-location>X</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:15588</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>SYTL4</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>AK094110</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>21753104</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>Q96C24</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>SYTL4_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>Exophilin-2</synonym>
          <synonym>Granuphilin</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0037164|Synaptotagmin-like protein 4
MSELLDLSFLSEEEKDLILSVLQRDEEVRKADEKRIRRLKNELLEIKRKGAKRGSQHYSD
RTCARCQESLGRLSPKTNTCRGCNHLVCRDCRIQESNGTWRCKVCAKEIELKKATGDWFY
DQKVNRFAYRTGSEIIRMSLRHKPAVSKRETVGQSLLHQTQMGDIWPGRKIIQERQKEPS
VLFEVPKLKSGKSALEAESESLDSFTADSDSTSRRDSLDKSGLFPEWKKMSAPKSQVEKE
TQPGGQNVVFVDEGEMIFKKNTRKILRPSEYTKSVIDLRPEDVVHESGSLGDRSKSVPGL
NVDMEEEEEEEDIDHLVKLHRQKLARSSMQSGSSMSTIGSMMSIYSEAGDFGNIFVTGRI
AFSLKYEQQTQSLVVHVKECHQLAYADEAKKRSNPYVKTYLLPDKSRQGKRKTSIKRDTI
NPLYDETLRYEIPESLLAQRTLQFSVWHHGRFGRNTFLGEAEIQMDSWKLDKKLDHCLPL
HGKISAESPTGLPSHKGELVVSLKYIPASKTPVGGDRKKSKGGEGGELQVWIKEAKNLTA
AKAGGTSDSFVKGYLLPMRNKASKRKTPVMKKTLNPHYNHTFVYNGVRLEDLQHMCLELT
VWDREPLASNDFLGGVRLGVGTGISNGEVVDWMDSTGEEVSLWQKMRQYPGSWAEGTLQL
RSSMAKQKLGL</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0011541|Synaptotagmin-like protein 4 (SYTL4)
ATGTCGGAGTTACTGGACCTTTCTTTTCTGTCTGAGGAGGAAAAGGATTTGATTCTCAGT
GTTCTACAGCGAGATGAAGAGGTCCGGAAAGCAGATGAGAAAAGGATTAGGCGACTAAAG
AATGAGTTACTGGAGATAAAAAGGAAAGGGGCCAAGAGGGGCAGCCAACACTACAGTGAT
CGGACCTGTGCCCGGTGCCAGGAGAGCCTGGGCCGTTTGAGTCCCAAAACCAATACTTGT
CGGGGTTGTAATCACCTGGTGTGTCGGGACTGCCGCATACAGGAAAGCAATGGTACCTGG
AGGTGCAAGGTGTGCGCCAAGGAAATAGAGTTGAAGAAAGCAACTGGGGACTGGTTTTAT
GACCAGAAAGTGAATCGCTTTGCTTACCGCACAGGTAGTGAGATAATCAGGATGTCCCTG
CGCCACAAACCTGCAGTGAGTAAAAGAGAGACAGTGGGACAGTCCCTCCTTCATCAGACA
CAGATGGGTGACATCTGGCCAGGAAGAAAGATCATTCAGGAGCGGCAGAAGGAGCCCAGT
GTGCTATTTGAAGTGCCAAAGCTGAAAAGTGGAAAGAGTGCATTGGAAGCTGAGAGTGAG
AGTCTGGATAGCTTCACAGCTGACTCGGATAGCACCTCCAGGAGAGACTCTCTGGATAAA
TCTGGCCTCTTTCCAGAATGGAAGAAGATGTCTGCTCCCAAATCTCAAGTAGAAAAGGAA
ACTCAGCCTGGAGGTCAAAATGTGGTATTTGTGGATGAGGGTGAGATGATATTTAAGAAG
AACACCAGAAAAATCCTCAGGCCTTCAGAGTACACTAAATCTGTGATAGATCTTCGCCCA
GAAGATGTGGTACATGAAAGTGGCTCCTTGGGAGACAGAAGCAAATCCGTCCCAGGCCTC
AATGTGGATATGGAAGAGGAAGAAGAAGAAGAAGACATTGACCACCTAGTGAAGTTACAT
CGCCAGAAGCTAGCCAGAAGCAGCATGCAAAGTGGCTCCTCCATGAGTACGATCGGCAGC
ATGATGAGCATCTACAGTGAAGCTGGTGATTTCGGGAACATCTTTGTGACTGGCAGGATT
GCCTTTTCCCTGAAGTATGAGCAGCAAACCCAGAGTCTGGTTGTCCATGTGAAGGAGTGC
CATCAGCTGGCCTATGCTGATGAAGCCAAGAAGCGCTCTAACCCATATGTGAAGACTTAC
CTTCTGCCTGACAAGTCCCGCCAAGGAAAAAGAAAAACCAGCATCAAGCGGGACACTATT
AATCCACTATATGATGAGACGCTGAGGTATGAGATCCCAGAATCTCTCCTGGCCCAGAGG
ACCCTGCAGTTCTCAGTTTGGCATCATGGTCGTTTTGGCAGAAACACTTTCCTTGGAGAG
GCAGAGATCCAGATGGATTCCTGGAAGCTTGATAAGAAACTGGATCATTGCCTCCCTTTA
CATGGAAAGATCAGTGCTGAGTCCCCGACTGGCTTGCCATCACACAAAGGCGAGTTGGTG
GTTTCATTGAAATACATCCCAGCCTCCAAAACCCCTGTTGGAGGTGACCGGAAAAAGAGT
AAAGGTGGGGAAGGGGGAGAGCTCCAGGTGTGGATCAAAGAAGCCAAGAACTTGACGGCT
GCCAAAGCAGGAGGGACTTCAGACAGCTTTGTCAAGGGATACCTCCTTCCCATGAGGAAC
AAGGCCAGTAAACGTAAAACTCCTGTGATGAAGAAGACCCTGAATCCTCACTACAACCAT
ACATTTGTCTACAATGGTGTGAGGCTGGAAGATCTACAGCATATGTGCCTGGAACTGACT
GTGTGGGACCGGGAGCCCCTGGCCAGCAATGACTTCCTGGGAGGGGTCAGGCTGGGTGTT
GGCACTGGGATCAGTAATGGGGAAGTGGTGGACTGGATGGACTCGACTGGGGAAGAAGTG
AGCCTGTGGCAGAAGATGCGACAGTACCCAGGGTCTTGGGCAGAAGGGACTCTGCAGCTC
CGTTCCTCAATGGCCAAGCAGAAGCTGGGTTTATGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00168</identifier>
            <name>C2</name>
          </pfam>
          <pfam>
            <identifier>PF02318</identifier>
            <name>FYVE_2</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>apical plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>centrosome</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>cytoplasm</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>endosome</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>exocytic vesicle</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>extrinsic component of membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>nucleoplasm</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>secretory granule membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>transport vesicle membrane</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>calcium ion binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>calcium-dependent phospholipid binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>clathrin binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>neurexin family protein binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>phospholipid binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>syntaxin binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>zinc ion binding</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>calcium ion-dependent exocytosis of neurotransmitter</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>intracellular protein transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>multivesicular body sorting pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of insulin secretion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of exocytosis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of protein secretion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of calcium ion-dependent exocytosis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>synaptic vesicle exocytosis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>vesicle fusion</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
  </targets>
  <enzymes>
    <enzyme position="15">
      <id>BE0002433</id>
      <name>Cytochrome P450 1A2</name>
      <organism>Humans</organism>
      <actions>
        <action>inducer</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A181319</ref-id>
            <pubmed-id>1562279</pubmed-id>
            <citation>Barnett CR, Wilson J, Wolf CR, Flatt PR, Ioannides C: Hyperinsulinaemia causes a preferential increase in hepatic P4501A2 activity. Biochem Pharmacol. 1992 Mar 17;43(6):1255-61. doi: 10.1016/0006-2952(92)90500-i.</citation>
          </article>
          <article>
            <ref-id>A181322</ref-id>
            <pubmed-id>12130701</pubmed-id>
            <citation>Pass GJ, Becker W, Kluge R, Linnartz K, Plum L, Giesen K, Joost HG: Effect of hyperinsulinemia and type 2 diabetes-like hyperglycemia on expression of hepatic cytochrome p450 and glutathione s-transferase isoforms in a New Zealand obese-derived mouse backcross population. J Pharmacol Exp Ther. 2002 Aug;302(2):442-50. doi: 10.1124/jpet.102.033553.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P05177" source="Swiss-Prot">
        <name>Cytochrome P450 1A2</name>
        <general-function>Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen</general-function>
        <specific-function>Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N3-demethylation. Also acts in the metabolism of aflatoxin B1 and acetaminophen. Participates in the bioactivation of carcinogenic aromatic and heterocyclic amines. Catalizes the N-hydroxylation of heterocyclic amines and the O-deethylation of phenacetin.</specific-function>
        <gene-name>CYP1A2</gene-name>
        <locus>15q24</locus>
        <cellular-location>Endoplasmic reticulum membrane</cellular-location>
        <transmembrane-regions/>
        <signal-regions/>
        <theoretical-pi>9.43</theoretical-pi>
        <molecular-weight>58293.76</molecular-weight>
        <chromosome-location>15</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:2596</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>CYP1A2</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>Z00036</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>1319</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P05177</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>CP1A2_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>1.14.14.1</synonym>
          <synonym>Cholesterol 25-hydroxylase</synonym>
          <synonym>CYPIA2</synonym>
          <synonym>Cytochrome P(3)450</synonym>
          <synonym>Cytochrome P450 4</synonym>
          <synonym>Cytochrome P450-P3</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0004778|Cytochrome P450 1A2
MALSQSVPFSATELLLASAIFCLVFWVLKGLRPRVPKGLKSPPEPWGWPLLGHVLTLGKN
PHLALSRMSQRYGDVLQIRIGSTPVLVLSRLDTIRQALVRQGDDFKGRPDLYTSTLITDG
QSLTFSTDSGPVWAARRRLAQNALNTFSIASDPASSSSCYLEEHVSKEAKALISRLQELM
AGPGHFDPYNQVVVSVANVIGAMCFGQHFPESSDEMLSLVKNTHEFVETASSGNPLDFFP
ILRYLPNPALQRFKAFNQRFLWFLQKTVQEHYQDFDKNSVRDITGALFKHSKKGPRASGN
LIPQEKIVNLVNDIFGAGFDTVTTAISWSLMYLVTKPEIQRKIQKELDTVIGRERRPRLS
DRPQLPYLEAFILETFRHSSFLPFTIPHSTTRDTTLNGFYIPKKCCVFVNQWQVNHDPEL
WEDPSEFRPERFLTADGTAINKPLSEKMMLFGMGKRRCIGEVLAKWEIFLFLAILLQQLE
FSVPPGVKVDLTPIYGLTMKHARCEHVQARRFSIN</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0011742|Cytochrome P450 1A2 (CYP1A2)
ATGGCATTGTCCCAGTCTGTTCCCTTCTCGGCCACAGAGCTTCTCCTGGCCTCTGCCATC
TTCTGCCTGGTATTCTGGGTGCTCAAGGGTTTGAGGCCTCGGGTCCCCAAAGGCCTGAAA
AGTCCACCAGAGCCATGGGGCTGGCCCTTGCTCGGGCATGTGCTGACCCTGGGGAAGAAC
CCGCACCTGGCACTGTCAAGGATGAGCCAGCGCTACGGGGACGTCCTGCAGATCCGCATT
GGCTCCACGCCCGTGCTGGTGCTGAGCCGCCTGGACACCATCCGGCAGGCCCTGGTGCGG
CAGGGCGACGATTTCAAGGGCCGGCCTGACCTCTACACCTCCACCCTCATCACTGATGGC
CAGAGCTTGACCTTCAGCACAGACTCTGGACCGGTGTGGGCTGCCCGCCGGCGCCTGGCC
CAGAATGCCCTCAACACCTTCTCCATCGCCTCTGACCCAGCTTCCTCATCCTCCTGCTAC
CTGGAGGAGCATGTGAGCAAGGAGGCTAAGGCCCTGATCAGCAGGTTGCAGGAGCTGATG
GCAGGGCCTGGGCACTTCGACCCTTACAATCAGGTGGTGGTGTCAGTGGCCAACGTCATT
GGTGCCATGTGCTTCGGACAGCACTTCCCTGAGAGTAGCGATGAGATGCTCAGCCTCGTG
AAGAACACTCATGAGTTCGTGGAGACTGCCTCCTCCGGGAACCCCCTGGACTTCTTCCCC
ATCCTTCGCTACCTGCCTAACCCTGCCCTGCAGAGGTTCAAGGCCTTCAACCAGAGGTTC
CTGTGGTTCCTGCAGAAAACAGTCCAGGAGCACTATCAGGACTTTGACAAGAACAGTGTC
CGGGACATCACGGGTGCCCTGTTCAAGCACAGCAAGAAGGGGCCTAGAGCCAGCGGCAAC
CTCATCCCACAGGAGAAGATTGTCAACCTTGTCAATGACATCTTTGGAGCAGGATTTGAC
ACAGTCACCACAGCCATCTCCTGGAGCCTCATGTACCTTGTGACCAAGCCTGAGATACAG
AGGAAGATCCAGAAGGAGCTGGACACTGTGATTGGCAGGGAGCGGCGGCCCCGGCTCTCT
GACAGACCCCAGCTGCCCTACTTGGAGGCCTTCATCCTGGAGACCTTCCGACACTCCTCC
TTCTTGCCCTTCACCATCCCCCACAGCACAACAAGGGACACAACGCTGAATGGCTTCTAC
ATCCCCAAGAAATGCTGTGTCTTCGTAAACCAGTGGCAGGTCAACCATGACCCAGAGCTG
TGGGAGGACCCCTCTGAGTTCCGGCCTGAGCGGTTCCTCACCGCCGATGGCACTGCCATT
AACAAGCCCTTGAGTGAGAAGATGATGCTGTTTGGCATGGGCAAGCGCCGGTGTATCGGG
GAAGTCCTGGCCAAGTGGGAGATCTTCCTCTTCCTGGCCATCCTGCTACAGCAACTGGAG
TTCAGCGTGCCGCCGGGCGTGAAAGTCGACCTGACCCCCATCTACGGGCTGACCATGAAG
CACGCCCGCTGTGAACATGTCCAGGCGCGGCTGCGCTTCTCCATCAATTGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00067</identifier>
            <name>p450</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>endoplasmic reticulum membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>intracellular membrane-bounded organelle</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>aromatase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>caffeine oxidase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>demethylase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>electron carrier activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>enzyme binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>heme binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>iron ion binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>monooxygenase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>oxidoreductase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>alkaloid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>arachidonic acid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular respiration</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to cadmium ion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>dibenzo-p-dioxin metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>drug catabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>drug metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>epoxygenase P450 pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>exogenous drug catabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>heterocycle metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>hydrogen peroxide biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>lung development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>methylation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>monocarboxylic acid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>monoterpenoid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>omega-hydroxylase P450 pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>oxidation-reduction process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>oxidative deethylation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>oxidative demethylation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>porphyrin-containing compound metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>post-embryonic development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of gene expression</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to estradiol</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to immobilization stress</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to lipopolysaccharide</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>small molecule metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>steroid catabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>toxin biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>xenobiotic metabolic process</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
      <inhibition-strength/>
      <induction-strength>unknown</induction-strength>
    </enzyme>
  </enzymes>
  <carriers/>
  <transporters/>
</drug>